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Chapter 1 
Introduction 
The body has a variety of defense mechanisms to protect it against invasion of 
potentially harmful agents such as viruses, bacteria, and parasites. The first line of 
defense Is a more physical barrier e.g. skin and mucosa. When organisms succeed 
in passing this first line of defense and enter the body, the immune system is 
activated and the ensuing immune response generally leads to elimination of the 
invaders and often results in resistance to the organism. The immune response 
involves the specific recognition of the organism which leads to humoral and/or 
cellular immunity and memory. Through the formation of memory cells the immune 
system is capable of responding to the same organism more rapid and effective 
upon subsequent encounter. In the humoral immune response, antibody producing 
B cells playa central role. Antibodies are secreted in body fluids and can bind to 
organisms with high specificity. Cellular immunity is primarily exerted by T cells, 
consisting of cytotoxic T cells, which kill virus-infected and tumor cells, or helper T 
cells which regulate the function of other cells via secreted cytokines. 
For different reasons, immune responses can be evoked in humans or animals 
via injection of an antigen (= substance to which an immune response is induced). 
For example, for vaccination purposes, humans and animals are injected with 
antigen to induce protection against harmful pathogens. Animals can be injected 
with antigen to generate specific antibodies applicable in research, diagnosis and 
therapy. Injection of an antigen is not always sufficient to induce an effective 
immune response. When this is the case, the immune system needs help. To 
augment an effective immune response, adjuvants (Latin: adjuvare, to help) may be 
used. Adjuvants are sUbstances (e.g. mineral salts, oil emulsions, bacterial products, 
saponins) which upon administration lead to non-specific immuno-stimulation. The 
non-specific immunostimulation can be used to enhance the specific immune 
response to the antigen. Adjuvants can influence the magnitude as well as the 
quality (e.g. isotype, specificity and avidity of antibodies and cytokine profiles of T 
cells) of the induced immune response. Besides the intended stimulation of the 
immune response, adjuvants can lead to unintended stimulation of different 
reactions. This unintended stimulation, induced by adjuvants, can result in unwanted 
side effects like fever, granulomatous inflammation, neurological disorders and 
carcinogenicity. When selecting an adjuvant, the immunostimulating and side effects 
of the adjuvant have to be evaluated. The intended immunostimulating effects of 
adjuvants are determined by the goal of the immunization. When the adjuvant is 
used in a vaccine, the goal is to induce immune responses and memory sufficient to 
protect against a harmful organism while for the production of antibodies the main 
goal is to elicit the highest specific antibody response achievable. The acceptability 
of side effects is determined by the species in which the adjuvant is applied. Two 
categories for adjuvant application can be distinguished: (1) applications for which 
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the efficacy aspect is more important than the safety aspect (e.g. laboratory and 
production animals) and (2) applications where safety is more important than 
efficacy (e.g. companion animals and humans). This thesis emphasizes the use of 
adjuvants for the production of antibodies in laboratory animals. The requirements of 
adjuvants for this purpose are: high antibody levels to a broad range of antigens, 
commercial availability, ease of use, and low price. Freund's complete adjuvant is 
often used for production of antibodies in laboratory animals because this adjuvant 
meets all these requirements. In 1993, before the 'Code of Practice for immu nization 
of laboratory animals' (Veterinary Public Heallh Inspectorate, 1993) was issued in 
the Netherlands, 64% of the researchers used Freund's adjuvant for routine 
immunizations and in 1995 two years after publication, still 52%, albeit more 
selective and sometimes in adapted protocols. FCA consists of a non-metabolizable 
mineral (paraffin) oil and heat-killed Mycobacterium butyricum or Mycobacterium 
tuberculosis and can induce, besides effective immune responses, severe side 
effects. These side effects include fibrous adhesions and sterile peritonitis after 
intraperitoneal injection and ulceration, sterile abscesses, and focal necrosis after 
subcutaneous injection. 
Growing public concern about the use of animals for research, is leading to new 
and stricter regulations; the use of FCA is or will be restricted in several countries 
because of its severe side effects. In the Netherlands, restrictions on the use of FCA 
were given in the 'Code of Practice for immunization of laboratory animals' 
(Veterinary Public Health Inspectorate, 1993). Selection of less toxic adjuvants 
became necessary. Various adjuvants, which might serve as an alternative, are 
available. However, adequate selection of an alternative to FCA is difficult because 
sufficient combined information on antibody responses and side- effects of these 
alternatives is usually lacking. 
Aim of the study 
The aim of the studies presented in this thesis was to compare FCA and several 
commercially available adjuvants on immunopotentiating properties and side effects, 
providing a basis for recommendations on the use of adjuvants in immunization 
procedures and ultimately reduce pain and distress in immunized animals. 
Introduction to the chapters 
In this study, emphasis is put on the evaluation of adjuvants to reduce pain and 
distress in immunized laboratory animals. Besides the adjuvant, other factors 
contribute to, or even determine, efficacy and side effects of an immunization. Such 
factors include: antigen type and dose, site of injection, scheduling of immunizations 
in time, genetic make-up and animal species. In Chapter 2, factors influencing the 
final result of an immunization are described. Chapter 2 may serve as a toolkit to 
10 
Chapter 1 
optimize in vivo immunizations of laboratory animals to generate antigen specific 
antibodies. 
Adequate selection of an adjuvant is not possible from the literature overview in 
Chapter 2. Consequently, we conducted a comparative study in rabbits (Chapter 3) 
to obtain information on efficacy and side effects of commercially available 
adjuvants. FCA ('gold standard') and three commercially available adjuvants 
(Specol, TiterMax, RIBI) were evaluated in one study for their efficacy and side 
effects after injection in combination with three weak immunogens. Efficacy was 
evaluated based on specific antibody production and side effects on clinical, 
behavioural and pathological changes in those rabbits. 
Rabbits are used for the production of polyclonal antibodies, whereas mice are 
the prime donors of B cells for preparation of monoclonal antibodies. Therefore we 
also wanted to study efficacy and side effects of adjuvants in mice. Special attention 
is paid to our observation in Chapter 3, that minimal clinical signs of pain were 
observed while pathological lesions were severe. In Chapter 4, behavioural studies 
were performed in mice to be able to detect possible painful side effects. Besides 
FCA, Specol was also studied in mice since pathological changes in rabbits were 
minimal and antibody responses were comparable to those observed after 
immunization with FCA. In this study, also two experimental adjuvants (Lactobacillus 
strains and ISCOMs) were tested. 
In view of the surprising results that immunization with effective adjuvants did not 
lead to severe pain (note that pathological changes are found), we looked at the 
side effects of adjuvants in a more detailed study (Chapter 5). Additional behavioural 
and pathological stUdies were performed to assess adjuvant-induced side effects. 
Besides specific antibody production, other parameters can be used to analyse 
adjuvant efficacy. To study the efficacy of adjuvants in mice in more detail, we 
compared FCA with four commercially available adjuvants (Specol, TiterMax, RIBI, 
Montanide ISA50) with respect to the quantity and the quality (isotype distribution 
and cross-reactivity with native protein) of the induced antibodies and to cytokine 
production (Chapter 6). Also side effects were evaluated in this study. Isotype 
distribution of antibodies and cytokine profiles after adjuvanUantigen injection were 
compared to study their correlation. 
Since cytokines are thought to be the primary regulators of the immune response, 
cytokine profiles generated directly after immunization may give information on the 
outcome of an immunization. By selecting an adjuvant based on cytokine profiles 
rapidly after immunization, the duration of potential pain and the number of animals 
used for immunization, can be decreased. In Chapter 7, the possibilities to predict 
the result of an immunization, based on early (within hours) cytokine production, is 
described. 
Knowledge of the mode of action of adjuvants can help in predicting the outcome 
of an immunization and therefore help in selecting the most appropriate adjuvant for 
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a specific purpose. The mode of action of many adjuvants is not yet completely 
elucidated. It is generally thought that macrophages, which take up particulate 
matter, are important in the enhancement of the immune response by adjuvants. By 
making use of a well-established macrophage elimination technique, we showed 
that macrophages indeed playa role in the induction of the immune response with 
water-in-oil emulsions, but that this can be a suppressive role (Chapter 8). This 
suppressive role of macrophages was confusing in the light of presumed 
macrophage involvement in adjuvant efficacy of water-in-oil emulsions. 
Consequently, we developed a new method (Chapter 9) to label the oil phase of 
water-in-oil emulsions with a lipophilic fluorescent dye (Oil) and studied oil 
distribution. After injection of water-in-Iabeled-oil emulsion in mice, localization of 
emulsion in lymphoid organs, with emphasis on macrophage uptake, was studied. 
We could show that only a fraction of antigen containing oil emulsion ends up in the 
(suppressive) macrophages, thereby possibly explaining the efficacy of water-in-oil 
emulsions i.e. by keeping the antigen away from macrophages which would degrade 
it and take it away from the immune system. 
Chapter 10 presents a general discussion on the main points emerging from the 
experimental work. Antibody responses and side effects induced by FCA and 
alternative adjuvants are assessed. Finally, recommendations are given on the use 
of adjuvants for antibody production in rabbits and mice to support guidelines for 
immunization of laboratory animals. 
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Antigens and antigen presentation 
P.P.A.M. Leenaars, E. Claassen, W.J.A. Boersma. 
In: Immunology Methods Manual, I. Lefkovits (Ed.), Academic Press Ltd., 
London, 1997,pp.989-1013. 

Chapter 2 
Introduction 
Antigens are those structures which the immune system recognizes as non-self. To 
achieve recognition and subsequent immune responsiveness the antigen has to be 
presented to the immune system in such a way that it is recognized in a form most 
suitable for elimination of the antigen. An antigen in this context is any substance 
that is recognized by antigen-specific structures of the immune system: antibodies, T 
cell receptors. Antibodies can bind to unmodified antigens as well as to fragments 
and degradation products thereof. For recognition by T cells, antigens have to be 
degraded to peptides, which complexed with MHC molecules are recognized by T 
cell receptors. Recognition by the immune system is a prerequisite for an antigen to 
elicit a response. Molecular structures that can elicit an immune response are called 
immunogens. Although almost any substance can be recognized as an antigen, the 
immunogenicity of a substance is determined by the intrinsic properties of the 
antigen: source, nature, structure, complexity, and size (Table 1). 
Table 1. General features influencing immunogenicity of antigens 
Parameter Immunogenicity 
Source 
Chemical nature 
Size 
Complexity' 
xenogeneic > allogeneic > syngeneic > autologous 
protein > polysaccharide > lipid 
high mol w1 > low mol w1 
complex > simple 
lmultiple antigenic/immunogenic molecules 
Nevertheless, exactly what determines the capacity of a structure to induce an 
immune response (immunogenicity) and to be recognized by an antibody is a 
subject of discussion (Hopp, 1986; Van Regenmortel, 1986, 1989; Boersma et al., 
1993). 
Here we will discuss antigens and their properties in in vivo immunization for the 
generation of immunodiagnostic reagents and in vaccine applications, with 
emphasis on induction of humoral immunity. 
The recipient organism 
In immunization and vaccination procedures most attention is usually focused on the 
properties of the antigen; however, the immune status of the immunized individual is 
also a decisive factor. The slow development of the immune system in young 
individuals, as the decline of the immune system in old individuals, determines the 
quality of an immune response. In newborns circulating maternal antibodies which 
form complexes with the antigen may have enhancing as well as inhibiting effects on 
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the immune responses dependent on antibody/antigen ratios. In young individuals, 
in general the response to (lipo )polysaccharides develops more slowly than 
responses to proteins; in a sense young individuals (mouse, man) are partly 
immunodeficient wilh respect to these antigens. In addition, protocols for intentional 
immunodeficiency induction (transplantation, malignancies), natural immuno-
deficiency by superinfection (HIV) have a strong negative influence on immune 
responses. 
Furthermore, genetic factors as sex, MHC haplotypes, and intrinsic low or high 
respondership may playa role in the outcome of an immunization procedure. 
Antigen presentation 
On the surface of cells, MHC molecules are expressed of which the function is to 
present auto-antigens and foreign antigens to potential responder cells with an 
immune surveillance function. Immunological antigen presentation is effected via 
two distinct routes. (1) For endogenous antigen presentation, intracellular proteins 
and therefore also viral proteins, for example, are expressed and processed in an 
active turnover process. As a consequence, peptides and fragments generated in 
this process are brought to the cell surface mainly bound to class I MHC molecules. 
There the complexed fragments are recognized by class I-responsive T cells (mainly 
COB T cells; cy1olysis, suppression). (2) Exogenous antigens can be taken up by 
complex sequences of events leading to transfer of antigen to the cy10plasma (e.g. 
phagocy1osis, pinocy1osis). Alternatively antigens which are recognized by surface 
immunoglobulins can be taken up directly in B cells. Antigens which are complexed 
with circulating antibodies can be bound via Fc receptors. In all cases an antigen 
processing pathway, different from that for endogenous molecules, is followed for 
digestion of antigens. After antigen processing, the antigen fragments are presented 
to the immune system in the context of MHC class II surface molecules. This form of 
presentation elicits a response mainly of C04 T cells (T cell help, delayed type 
hypersensitivity (OTH)). So-called professional antigen-presenting cells (APC) apart 
from B cells include dendritic cells and macrophages. 
The main functions of activated T cells are: (1) cell mediated responses which are 
mainly direct cy1otoxic responses to cells expressing specific antigens (in MHC 
bound form) and can be performed by C04 and COB type T cells, (2) T cell help (Th) 
for B cells. Th1 and Th2 cells are each able to generate different sets of cy10kines to 
modulate immune responsiveness of other cells. T and B cells interact not only via 
recognition of antigen by antigen receptors but also via mutual recognition of series 
of activation markers, i.e. receptors and ligands expressed on the surface, as 
discussed for C040 and C040 ligand by Laman and de Boer (1997). As a result, 
some antigens upon recognition will lead to production of other antibody isotypes 
than others. Also, the response of monocy1es and macrophages in a OTH response 
is orchestrated by Th cells. 
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Primary immunization and memory 
Primary immunization and vaccination aim at introduction of antigens so as to evoke 
an optimal immune response and to generate memory formation for secondary 
responsiveness. For antibody responses, priming generally leads to strong 
responses of IgM isotype and low levels of antibodies for which class switching is 
required (lgG, IgA, IgE). For class switching and memory formation, the activation of 
either Th1 or Th2 cells is necessary. 
In general, expression of isotypes other than IgM in a primary immune response 
is low. After a second encounter with the same antigen, the isotype will be 
expressed mainly which is related to antigen and immunization conditions as 
discussed below. In the secondary or booster reaction both the quantity (level) as 
well as the quality of the response is enhanced (higher affinity, specific isotype). 
Specific antigenic properties may lead to specific isotype expression in immune 
responses (Table 2). In general, IgG will be elicited with (glyco)proteins, when the 
antigen is presented to the peripheral immune system. In human and mouse, the 
major isotype produced in response to proteins is IgG1. IgG3, apart from bacterial 
infections where polysaccharide playa role, in general is low in mice and in man. In 
man, in addition, IgG4 is relatively low. Isotype induction is dependent on nature of 
the antigen, route of introduction, and the formulation in which the antigen is 
introduced. When similar antigens are presented to the immune system via the 
mucosal surface, the resulting isotype will be IgA. IgE is mainly induced by parasitic 
(surface) antigens which locally may act like allergens. Allergenic responses to other 
harmless antigens are also of the IgE isotype. Antigen-lgE complexes lead to 
activation of effector cells. 
DTH reactions are in general developed to all protein antigens when introduced in 
low concentrations in the skin, where specific antigen-presenting cells (Langerhans 
cells, interdigitating cells) will take them up and migrate to the draining lymph nodes 
to activate specific T cells. The recruited effector cells are mainly monocytes and 
macrophages. DTH reactions can also be elicited with more complex and particulate 
antigens (such as xenogeneic erythrocytes, dead micro-organisms). 
Memory T cells playa pivotal role in the elicitation of secondary responses. In 
secondary responses mainly that isotype is expressed for which T help (Th1rrh2) is 
provided. Memory T cells as well as memory B cells formed as a result of the 
priming immunization allow the immune system to respond more vigorously and 
more rapidly in a secondary or booster response. 
T- independent antigens 
Binding of antigen fragments to class I or class II MHC molecules is observed for 
proteins. Other antigens, such as polysaccharides and lipids, do not follow the 
antigen presentation pathways as described above. As a result they generally do not 
activate T cells and are therefore called T-independent antigens. The consequence 
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is that these antigens in general do not lead to immune responses of other isotypes 
than IgM and in part to IgG3 (mouse) or IgG2 (man). T-independent activation of B 
cells in general occurs with polymeric antigens that are cross-linking surface 
immunoglobulins (for review see Laman and Claassen, 1995; Van den Eertwegh 
et al., 1992). Memory formation, affinity maturation as well as germinal center 
formation, is absent. To elicit IgG responses to this category of antigens, the 
conjugation to T-dependent antigens (proteins) is necessary. 
Table 2. General antigen categories and induced response 
MHCI MHCII 
Antigens pathway pathway Isotype 
Soluble 
Protein + IgG1 > IgG2(a,b)>> 
IgG3> (lgG4), IgE 
Polysaccharide +1- IgM/IgG3 > IgG2a,b (mice) 
IgG2 (human) 
Lipid 
Particulatelcomplex 
Dead Complex' + antigen dependent 
Micro-organism + antigen dependent 
Live Intracellular 
virus + + IgG1, (mice) 
IgG1, IgG3 (human) 
parasite (+) +, DTH IgG, IgE (mice) 
IgG1, IgG3, IgG4, IgE (human) 
bacteria (+) + IgG1/1gG3 (mice) 
IgG111gG2 (human) 
Extracellular 
virus + IgG1 (mice) 
IgG1, IgG3 (human) 
parasite + IgG, IgE (mice) 
IgG, IgE (human) 
bacteria + IgM, IgG2a/lgG3 (mice) 
IgM, IgG1/1gG2 (human) 
iSee Table 1. 
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/sotypes of antibody and Fc receptors 
Antibodies of different isotypes have specific roles in protective immune responses. 
Binding to Fc receptors may facilitate the opsonization of micro-organisms and 
mediates antibody-dependent cellular cytolysis. Complement binding to the Fe part 
is of importance for activation of the complement system. Fc parts of IgG2a and 
IgG2b (in mouse) and IgG1 and IgG3 (human) have complement binding sites. 
These isotypes are therefore most effective in protection against viruses and other 
pathogens. 
Antigens: source, chemical nature, size 
The immune system of an organism reacts against any foreign compound (antigen) 
which crosses the defense lines of epithelia and skin and in general is tolerant 
(unable to react) towards its own body components, which may be immunogenic in 
other organisms. The intensity of an immune response is directly related to the 
degree of foreignness. The greater the phylogenetic distance between donor animal 
and the animal to be immunized, the better the immune response that it evokes (see 
Table 1). It is likely that in those cases peptides will bind to MHC molecules which 
are distinguishable from self peptides. 
Antigens include substances as structurally diverse as proteins, polysaccharides, 
lipids, and nucleic acids. Most effective as immunogens are molecules which display 
diverse chemical and structural characteristics. Natural immune responses are 
directed mainly to proteins, glycoproteins, lipoproteins, lipopolysaccharides, and 
carbohydrates as part of the defense to infectious or invasive agents. 
Proteins are synthesized as long, flexible polypeptide chains that assume a 
unique three-dimensional shape. Proteins are either rod-like fibrous (structural) 
proteins or globular proteins. Both structures are unfolded or denatured by extremes 
of pH and temperature and by high concentrations of dissociating agents (e.g. urea, 
guanidine, and sodium dodecyl sulphate), whereas more subtle alterations in 
conformation can be engendered by suitable modification of the amino acid side-
chains. In general, these alterations in conformation, especially for structure-related 
determinants, are associated with changes in the antigenic reactivity. 
Antigens with a low molecular weight are in general not immunogenic. These so-
called haptens may be small organic structures or short synthetic peptides which 
consist of a B cell epitope only. They may evoke immune response only when 
coupled to potent immunogens, e.g. proteins which provide the necessary T cell 
epitopes. The minimal molecular size required for immunogenicity can be debated. 
In principle the antigen needs at minimum one T cell epitope to be included, which 
may be expected in proteins/peptides which are of a size over 2-5 kOa. 
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(Glyco )proteins and (Ii po )proteins dependent on the route of introduction and the 
adjuvant applied lead to T cell responses directed towards the protein backbone as 
well as antibody formation of isotypes other than IgM. 
Polysaccharides exist in the capsules of bacteria, or may occur as 
lipopolysaccharides as part of the cell walls of Gram-negative bacteria. Purified 
polysaccharide antigens can serve as immunogens in certain species (e.g. mice and 
humans) but not in others (e.g. rabbits and guinea-pigs). Microbial polysaccharides 
are located on the cell surface and are, therefore, of importance in recognition and 
immune responses of a higher organism to microbacterial infection. Complex 
lipopolysaccharide antigens are found in a large variety of micro-organisms, notably 
in Gram-negative bacteria. As they are largely T-independent, responses to 
(Iipo)polysaccharides are mainly of the IgM isotype. Dependent on local antigen 
presentation, specific IgG isotypes (lgG3 in mouse) and IgA may be elicited. Pure 
lipids are not immunogenic. Coupled to proteins, they may act like haptens. Also, 
glycolipids such as cardiolipin may become immunogenic after binding to a carrier. 
Role of physicochemical properties of antigens 
In antibody responses the influence of physical parameters of the antigens is 
predicted in part based on common-sense reasoning. Antigenic sites of intact 
proteins are accessible to large molecules, like antibodies, only when exposed on 
the outside of a protein. Hydrophilic sequences readily soluble in aqueous solutions 
are thus most likely to be antigenic. Flexibility might enhance the fitting of antigen 
and antibody (Westhof et al., 1984; Karplus and Schulz, 1985; Fieser et al., 1987) 
and hence segmental mobility of the epitope may enhance antigenicity (Novotny et 
al., 1986). Loops of the protein may stick out from the globular form of a protein and 
as a result they may be more readily be engaged In binding to a circulating antibody 
(Ky1e and Doolittle, 1982). Synthetic peptides forced into a loop were shown to have 
an enhanced affinity for preselected antibodies (Jemmerson and Hutchinson, 1990). 
Methods have been developed to describe the tendency to form secondary 
structures: a-helix or p-sheet or p-turns (Chou and Fasman, 1978; Garnier et al., 
1978; Hopp and Woods, 1981; Emini et al., 1985). A relative value is attributed to 
each amino acid which represents its ranking in terms of hydrophilic behaviour 
(Hopp and Woods, 1981; Ky1e and Doolittle, 1982). The 'surface seeking' tendency 
or affinity for the membrane interior was computed by Eisenberg et al. (1984a, b). 
Normalized hydrophobicity values have been specially developed and adapted for 
the prediction of transmembrane sections of proteins which function as membrane-
spanning transport proteins (Eisenberg et al., 1984a,b). The mean value for a 
number of these physicochemical parameters, combined in an antigenic index, gives 
an estimate of the antigenic properties (index) of a protein segment (Wolf et al., 
1988). Amino acids exert mutual influences over short distances (Bangham, 1988). 
In addition, amino acid sequences which, on a linear scale, are at great distance 
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may interact by forming backfolding loops. It is of great importance to take this into 
account when choosing the length of peptides used for immunization (Jacob et al., 
1986; Horiuchi et al., 1987). 
Antigen complexity 
Antigens may be divided into two groups: particulate complex multi-antigens and 
single antigens. The group of particulate complex antigens includes intact micro-
organisms like bacteria, viruses, parasites, protozoans, and mammalian cells, but 
also artificial particles (e.g. poly(lactic acid) derivatives). Antigen presentation of 
particles generally follows the class II MHC pathway in specialized phagocy1ic cells. 
Polyclonal responses are directed to all constituents. Antigens which consist of one 
molecular species which include proteins, peptides, polysaccharides, glycolipids, 
oligosaccharides, haptens, and nucleic acids, evoke polyclonal responses to the 
various intra-antigen epitopes present. Immunodominance of specific determinants 
may lead to overrepresentation of specific responses. 
Responses to dead micro-organisms follow in general the profile for particulate 
antigens. For live micro·organisms, antigen presentation is dependent on the 
character of the organism. Invasive micro-organisms may become intracellular 
parasites to which In general DTH responses are directed (class II). More recently 
the involvement of r/& CD8 cells together with alII CD4 Th1 and Th2 cells has been 
substantiated (Kaufmann, 1995). Viruses which infect cells are processed as class I 
MHC restricted antigens. 
Isotypes of antibody responses to micro·organisms are dependent on the 
structure of surface molecules and other constituents; e.g. for bacterium Brucella 
abortus, IgG2a, IgG3 (Snapper and Mond, 1993). For nematode parasites, IgG1 and 
IgE restricted responses were observed (Snapper and Mond, 1993). 
When antigens are presented to the mucosal immune system, the uptake of soluble 
antigens takes place mainly via the endothelial cells of the mucosa, which then 
produce cy10kines to enhance the specific immune response. Particulate antigens 
are generally taken up by the microfold cells (M-cells) of the Peyer's patches and 
are presented there to the resting naive cells. Toxins and micro-organisms may 
have specific receptors on cells along the mucosal lining. These mostly pathogenic 
agents do encounter the immune system each in their specific way. 
Antigen construction and preparation 
The specificity of the immune response obtained (antiserum, T cell response) is 
dependent on the purity of the antigen applied. Minute impurities «1 'Yo) may prove 
to be Immunodominant, as is the case with many bacterial antigens. This is a 
problem encountered with any antigen produced via recombinant DNA techniques 
and not marked with special tags for identification. In that case the selection of 
specific monoclonal antibodies may lead to specific reagents. Alternatively, the 
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antigen may be synthesized. This, however, is only sensible for small peptides «50 
amino acids) and other low-molecular-weight substances. 
Synthetic antigenic determinants have a wide variety of applications. The actual 
role of a determinant can best be judged from the results of immunizations, e.g. the 
antibody responses in sera, the recognition of antigenic determinants by antibodies 
in various immunoassays, each with its typical micro-environmental conditions, and 
the specificity of the mAbs selected. Certainly for short peptldes and haptens, 
polyclonal antibodies tend to be determinant-specific (monospecific) since they 
recognize one or a few more extensively overlapping determinants in a short 
sequence. Such pAbs may differ slightly in epitope specificity and thus may show an 
in-assay behaviour similar to that of mAbs. 
Haptens in general are small rigid molecules which are recognized independent 
of the conditions of assays. In general, short peptides tend to elicit antibodies which 
recognize the denatured form of the protein only (Boersma et al. 1988a). Application 
of short peptides therefore may be of advantage for the elicitation of antibodies to be 
used in assays where the antigen is encountered in denatured form e.g. in SDS-
PAGE, fixed tissue specimens etc. (Van Denderen et al., 1989, 1990). In contrast, 
Dyson et al. (1985) showed that an immunogenic nona-peptide which showed a 
preferential conformation in aqueous solutions, elicited anti-native antibodies to 
heamagglutinin of influenza virus. Ultrastructural analysis showed that longer 
peptides indeed tend to mimic the native structure of a protein much better since 
these peptides maintain a specific space filling structure (Horiuchi et al., 1987). 
An important clue to the successful use of haptens and peptides (SP) as 
immunogens is the mode of presentation of the selected antigens to the immune 
system. Using these small antigens, the construct applied is usually an assembly 
consisting of a carrier protein, a hapten or peptide and bridging coupling reagents 
(for review see Boersma et al., 1993). 
Antigen carrier 
Antigens which in themselves do not contain elements for T cell activation (small 
peptides or polysaccharides) need a protein-carrier which provides these elements 
(T cell epitopes). 
The properties of a carrier protein determine to a large extent the outcome of 
immunizations with the conjugated antigenic determinant, e.g. haptens and small 
peptides. Larger proteins (>60 kDa) are preferred as carriers because they contain a 
sufficient number of -NH2' -SH, arginine, etc., groups for coupling to generate 
satisfactory determinant/protein ratios. In principle most proteins will suffice as 
carriers if derived from a non-self source. However, the more genetically distant a 
protein is from the animal to be used for immunization experiments, the better the 
chances for potent immunogenicity. Keyhole limpet haemocyanin (KLH), a large 
aggregated protein from a gastropod, is therefore often used as a carrier protein in 
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mice, rabbits, goats, and sheep. Other widely used carriers are of bacterial origin: 
tetanus toxoid (TT), purified protein derivative of tuberculin (PPD), and diphtheria 
toxoid. Less efficient in mammals are ovalbumin (OVA) and bovine serum albumin 
(BSA) (Geerligs et al., 1989), probably because of tolerance to these highly 
conserved proteins. Chicken gamma-globulin (CGG) is rather immunogenic in mice. 
However, coupling of relatively large numbers of determinants, depending on the 
protein, can have a negative influence on the properties of a conjugate. Overloading 
may lead to precipitation and decreased immunogenicity (Peeters et al., 1989). Also, 
cross-linking agents such as diazo compounds and glutaraldehyde may drastically 
decrease the solubility and immunogenicity of a carrier-determinant conjugate. 
For non-immunogenic peptides, (e.g. B cell epitopes only) and haptens, coupling 
to a carrier protein to provide T cell help is required. This is not a matter of molecular 
mass since immunogenicity of peptides is in general not increased by 
homopolymerization with, for example, glutaraldehyde (Boersma, unpublished 
results). Polymerization using carbodiimides led to encouraging results, though in 
part based on the coupling of T-determinants (Borras-Cuesta et al., 1988). 
Straightforward covalent elongation with a selected T cell determinant is an 
alternative option (Hackett et al., 1985; Francis et al., 1987; Zegers et al., 1993). 
A method has been developed for the synthesis of branched peptides or 
multiantigen peptides (MAP) (Tam and Zavala, 1989). This multiple antigen peptide 
method was developed for sensitive detection of anti-peptide antibodies, but in 
addition the multimeric peptides show enhanced immunogenicity compared to free 
peptides, peptide conjugates, or peptides still attached to their solid support 
(McLean et al., 1991). MAP which include a specific T cell epitope may function as 
efficient immunogens. 
Admixture of T cell epitopes and B cell epitopes under specific conditions may be 
sufficient for T cell and B cell activation. Such conditions can be found in water-in-oil 
emulsions and in liposomes. There the orientation of epltopes, dependent on their 
amphipathic character, may be such that they are presented so that T-B cell 
interaction is possible (Sarobe et al., 1991; Partidos et al., 1992; Prieto et al .. 1995). 
Immunization procedures 
Besides the immunogenicity of the antigen, a large number of parameters influence 
the result of each immunization: (1) the site at which the antigen is introduced; (2) 
the dose of antigen; (3) the scheduling of immunizations over time; (4) the type of 
adjuvant applied; and (5) the genetic make-up of the recipient (discussed above). 
These parameters determine which antigen-presenting cells the antigen meets first, 
how many and which cells will be involved in the response, as well as the quantity of 
the response (Tables 2 and 3). 
The location at which the antigen is deposited in part determines the lymphoid 
organs activated and the isotype of the antibody response. For detailed description 
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based on histocytochemical analyses, see Laman and Claassen (1995). Routine 
immunizations, intraperitoneal (in mice) and subcutaneous (in rabbits and mice), 
rapidly deposit antigen mainly in spleen and peripheral lymph nodes. Soluble 
antigens injected intravenously (in the tail vein or retro-orbitally) also rapidly end up 
in the spleen. 
Oral application in general leads to induction of tolerance. For effective immune 
responses (lgA) antigen presentation requires a vehicle which may either be a 
micro-organism, a particle of specific size (1-10 11m), or a toxin. Application of 
antigen via the lungs (intratracheally) will in general follow the same rules as for oral 
application. Nasal application may efficiently lead to IgA induction. 
Deposition of antigen at subcutaneous, intracutaneous, or intramuscular sites will 
in general lead to slow release of the antigen into the immune system. This slow 
release generally leads to continuous stimulation and strong immune responses. 
Leenaars et a/. (1994) studied the effect of s.c. injeclion of a volume of FCAlantigen 
(0.5 ml/rabbit ) in one injeclion site compared to the same volume spread over 2 or 4 
injection sites. Similar antibody responses were observed, for both immunization 
procedures, suggesting that dividing antigen over more sites does not increase the 
antibody response. 
How the route of antigen administration controls the nature and intensity of the 
response is not known. Antigen-presenting cells (APC), different lymphoid tissues 
and the special characteristics of the regional immune system play an important role 
in the induction of the response. De Becker et a/. (1994) showed that the isotype 
and the amplitude of the B cell response can be regulated by the nature of the APC. 
The antigen presented by dendritic cells induces the production of Th1-dependent 
isotypes (lgG2a), whereas an antigen pulsed on peritoneal macrophages seems to 
induce a Th2-associated response (lgG1, IgE). The route of injection determines 
which APC comes in contact with the antigen. The route of injection is limited by the 
form of the antigen. Insoluble antigens cannot be immunized intravenously. In order 
to waste little of the antigen in the periphery, the antigen can be directly applied 
locally in the spleen either free or attached to a vehicle (nitrocellulose, sepharose 
beads). Owing to reduction of antigen loss in the circulation, doses 50-100x lower 
than normal could be used on intrasplenic immunization (Spitz, 1986; Hong et al., 
1989). Certain immunogens, when injected parenterally, lead to the production of 
circulating antibody; when given intradermally, the same immunogen in relatively low 
doses may provoke delayed-type hypersensitivity in the absence of circulating 
antibody. 
Peptides which appear to be low immunogenic upon routine i.p. or i.v. 
immunization may be immunized locally to sensitize peripheral lymph node cells. In 
the mouse, immunization in the footpad or subcutaneously in the back may very 
efficiently activate regional lymph nodes when strong adjuvants are applied 
(Freund's adjuvant). 
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Table 3. Immunomodulation by adjuvants 
support support 
Effect on antigen MHCI MHCII Isotypes 
Function presentation Adjuvant presentation presentation Cytokines (mice) 
Vehicle localiza~on, - inert beads + IgG1/lgE 
enhanced uptake _ mineral salts 1 +, poor DTH IL-3,IL-4, IgG1/lgE 
IL-5, IL-6' 
8 oil emulsions2 +,DTH IL4 IgG1/lgE 
Depot slow release - mineral salts +, poor DTH IL-3,IL-4, IgG1/lgE 
IL-5, IL-6 
- oil emulsions +,DTH IL-4 IgG1/lgE 
Micelle induction enhanced uptake -liposomes3 + + IgG1/lgG2a,2b 
-ISeOMs' + + IgG1/lgG2a,2b 
Macrophage activation enhanced uptake _NBps +,DTH IgG2a,2b 
-DDA' +,DTH IgG2a,2b 
- microbial products' +,DTH IFN-y,IL-4 IgG2a,2b 
- oil emulsions +,DTH IL-4 IgG1/lgE 
Direct B cell activation - microbial products +,DTH IFN-y,IL-4 IgG2a,2b 
Growth/differentiation of B cells - cytokines' 
IL-1 
IL-2 IL-2 IgM 
IFN-y +,DTH IFN-y IgG2a 
'Nicklas, 1992; 'Soersma ef al., 1992 'Suiting ef al., 1992; 'Claassen and Osterhaus, 1992; 'Hilgers and Snippe, 1992; 
'verheul and Snippe, 1992; 'Warren ef al., 1986; 'Heath and Playfair, 1992; 'valensi ef al., 1994. l!;l 
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Antigens and antigen presentation 
Targeting of antigens to certain molecular structures on cells is a form of specific 
routing of antigen. For peptides, enhanced responsiveness has been shown to 
occur by targeting of these peptides to surface immunoglobulin or class I molecules 
(Casten, 1988). For BSA, Lees et af. (1990) showed that especially targeting with 
anti-lgD led to strong potentiation of antibody responses. Immunological targeting to, 
for example, MHC molecules acts as a replacement of adjuvant in that it targets the 
antigen and at the same time acts to activate the antigen·presenting cells. To this 
end, MHC-specific antibodies have been applied (Carayanniotis et af., 1988; 
Carayanniotis and Barber, 1990). 
Dose of antigen 
Immune responses are antigen dose-dependent. For most antigens an optimum is 
found in the dose-response relationship. A low dose induces the formation of small 
amounts of antibodies with relatively high affinity and specificity. Weak responses 
may be enhanced by coadministration of adjuvants (see below). The order of 
magnitude of optimal doses do not differ among various animals. For vaccination in 
humans, for most antigens 1-50 fJg of antigen is administered. Similar optimal doses 
are found in cattle and small laboratory animals. For T-independent antigens, about 
20 fJg intravenously. or intraperitoneally is sufficient in mice (Laman and Claassen, 
1995). 
Studies of immunologic tolerance illustrate that a very low or a very high dose of a 
foreign material can inhibit future responses to subsequent injection of an otherwise 
immunogenic dose. 
Proteins with specific routes of entry into the immune system (e.g. toxins) may 
elicit immune responses in extremely low doses: 10.14 g for endotoxin in rodents. In 
general, doses of a few fJg are sufficient for an efficient priming reaction. This shows 
that low antigen doses may efficiently stimulate T cells and that immunological 
memory may be induced by doses that do not produce detectable antibody 
responses. DTH reactions to specific antigens are evoked at lower doses than are 
needed for antibody responses to the same antigen. 
Functions of adjuvants 
When antigens are poorly immunogenic the immune system needs a stimulus to 
evoke a response. Adjuvants are used for this purpose. Adjuvants are simple or 
complex admixtures (natural or synthetic) of compounds which upon administration 
to individuals lead to an aspecific immune stimulation (Tables 3 and 4). The route of 
administration determines the localization. In addition, adjuvants often also function 
as the vehicle which takes care of localization of the antigen. Specific localization 
(intraperitoneal, intra- or subcutaneous, intrasplenal) of the antigen can be obtained 
by administration of antigen in water-in·oil or oil·in-water emulsions, antigen bound 
to or enclosed In liposomes, antigen bound or absorbed on to amorphous or 
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crystalline material as in alum hydroxide-phosphate gels, or with nitrocellulose or 
solid beads of various compositions. 
These immunizations have in common that the administration of antigen results in 
local immune responses. The surface area of the vehicle to which the antigen is 
attached determines the load and density of the antigen during antigen presentation. 
Vehicles convert soluble antigens into particulate material which is more readily 
ingested by antigen-presenting cells such as macro phages. Some vehicles such as 
alum and oil emulsions have immunostimulating (adjuvant) properties, while others, 
such as sepharose beads and nitrocellulose are relatively inert in an immunological 
sense. 
Table 4. Mode of action of adjuvants 
Category 
Mineral salts 
Oil emulsions 
Microbacterial 
producls 
Saponins 
Synlhetic 
producls 
Examples 
AI(OH)" AIPO,' 
FIA, Monlanide, Specai' 
LPS, MOP, MPL,TDM' 
QuilA' 
OOA5 
ISCOMs' 
Liposomes' 
Nonionic block polymer 
(NBP)' 
Mode of action 
- vehicle 
- depot-effect 
- vehicle 
- depot-effect 
- activation of macrophages 
- direct stimulation of B cells (LPS) 
- activation of macrophages 
- stimulation of T cells 
- activation of complement 
- enhanced antigen uptake 
- facilitate cell-cell interaction 
- aggregation of antigen 
- activation of macrophages 
- activation of complement 
- facilitate cell-cell Interaction 
- stimulation of T cells 
- aggregation of antigen 
- vehicle 
- enhanced antigen uptake 
- activation of macrophages 
- activation of complement 
Cytokines IL-2, IL-1I1, IFN·l - growth/differentiation T and B cells 
- enhanced antigen-presentation 
'Nicklas, 1992; 2Soersma at al., 1992; JWarren at al., 1986; 4Campbell and Peerbaye, 1992; SHilgers 
and Snippe, 1992; 6 Claassen and Osterhaus, 1992; lSuiUng at al., 1992; 6Verheul and Snlppe. 1992; 
'Heath and Playfatr, 1992. 
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Various adjuvants also offer a depot function. When deposited at a given site the 
antigen leaks slowly from the adjuvant compound and gradually becomes available 
for stimulation of the immune system. 
Adjuvants are foreign to the body and therefore depending on the natu re of the 
constituents, may in themselves be antigenic. If appropriately administered they lead 
to sterile inflammations that attract the various cells of the aspecific defense system 
-macrophages- which in turn produce immunomodulating factors that increase the 
level of immune surveillance. Macrophages as well as other antigen-presenting cells 
therefore play an important role in the generation of the adjuvant effect. Most 
adjuvants directly or indirectly stimulate the generation of interleukin-1 and also 
other factors that support growth and differentiation. 
In summary: adjuvants contribute to improved antigen presentation and 
immunomodulation; this is the true adjuvant function. The choice of the adjuvant is 
dependent on the type of antigen and on the desired immune response (cellular 
versus humoral). In vaccines adjuvants should preferentially enhance the immune 
response of all cell types involved in the process of generating protection. To this 
end, the stimulation of the antigen presentation, the T regulator cells (Th1 and Th2), 
the B cell, and effector T cells is most important. For the generation of antibodies as 
immunoreagents, the requirements of immune stimulation are less stringent. 
Properties of various adjuvants 
The exact way in which adjuvants stimulate the immune system is not always 
known. The properties of various adjuvant products are summarized in Tables 3, 4. 
Mineral salts 
Mineral salts consist of hydrated gels of aluminium hydroxide, aluminium phosphate, 
or calcium phosphate which form efficient vehicles to which proteins readily adsorb 
dependent on ionic strength and pH. The depot function is most prominent, whereas 
the immune stimulative capacity is weak. Mineral salts have the major drawback that 
they do not support cell-mediated immunity very well. The irritation caused suggests 
that these adjuvant function by local production of cytokines to activate antigen-
presenting cells. Their relatively harmless character led to approval of these 
adjuvants in humans by the US Food and Drug Administration and the World Health 
Organization. Local (e.g. vaginal) application led to humoral response induction 
without harmful side effects seen with other adjuvants. The effective depot function 
has led to combined use of mineral salts with other adjuvants such as micro-
organisms (Bordetella pertussis; Bomford, 1980). Aluminium compounds may be 
suited for antigens which are highly immunogenic and available in large amount, but 
they are not recommended when only weak immunogens (e.g. peptides, subunit 
vaccines) are used or when there is limited amount of antigen available. Compared 
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to other adjuvants, mineral salts are rarely used for experimental immunization of 
laboratory animals. 
Upon administration of aluminium salts in mice, Valensi et al. (1994) detected IL-
3, IL-4, IL-5, and IL-6 in serum 3-24 hours after Lm. injection, while IL-1ct, IL-2, IFN-
r, and IL-10 were measured but not detectable in serum. 
After primary immunization of mice with BSA in AI(OHla, Bomford (1980) found 
only antibodies of the IgG1 isotype, whereas during the secondary response an 
IgG1 and IgG2a response was stimulated by AI(OHh This was confirmed by Byars 
et al. (1991) who found, in contrast to several other adjuvants, that predominantly 
the IgG 1 isotype and only little IgG2a and IgG2b was produced. Haaijman et al. 
(1988) also found mainly IgG1 responses in BALB/c mice. It is suggested that this is 
of special importance when protective immunity is required, as antibodies of the 
IgG2a and IgG2b isotype act synergistically with complement and antibody-
dependent effector cells. Aluminium adjuvants are very efficient in enhancing the 
synthesis of IgE antibodies in rabbits and rodents. AIP04 does not induce IgE 
antibodies (Allison and Byars, 1986). 
Micro-organisms and microbial products 
Micro-organisms and microbial products can exhibit strong adjuvant activity. In 
general the bacteria are applied in heat-killed form and coadministered with the 
immunogen under study. Mycobacteria cause severe side effects (e.g. sterile 
inflammations and granulomas; Claassen et al., 1992). Mycobacterial cell wall 
products have been studied to obtain fractions with similar immune-stimulating 
properties but without severe side effects. Trehalose dimycolate (TOM, cord factor) 
was identified and found to have immunostimulating properties. The smallest subunit 
of the mycobacterial cell wall that still results in adjuvant activity is N-acetylmuramyl-
L-alanyl-D-isoglutamine, abbreviated as muramyl dipeptide (MOP) (Azuma et al., 
1976). 
Lipopolysaccharide (LPS) is the main surface structure of Gram-negative 
bacteria. The adjuvant activity of LPS was first described in 1956 by Johnson et al. 
(1956). Its high toxicity precludes its clinical use. Low toxicity analogues of LPS have 
been developed which retain their immunostimulatory properties. The lipid A moiety 
has received most attention in this respect, it can be prepared by chemical treatment 
of natural lipid A (Alving et al., 1984) or by chemical synthesis of lipid A (Yasuda et 
al., 1982). Monophosphoryllipid A (MPL) is an example of a lipid A derivative of LPS 
which retains all the immunostimulating properties of LPS (Gustafson and Rhodos, 
1992). 
Microbial products may lead to mitogenic activation of B cells (LPS), and 
activation of macrophages, T cells and the complement system (reviewed by Warren 
et al., 1986). Lipid A, as well as lipopolysaccharide, is hydrophobic, while lipid A is 
also amphiphilic. Administration of this adjuvant separately or together with antigen 
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leads to generation of cytokines. Most prominent is the production of I FN-y by 
natural killer (NK) cells. This cytokine in turn activates antigen-presenting cells such 
as macrophages. Activated macrophages generate tumor necrosis factor-a. The 
activation of antigen presentation and production of cytokines following the 
administration of this adjuvant switches the humoral immune response in the mouse 
to IgG2a (Takayama et a/., 1991). In the promotion of protective immunity against 
bacteria and viruses antibodies of the IgG2a isotype are considered to be superior 
owing to their complement fixation (Gustafson and Rhodes, 1992). Only few non-
pathogens can serve as adjuvant at the mucosal surfaces. Live Lactobacillus of 
various strains (casei, plantarum), can serve as adjuvants after intraperitoneal but 
also after oral administration (Boersma et al., 1994). Their efficacy using peptide 
antigens is relatively low. Peptides need to be coupled or produced at the surface by 
Lactobacillus to generate acceptable levels of immune responsiveness (Claassen et 
al., 1994, 1995a; Boersma et al., 1994). 
Combination of lipid A or lipopolysaccharide with nonionic block polymers or alum 
leads to a shift to IgG1 antibodies. The same effect can be obtained with 
recombinant IFN-y, which is much more expensive than LPS or lipid A and in 
addition cannot be applied to the sites where the local immune response is 
generated. LPS also stimulates cell-mediated immunity as measured by DTH. 
Preparations consisting of a mixture of components from a diversity of micro-
organisms have been shown to influence severely the traffic of lymphocytes within 
the mucosal immune system, thereby enabling immunization on site to support 
responses in other mucosaliocations also (Ruedi et al., 1993). 
The adjuvanticity of microbial products can be enhanced by mixing them with 
depot preparations of the immunogen (e.g. mineral salts, oil emulsions). The best-
known example is Freund's complete adjuvant (FCA). The side effects of FCA led to 
its being banned in various countries (see Claassen and Boersma, 1992; Claassen 
et a/., 1992). 
Toxins have been widely applied as immunological carriers with a high immune-
stimulating potential. Heat-labile toxin of E.coli, tetanus toxoid as well as cholera 
toxin are the best-known examples (Vajdy and Lycke, 1992). Simple coupling of 
peptides to these protein carriers leads to efficient immune response generation 
(Arnon, 1989). Cholera toxin is most investigated for its mucosal immune-stimulating 
character. Cholera toxin was shown to enhance the IL-1 production by 
macrophages. However, it inhibits T cell IL-2 production but enhances proliferation. 
In vitro enhanced IgA synthesis In lipopolysaccharide-stimulated B cells was 
demonstrated (Lycke et a/., 1989). 
Other microbial products which have been tested as adjuvants include the water-
soluble adjuvants from Nocardia species, yeast glucans, various peptidoglycans, 
and certain bacterial exotoxins (Munoz, 1964; White, 1976). 
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Water-in-oil emulsions 
Water-in-oil, reversed, and double emulsions with vaccines have been in use for a 
considerable time. Freund (1956) applied refined paraffin oil (Freund's incomplete 
adjuvant, FIA) with vaccines and since then this oil has been used as an adjuvant 
mainly for experimental purposes. Oil emulsions have a depot function, they can 
stimulate macrophages, and they promote uptake of antigen (Waksman, 1979). The 
depot function of oil emulsions is enhanced by intraperitoneal, subcutaneous, 
intradermal, or intramuscular administration. The most potent adjuvant known for 
stimulating both humoral and cellular immunity is a combination of an emulsion of 
mineral oil and killed mycobacteria (FCA). Adjuvants like FCA stimulate the immune 
response very effectively but can have dramatic side effects. As a result not all 
adjuvants are permitted for human use or for application in veterinary medicine. In 
addition in many countries guidelines on animal experimentation limit the use of the 
most potent adjuvants for ethical reasons. 
From the results of cytokine production, no skewing in either Th1 or Th2 response 
direction can be determined for this type of adjuvant. The mode of action relies on 
the enhancement of hydrophobicity of antigens, targeting to antigen-presenting 
cells, and on the presentation of antigens on a large surface area. The oil 
microspheres carry antigen to the surface of antigen-presenting cells. Endocytosis 
and presentation in the context of MHC class " is therefore expected (Boersma et 
a/., 1992). 
The antigen to which an Immune response has to be elicited is generally taken up 
into the hydrophilic phase. (Bokhout et al., 1981; Woodard and Jasman, 1985; 
McKercher, 1986; Woodard, 1990). 
Bokhout et al. (1981) first described Specol, a selected water-in-oil emulsion; its 
application has been evaluated in the prevention of future diseases by vaccination 
as well as in the enhancement of natural in vivo immune responses. This adjuvant 
was developed from their observation that vaccinated pigs were protected against 
pathogens not present in the vaccine. Specol certainly has advantageous properties 
with respect to animal care, ease and reproducibility of preparation and 
administration, and the use of constituents which generally are regarded as safe for 
use in animals. 
Although proliferative T cell responses and DTH reactions could be demonstrated 
with use of Specol, formal proof of the support of a cytolytic T cell response has yet 
to be produced. In contrast to most adjuvant admixtures, Specol can be prepared 
easily and highly reproducibly since all constituents can be obtained from the 
suppliers in quality-controlled batches. The low viscosity of Specol compared to 
many blends (FIA) facilitates administration by injection (Boersma et al., 1992). 
Water-in-oil emulsions activate macrophages, suggesting that the cytokine 
involved is most likely IL-1 (for review see Boersma et al., 1992). Recent 
experiments suggest induction of IL-2, IL-4, and IFN-y together with expression of 
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the T cell activation marker gp39 (Zegers et al. unpublished results). Most water-in-
oil emulsion evoke the production of IgG1 responses (Allison and Byars, 1991). With 
Specol in BALB/c mice, IgG1 responses were frequently observed. In the mouse, IL-
4 stimulates the generation of IgG1 and IgE while IFN-y is involved in the IgG2a 
responses (Finkelman et al., 1988a,b). 
Liposomes 
Liposome adjuvanticity is influenced by the charge, composition and the method of 
preparation. In vivo, liposomes act by facilitation of antigen uptake, ingestion, 
fragmentation, processing, and presentation, mainly by macrophages (for review 
see Claassen, 1991). The antigen is encapsulated in the water or lipid phase or can 
be coupled til the surface (for review see Buiting et al., 1992). Van Rooijen and Van 
Nieuwmegen (1980) showed that surface exposition of antigens is most efficient in 
antigen presentation. For peptides, the elongation with a hydrophobic tail 
(lipopeptides) enhances the uptake and correct surface orientation of the 
determinants of interest in a given antigen. As such, a liposome can be envisaged 
as a hapten-vehicle with a large surface. The repetitive presence of the determinant 
may lead to B cell activation (lgM responses). T cell dependent responses are found 
only when a T cell determinant is included in the antigen. The fusion of liposomal 
and endosomal membranes delivers the antigen essentially in the MHC class II 
processing pathway (Germain, 1986; Bevan, 1987). Liposomes seem to support 
primarily C04-dependent T cell responses (OTH, B cell help). Recently, activation of 
C08 cells in cytolysis (class I dependent) after application of antigen with pH-
sensitive liposomes has been documented. These liposomes introduce antigen in 
the cytoplasmic phase of antigen processing. However, questions with respect to the 
quantitative contribution of this route of processing based on liposomal delivery of 
antigen remain to be clarified. 
The potency of liposomes can be further increased by the inclusion of other 
immune-stimulating agents such as bacterial lipopolysaccharide, lipid A, MOP, and 
saponins. Targeting of liposomes using antibodies anchored in the membrane is 
controversial (Buiting et al., 1992). Liposome-associated proteins elicited IgG2a and 
IgG2b antibodies in the mouse (Phillips and Emili, 1992). Whereas MOP 
preferentially stimUlated IgG1 in their experiments, with a combination of liposomes 
and MOP a shift to IgG2 was observed. After oral application of pH-stable 
liposomes, Jackson et al. (1990) observed secretory humoral immunity (lgA). 
Humoral responses elicited with antigens presented in liposomes in general show 
response profiles similar to responses elicited with water-in-oil emulsions. 
Saponins 
Saponins are plant-derived, rather complex, glycoside-containing compounds which 
are amphiphilic in nature and tend to form micelles. The best-known example of a 
saponin adjuvant is derived from the bark of Quil/aja saponaria Molina. Quillaja 
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saponin is a mixture of potent adjuvants. Crude saponin extracts are unreliable. Quil 
A, one of the purified derivatives, is used as the basis for the formation of immune-
stimulating complexes (iscoms) (Dalsgaard, 1978; Morein, 1990). Together with 
cholesterol (mostly also phospholipids) Quil A tends to form particulate matrix 
structures with high adjuvanticity (ISCOM matrix). Though hydrophobic interaction, 
proteins can strongly complex with these structures to form immune-stimulating 
complexes, so-called ISCOMs (Llivgren and Morein, 1988). 
Saponins and ISCOMs promote a strong immunogenic enhancement most 
probably by direct interaction with cellular membranes. The role of macrophages in 
the effectiveness of ISCOMs has been described by Claassen et al. (1995b). Apart 
from humoral responses, saponins also seem to support CD8 (class I restricted) 
mediated cellular cytotoxicity (Newman et al., 1992; Campbell and Peerbaye, 1992). 
CD8 T cell effected cytolysis has been demonstrated which might be dependent on 
IFN-y production. The generation of IgG2a humoral responses in mice is indicative 
for this mode of action. It is not known how the induction of IFN-y is established. 
Saponins are toxic, and local depot-like administration may lead to necrosis. Oral 
immunizations of animals with ISCOMs have been only partly successful. Relatively 
high doses of antigen (100 I1g) were needed, but class I restricted responses were 
also demonstrated (with the antigen ovalbumin). The support of mucosal immune 
responses has been documented upon intranasal application of antigenslvaccines 
(Jones et al., 1988). Intravaginal responses have also been demonstrated but these 
required relatively high amounts of antigen (Thapar et al., 1991). For application via 
the oral route the induction of IFN-y is thought to be most important. This is in 
agreement with the antibody isotypes observed (Finkelman et al., 1988a). In mice, 
saponins stimulate production of IgG1, IgG2a, and IgG2b. The major part of the 
response is formed by IgG2a antibodies. IgE was not observed (Kensil et al., 1991). 
Quil A elicited mainly IgG1 in mice (Kenney et al., 1989), whereas IgE responses 
have also been reported (Allison and Byars, 1992). For those responses where 
elicitation of IgE has to be avoided (vaccination), the choice of adjuvant should be 
made carefully. 
With MHC class II targeting, enhanced responsiveness in humoral immunity was 
mainly restricted to IgG1-restricted isotype (70%), whereas about 25% was of the 
IgG2a isotype in mouse (Skea and Barber, 1993). 
Synthetic adjuvants 
Synthetic adjuvants are rather heterogeneous. The mode of action of nonionic block 
polymers (NBP) is not fully understood but the activation of the complement system 
as well as the activation of macro phages seems to play an important role. NBP have 
a low intrinsic toxicity. They are build from repetitive combinations of poly-oxy-
ethylenes and pOly-oxy-propylenes. NBP usually have an amphipathic character. 
They stabilize water-in-oil emulsions and thereby may stabilize the tertiary structure 
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of antigens as well. In contrast to most adjuvants studied, NBP have a strong 
adjuvant effect for poly- and oligosaccharides in particular, whereas for most 
proteins they are not as potent as many other adjuvants. The mode of action may be 
similar to that of lipid A since the predominant antibody response is IgG2a in the 
mouse, which is enhanced by IFN-y production. The isotype distribution is influenced 
by the balance between the proportions of hydrophobic and hydrophilic moieties in 
the NBP composition. CTl responses have not been documented, but it has been 
demonstrated that DTH responses are supported (for review see Verheul and 
Snippe, 1992). Owing to their partly hydrophilic and partly hydrophobic nature, NBP 
are readily usable with liposomes and water-in-oil emulsions. With SAF, the 
combination adjuvant which includes a muramyldipeptide analogue, a non ionic block 
polymer in a water-in-oil emulsion (Byars et al., 1990), a skewing of the response to 
IgG2a antibodies was demonstrated in mice which was attributed to the induction of 
IFN-y production (Th1 responses) (Kenney et al., 1989; Byars, 1990; Byars et al., 
1991). 
Dimethyldioctadecylammonium bromide (DDA) is a representative of a specific 
category of adjuvants, the quaternary amines. The lipophilic character of DDA, 
which forms liposome-like structures in aqueous solutions, might be responsible for 
its capacity to enhance T cell responses. However, most responses documented are 
DTH responses, which is a CD4 T cell function, and CTl responses have not yet 
been described in detail. Adjuvant and antigen need to be administered together, 
following the same route, which suggests that in general binding of antigen and 
adjuvant is required to generate optimal responses. Binding of antigen to DDA 
serves the purpose of increasing the hydrophobicity of the antigen and neutralization 
of negatively charged moieties, but, DDA is not an optimal adjuvant to elicit antibody 
responses. For a sufficient antibody response combination with alum or water-in-oil 
emulsions, for example, is required. The mild side effects of DDA and some other 
quaternary amines make them promising adjuvants for veterinary application. For 
application in man, new less irritative analogues need to be developed (for review 
see Hilgers and Snippe, 1992). 
Lipopep/ides are nontoxic and non-immunogenic analogues of bacterial cell walls 
of Gram-negative bacteria {WiesmOlier et al., 1983}. They present a novel intrinsic 
adjuvant model for peptide immunization. Upopeptides can not only serve efficiently 
to immunize peptides, in addition they can serve as a carrier with adjuvanticity (for 
review see Bessler and Jung, 1992). They are amphipathic in nature, which seems 
to be a favourable property for adjuvanticity. Upopeptides coupled to low-molecular-
weight haptens are able to elicit high antigen-specific antibody responses in mice 
and rabbits. In vivo as well as in vitro their ability to generate CTl responses even to 
single CTl epitopes has been demonstrated (Martinon et al., 1992; Nair et al., 
1992). Conjugation as well as simultaneous and separate administration of adjuvant 
and antigen elicits immune responses. A drawback is that relatively high doses of 
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antigen (10 times the dose used for regular immunization to generate antibody 
formation with adjuvant) are needed in most cases, but then high antibody titres 
have been obtained. In a number of cases valuable characteristics of lipopeptides 
were demonstrated. The toxicity of toxins decreased after conjugation without loss of 
immunogenicity. Other non- or poorly immunogenic substances showed enhanced 
immunogenicity (Bessler and Jung, 1992). Lipopeptides are very easily applied and 
are commercially available. Recently the use of virus particles (HbsAg) as a carrier 
for peptides with a hydrophobic tail that dissolves in the outermembrane has been 
proposed as an alternative for both carrier and adjuvant (Neurath et a/., 1989). 
As has been summarized above, most adjuvants which support cell-mediated 
immune responses (CMI), especially CTl responses, require an increase in the 
hydrophobicity of the antigen. It remains unclear what the mode of action might be. 
The chemical nature of most adjuvants which support CTl responses (micelles, 
specific liposomes, and ISCOMs) suggests that binding or association with 
membranes of antigen-presenting cells is facilitated. With IFN-y the conjugation of 
antigen enhanced the immune response (Heath and Playfair, 1990). 
Natural adjuvants 
Cytokines are pleiotropic immunomodulatory agents which together form a partly 
degenerate system. The mode of action of various adjuvants has been unraveled to 
the level of immunomodulatory substances, among which are cytokines (Table 3). 
Cytokines mutually influence each other's function. Since cytokines are the primary 
immune response regulators, the analysis of adjuvant effects, apart from antibody 
production, DTH responses, and cellular cytolysis is based on demonstration of 
cytokine production. Cytokines may mimic the actions that are generated with 
adjuvants. As a consequence immunomodulation is aimed at mimicking of adjuvant 
effects by administration of the cytokines themselves. These body-derived or 
physiological adjuvants can be administered or produced locally as a secondary 
effect of an immunization procedure using various other adjuvants (micro-
organisms, microbial membranes). Some cytokines have been evaluated for their 
adjuvant activity: Il-1, Il-2, and IFN-y. These cytokines influence growth and 
differentiation of T and B cells as well as antigen presentation by various cells. 
However, because the mode of action of cytokines is complex, cytokine subunits 
with specific response-enhancing modalities were developed (ll-1). Fragments of 
cytokines have been selected which induce immune responsiveness without 
expressing the adverse side effects. The application of the active component 
together with antigen has led to promising results for thymus-dependent as well as 
for thymus-independent antigens. Various modes of administration have been 
investigated; experimentally, intraperioneal administration is most effective (Staruch 
and Wood, 1983; Boraschi at al., 1988; Tagliabue and Boraschi, 1993). 
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Scheduling of immunization 
T cell proliferation and production of response modifiers (cytokines) precedes the 
development of T-dependent antibody responses (class switch). For T cell 
responses in vitro in general the cells are isolated from lymphoid organs between 5 
and 10 days after in vivo priming. 
For optimal B cell responses it is helpful to allow resting periods of more than 4 
weeks between the first and subsequent immunizations. The effective response is 
probably based on synchronization of resting B memory cells. Whether the decrease 
of primary antibody titres is a prerequisite for the second immunization to be given is 
a matter of debate. On one hand, the circulation of specific antibodies may lead to 
immune complex formation which may enhance antigen presentation; on the other 
hand, the reduction in antigen load by circulating antibodies, dependent on the ratio 
of antigen over antibody, determines whether immune complexes may lead either to 
stimulation (antigen excess) or to possibly inhibition of responsiveness (antibody 
excess). For hybridoma production, a prefusion booster immunization was given 
after a long interval (a few months). The frequency of specific antibody-forming 
clones exceeded the level expected on the basis of the previous serum antibody 
responses. Repeated immunization with relatively low doses of antigen leads to 
stimulation and selection of clones that produce relatively high-affinity antibodies. 
This affinity maturation is used in the generation of strong polyclonal antisera. 
Immunizations with peptide-carrier conjugates are given at 4-week intervals. In 
general, the maximum titres are obtained after two to three subsequent 
immunizations. The best results following booster immunizations are obtained when 
priming titres have decreased. However, using KLH, a large aggregated protein 
which itself has adjuvant properties, anti-carrier titres will remain high for months. 
After priming with KLH as a carrier protein in mice serum antibodies (lgG + IgM) 
increased gradually up to at least 21 days. Nevertheless, 4-week immunization 
schedules can be completed. 
The timing of the immunization preceding spleen cell fusion depends on the 
routing: soluble antigens (conjugates) can be introduced intravenously three days 
before fusion. Less-soluble antigens are given intraperitoneally with FIA, as a water-
in-oil emulsion or precipitated on aluminium hydroxide gel 4 days before an intended 
spleen cellfusion. Although we prefer spleen cells for fusion, for fusion of lymph 
nodes regional nodes are activated by immunization with adjuvant (as for Lp. 
immunization). Mirza et al. (1987) performed fusion of lymph node cells at day 14 
after primary immunization for the production of anti-insulin mAbs. 
ISCOMs are generally applied intramuscularly or subcutaneously. In contrast to 
many other adjuvants, the administration of ISCOMs-related antigen along these 
routes is most effective when the interval between two administrations is 6 to 8 
weeks. Short intervals give low antibody titres (Lovgren et al., 1990). 
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The timing of immunizations and responses is dependent on the mode of antigen 
presentation; the antigen preparation and formulation is important in this. Slow 
release of antigen from emulsions or crystalline deposits may introduce a delay. 
Side effects and safety of immunization procedures 
In a Dutch Code of Practice (Veterinary Public Health Inspectorate, 1993) the side 
effects of immunization procedures are scaled in arbitrary units of injury from I (low) 
to III (severe). Intravenous antigen application (when possible) and intraperitoneal 
and subcutaneous injections score injury level I; intradermal and intramuscular 
application score injury level II, whereas intrasplenal immunization and immunization 
in the foot are level III. 
The degree of injury is determined not only by routing but also by the nature of 
the adjuvant. Freund's complete adjuvant and ISCOMs by various routes (e.g. 
intraperitoneally) cause a high degree of injury and therefore are either better not 
used (FCA) or applied via routes that cause only a low degree of harm. 
Snippe et al. (1992) distinguish two categories of adjuvants applications: (1) 
includes adjuvant applications for which the efficacy aspect is more important than 
the safety/toxicology aspect and (2) applications where safety is more important 
than efficacy. 
Group (1) consists of applications of adjuvants In experimental and production 
animals. All adjuvants seem to be applied in the former category and only four -
water-in-oil and oil-in-water emulsions as well as aluminium salts and liposomes -
in the latter category. For production animals, only FCA is considered not-allowed, 
whereas some doubts are expressed with respect to application of most other 
adjuvants. In this category the application of an adjuvant may be considered based 
on the presently available safety records of the adjuvants. However, sufficient 
alternatives are available to eliminate FCA from animal experimentation in most 
fields of biomedical research. 
In group (2) applications of adjuvants in companion animals and humans are 
distinguished. For humans, only aluminium salts are allowed. Most other adjuvants 
are not considered for application except for specific purposes. Water-in-oil and oil-
in-water as well as FCA are considered not to be applicable in humans at all. For 
companion animals, ISCOMs are thought to be sufficiently safe enough for 
application. Water-in-oil emulsions as well as FCA are considered not to be 
applicable in companion animals. All other adjuvants are worth considering for 
application on the basis of the presently available safety records. 
For application in humans, production animals and pets the development of safe 
adjuvant formulations is still of great importance. The efficacy of present adjuvants 
seems in most cases to be in opposition to safety. For many vaccines an 
appropriate level of adjuvanticity is required to reach a sufficient level of vaccine 
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efficacy. The ability to provide formulations which combine efficacy with safety is a 
challenge (see also Gupta et al., 1993). 
Conclusions and suggestions 
Immunization, which aims at optimal antigen presentation, is a complex multivariate 
issue. The properties of the antigen, of the route of introduction, of the formulation, 
and of the recipient all contribute to the final result. Therefore, finding the optimum 
immunization results is a matter of experimentation and experience. 
The tables included in this chapter may provide a guide to the choices to be made 
when specific immune responses to antigens have to be elicited. 
Purity of an antigen determines the specificity of the responses. Subunits require 
better adjuvant than intact complex antigen. T cell determinants in general are MHC 
class restricted, however promiscuous epitopes are frequently encountered. Use of 
the latter epitopes with haptens produces efficient immunogens. Single epitopes 
(haptens) conjugated to an efficient carrier form efficient immunogens. The use of a 
'foreign' protein as a carrier (KLH in mammals) is more efficient than a related carrier 
protein (BSA in mammals) (Boersma et al., 1993) See also Table 1. 
When generation of antibody for use in detection is the main aim of 
immunizations, there is a rather broad choice of routes of introduction depending on 
the solubility of the antigen. Care should be taken to immunize more than once to 
obtain sera with relatively low titres of IgM antibodies, which in many immunoassays 
lead to background and cross reactivity. Water-in-oil emulsions are simple to use, 
and need no complex laboratory equipment. subcutaneous or intraperitoneal 
application is easy to perform with a low injury index. 
For production of monoclonal antibodies, cell fusion is best performed after a 
booster immunization (intravenously if possible) without adjuvant so as to avoid 
depot effects, and if necessary with alum-antigen precipitates as a vehicle 
(intraperitoneally)(Table 4). 
When expression of specific isotypes is needed (complement fixation), the 
response can be skewed in that direction by the choice of adjuvant 
(lipopolysaccharides, liposomes, ISCOMs, NBP) (Tables 2 and 3). 
For DTH reactions the choices of adjuvants for specific antigens depend on the 
antigen properties. Mineral salts are not efficient. Water-in-oil emulsions, liposomes, 
various synthetic antigens, and ISCOMs are very efficient (Tables 2- 4). 
When cell-mediated immunity on the level of class I restricted responses is 
required for protection, then the choice of adjuvants is highly restricted. In fact, only 
ISCOMs and to a lesser extent liposomes seem to be very efficient in elicitation of 
class I restricted responses. However, this type of construction is needed only when 
we use selected fragments of antigens (isolated viral proteins, cell surface 
molecules) for the induction. When whole live viruses or cells are applied for 
immunization, class I restricted responses are easily induced. 
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We have given above an outline of choices to be made with many variables. 
Although most of the data are from mouse and man, in general the picture is similar 
in other animals. For these other animals, however, the distribution of isotypes in 
immunoglobulins, and the balance between Th1 and Th2 may be somewhat 
different. We hope that our guidelines will lead to successful immunizations. 
New and exiting developments are moving rapidly from preliminary evidence to 
clinical application. Production and purification are difficult for many antigens. 
Recombinant DNA expression systems have therefore been developed for many 
antigens. An alternative route of influence over antigen presentation is the direct 
introduction of naked DNA (plasmids, vectors) into cells which bring the introduced 
sequence to expression. The antigens have proper glycosylation. This technique 
leads to antigen presentation via class I and possibly class II MHC molecules such 
that an immune response results. Not all easily accessible cells (skin, muscle) may 
be good antigen-presenting cells. However, when vectors are developed which, 
apart from sequences coding for antigens, in addition code for cytokines which 
induce the right molecular structures for antigen presentation it seems that most 
problems can be solved. 
It is envisaged that this method of immunization will open new ways to treat 
malignancies (idiotypic vaccines) as well as chronic infections. The new 'DNA-
vaccines' will be easily produced, purified, stored, and administered. The 
development of this alternative approach leads the immunization from expression 
products to the 'source' (genetic material). However, it will take some time before all 
regular vaccinations will follow this approach. 
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Chapter 3 
Evaluation of several adjuvants as alternatives 
to the use of Freund's adjuvant in rabbits 
P.P.A.M. Leenaars, C.F.M. Hendriksen, A.F. Angulo, M.A. Koedam 
and E. Claassen, Vet. Immunol. Immunopathol., 1994,40,225-241. 
Comparison in rabbits 
Abstract 
In three experiments we evaluated several types of adjuvants as an alternative to 
Freund's adjuvant (FA). In the first experiment three adjuvant preparations (a water-
in-oil emulsion (Specol), a combination preparation of mono phosphoryl lipid A + 
trehalose dimycolate + cell wall skeleton (RIB I) and a nonionic block polymer 
surfactant (TiterMax)) were evaluated. The adjuvants were combined wah three 
different types of (weak immunogenic) antigens (synthetic peptide, glycolipid and 
particulate antigen) and administered following the intramuscular or subcutaneous 
route. The evaluation was based on clinical, pathological and immunological 
parameters. The animals did not appear to be severely or chronically impaired by 
the experiment. After injection of the RIBI adjuvant, the severity of the side effects 
was similar to or exceeded those induced after FA injection, while low antibody titres 
were produced. TiterMax caused little side effects, while antibody responses were 
very low. In comparing Specol and FA; Specol had far less adverse effects than FA. 
However, Specol had immunostimulating properties of the same level as FA. In the 
second experiment, the effect of injected volume of FA on side effects and antibody 
titre was studied. Immunization of rabbits with a total of 0.5 ml FA at different sites 
does not seem to increase the immune response when compared with the immune 
response seen after injection of 0.5 ml FA at one site. However, side effects were 
seen in all the animals. In the third experiment, the side effects of intradermal (i.d.) 
injection of the adjuvants were studied. After Ld. injection of FA or RIBI, undesirable 
effects were found. No side effects occurred after Ld. injection of Specol or TiterMax. 
From the studies it is concluded that Specol is an alternative to FA for 
hyperactivation of the immune response in rabbits. 
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Introduction 
In experimental animals, the induction of effective Band T cell responses to antigens 
usually requires that the antigen is administered with a potent adjuvant. For this 
purpose Freund's adjuvant (FA) has been used in laboratory animals for decades. 
Administration of Freund's complete adjuvant (FCA) and to a lesser extent of Freund's 
incomplete adjuvant (FIA) induces local and systemic lesions (Broderson, 1989). The 
side effects following administration of FA suggest that FA has a great potential to 
cause pain and distress in animals (Morton and Griffiths, 1985). For this reason, 
guidelines in Canada, the USA and the Netherlands restrict researchers in using FA 
(Claassen et al., 1992). 
Experimental studies in animals have revealed an array of diverse products which 
could function as an adjuvant and probably be used as an alternative to FA. An ideal 
alternative adjuvant should have the effectiveness (with different types of antigen) of 
FA but does not induce adverse effects. In this study, the induction of effective B cell 
responses in rabbits was investigated, as this species is commonly used for the 
production of hyperimmune serum. In the 44th Forum in Immunology an overview of 
most of the adjuvants presently available is given (Claassen and Boersma, 1992). 
Many types of water-in-oil (w/o) emulsions are used as adjuvants. An example of a 
wlo emulsion is Specol (Bokhout et al., 1981; Boersma et al., 1992). Since 1981, the 
immunomodulating properties of a group of synthetic matenals, the non ionic block 
polymer surfactants (NBP), have been studied (Hunter and Bennett, 1984). At the 
moment, two adjuvant formulations are commercially available in which NBP are an 
essential component: TiterMax (CytRx Corporation, Atlanta, GA) and Syntex adjuvant 
formulation (SAF-M: Syntex Research, Palo Alto, CAl. Other types of synthetic 
adjuvant are muramyl dipeptide (MOP), trehalose dimycolate (TOM), 
dimethyldioctadecylammonium bromide (OOA) and avridine (Woodard, 1990). Among 
the surface active adjuvants, the Saponin adjuvants like Quil A and ISCOM (immune-
stimulating complexes) (Claassen and Osterhaus, 1992) are commonly used. 
Commercial combination preparations, such as RIBI (MPL + TOM+CWS 
(monophosphoryl lipid A and trehalose dimycolate and cell wall skeleton) emulsion) 
are available. 
This study was designed to evaluate several types of adjuvants, with a different 
mode of action, as an alternative to FA. The evaluation was based on clinical, 
immunological and pathological parameters. The adjuvants selected were one step 
mixing products and included: FA, Specol, RIBI and TiterMax. The antigens used were 
a synthetic peptide (SPek15a), a glycolipid (galactocerebroside) and a particulate 
antigen (Mycoplasma pneumonlae). The effect of an injected volume of FA on side 
effects and antibody titre and the side effects of intradermal (Ld.) injection of the 
adjuvants were also studied. 
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Animals, materials and methods 
Animals 
Seventy eight (surplus) New Zealand White rabbits (O!}'cto/agus cuniculus) of both 
sexes were obtained from the specific pathogen free (SPF) breeding centre of the 
RIVM. The rabbits were 6 months and weighed between 3.5 and 4.0 kg initially. They 
were housed individually in standard stainless-steel cages at a room temperature of 
20-21·C under a 12 h day-night light cycle. The relative humidity was between 45-
60%. The rabbits were fed rabbit chow (80 g day'1, Hope Farms BV, Woerden, the 
Netherlands) and tap water was available ad libitum. 
Materials 
The following materials were used in the experiments described below: 
Freund's complete adjuvant (FCA; Difco Laboratories, Detroit, MI), Freund's 
incomplete adjuvant (FIA; Difco Laboratories), Specol (water-in-mineral oil emulsion 
described by Bokhout et al. (1981); ID-DLO, Lelystad, the Netherlands), RIBI 
(MPL +TDM+CWS emulsion; Sanbio BV, Uden, the Netherlands) and TiterMax (NBP; 
CytRx Corporation, Atlanta, GA). 
Antigens 
Three different types of antigen were used; synthetic peptide (SPek15a, complexing B 
and T cell epitope (Zegers et al., 1992; MBL-TNO, Rijswijk, the Netherlands), 
glycolipid (galactocerebroside; MBL-TNO, Rijswijk, the Netherlands) and particulate 
antigen (Mycoplasma pneumoniae, whole antigen inactivated 30 min. at 57"C; RIVM, 
the Netherlands). In order to discriminate between poor and potent adjuvants, the 
antigens used were selected for their low immunogenieity and they were not coupled 
to a carrier protein. The SPek15a and Mycoplasma pneumoniae antigen were diluted 
in PBS (phosphate-buffered saline), galactocerebroside antigen was diluted in DMSO 
((dimethyl sulphoxide): PBS=1 : 1). The amount of antigen injected per rabbit was 
200 ~g SPek15a, 200 ~g galactocerebroside or 87 ~g Mycoplasma pneumoniae in 
primary and secondary immunization. 
Adjuvant/antigen preparation 
Freund's adjuvant (FCA and FIA) was emulsified with an equal volume of antigen in 
solution using two syringes and a double hub connector. The antigen in solution was 
added to FA via the connector and mixed for 1 min. Speeol adjuvant and antigen in 
solution was emulsified 11: 9. In the first experiment, Specol was mixed as 
described for the FA mixtures. In a second experiment, Specol was mixed on a 
vortex and the antigen in solution added dropwise while vortexing. RIBI adjuvant 
was prepared according to the manufacturer's instructions by reconstituting a final 
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volume of 2 ml with antigen/solution mixture in the RIBI vial. TiterMax was emulsified 
in the same way as FA. However, the antigen in solution was added to the adjuvant 
in two steps. 
Immunization experiments 
Experiment 1 
The adjuvants to be studied were combined with the three different types of antigens. 
On day 0 the animals were immunized (two rabbits by subcutaneous (s.c.) route and 
two intramuscularly (Lm.)) with either 0.5 ml FCAIantigen mixture, 0.5 ml 
Specol/antigen mixture, 2 x 0.5 ml RIBI/antigen mixture or 0.08 ml of a 
TiterMaxiantigen combination. The injected volumes of the RIBI and TiterMax 
adjuvants followed the specifications of the manufacturer. The control group was 
injected (two animals subcutaneously and two intramuscularly) with 0.5 ml antigen in 
solution mixture. On day 28 a secondary injection was given. The secondary 
immunization contained the same mixture as the prima'ry immunization with the 
exception of FCA being replaced by FlA. As shown previously, FCA and FIA, when 
used for secondary immunization, have the same effect on the immune response (De 
Greeve et al., 1982). However, the side effects after secondary immunization with FIA 
are less severe than after secondary immunization with FCA (Broderson, 1989). 
On day 0 the animals were injected at the left side of the body, while the secondary 
injection (day 28) was given at the right side. The site of injection was shaved and 
cleaned with ethanol (70%). The s.c. injections were made dorsally just behind the 
scapula. The Lm. injections were given in the muscles of the posterior thigh. The 
second Lm. injection of the RIBI injected animals was given in the dorsal muscles in 
the lumbar region. Sterile 20-gauge needles were used for s.c. and Lm. injections. 
Experiment 2 
The effect of volume of injection on adverse effects and antibody titre was studied by 
immunizing rabbits subcutaneously with 1 ml, 0.5 ml, 2 x 0.25 ml and 4 x 0.125 ml FA 
emulsion. SPek15a was used as antigen. Two rabbits were used per volume. Animals 
immunized with 2 x 0.25 ml were injected in two sites, animals immunized with 
4 x 0.125 ml received the mixture at four sites. Two control animals were injected with 
1 ml antigen in PBS. As in Experiment 1, the animals were injected in the left site on 
day 0, while the secondary injection (day 28) was given in the right site. On day 0, 
FCA was injected, on day 28, FCA was substituted by FIA. The animals injected with 1 
and 0.5 ml, were injected in the same way as the s.c. injected animals in Experiment 
1. The 2 x 0.25 ml injected animals received one injection 5 cm caudal from the 
scapula and 5 cm from the median line, the second 5 cm cranial from the crista iliaca 
and 5 cm from the median line. The four s.c. injections of 0.125 ml per site were given 
in a zigzag formation to each flank. 
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Experiment 3 
The effect of Ld. inoculation of the adjuvants was evaluated in a third experiment. The 
animals were injected Ld. on day 0 receiving two inoculations of 50 ~I adjuvant 
solution (FCA, Specol, RIBI or TiterMax) in different sites (one animal per adjuvant). 
No antigen was administered. The adjuvants were mixed as described above, with 
PBS as aqueous solution. The site of injection was shaved and depilated and cleaned 
with ethanol (70%). Sterile 25-gauge needles were used for injections. The i.d. 
inoculations were given at comparable sites as the 0.25 ml injections described in 
Experiment 2. 
Clinical observation 
The animals were observed every 2 days for clinical signs of disease. Body weight 
was recorded once each week. The body temperature of the Mycoplasma 
pneumoniae injected animals was recorded twice a week. The rabbits were placed in 
a rabbit box; after an initial acclimatization of 30 min., the rectal temperature was 
recorded four times in 30 min. The average of these four temperatures was taken as 
the body temperature. Locomotor activity was observed twice during the first week 
after primary and secondary immunization. 
Bleeding samples 
Blood (5 ml) was sampled immediately prior to the first injection (prebleed) and then at 
7-day intervals. After sedation with Hypnorm 0.2 ml per animal (Janssen Pharma-
ceutica BV, Tilburg, the Netherlands) blood was obtained from the marginal vein of the 
rabbit's ear. The blood was centrifuged at 2000 g for 20 min. and the sera were stored 
at -20"C. Blood samples were taken for antibody titration. 
Immunoassays 
Antibody responses in the serum were evaluated using a direct enzyme-linked 
immunosorbent assay (ELISA) (in which the antigen was coated directly to the plate 
by passive adsorption) and immunofluorescence (only determined for the Mycoplasma 
pneumoniae group). 
Serum antibody titrations for the SPek15a and galactocerebroside immunized 
animals were performed using the ELISA method described by Zegers et al. (1991). 
The antibody responses to a,-antitrypsin (T cell epitope; MBL-TNO, Rijswijk, the 
Netherlands) were performed in the sera of animals immunized with SPek15a using 
an ELISA procedure. The plates were coated overnight at 4"C with 50 IJI PBS 
containing 10 ~g/ml SPek15a or with 50 ~I ethanol/PBS (1 : 1) containing 80 ~g/ml 
galactocerebroside or with 50 ~I PBS containing 5 ~g/ml a,-antitrypsin. Swine anti-
rabbit serum conjugated to alkaline phosphatase, diluted 1 : 200, was used. After 
30 min. the absorbance was read at 405 nm in a Titertek Multiskan reader (Flow 
Laboratories, Irvine, UK). The sera were diluted using serial 2-fold dilutions from 1 : 20 
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to 1 : 40960. The titre in the ELISA was chosen as the dilution at which the 
absorbance was half of the maximum absorbance. 
The ELISA procedure for the Mycoplasma pneumoniae antibodies was performed 
as described by Cassell and Brown (1983). To obtain an ELISA antigen from Myco-
plasma pneumoniae, the Tween 20 solubilization method was used. The supernatant 
fluid was filtered through a 0.45 ~m pore diameter membrane. Horse radish 
peroxidase conjugated donkey anti-rabbit serum (Amersham, Buckinghamshire, UK) 
was used. The sera were diluted using 2-fold dilution from 1 : 20 to 1 : 2560. 
The antibody responses to Mycoplasma pneumoniae were determined by 
immunofluorescence in accordance with Rosendal and Black (1972). Cultivations of 
Mycoplasma pneumoniae on Chanock agar and horse anti-rabbit serum conjugated 
with fluorescein isothiocyanate (FITC) were used. Microscopical observation was done 
at a magnification of 100X by using an Orthoplan Leitz microscope with an incident 
illumination of 490 nm wavelength. 
Pathology 
After 42 days animals were killed by intravenous injection of 2.5 ml euthanasia 
solution (Nembutal; Sanofi BV, Maassluis, the Netherlands). Necropsy consisted of 
dissection and careful examination of injection sites and draining lymph nodes, 
supplemented by examination of major organs in selected cases. For histology, 
tissues were fixed in 4% neutral buffered formaldehyde. Lesion sites were embedded 
in glycol methacrylate and sectioned at 1 ~m while lymph nodes were embedded in 
paraplast and sectioned at 5 ~m. All sections were stained with haematoxylin and 
eosin. 
Results 
Immune response 
Immunization of rabbits with the different adjuvant and antigen combinations resulted 
in primary and secondary antibody responses depending on type of adjuvant and 
antigen. Data are presented separately for Experiments 1, 2 and 3. 
Experiment 1 
Animals immunized with the synthetic peptide SPek15a (Fig. 1 and 2) produced the 
highest antibody titres when Specol or FA was used as adjuvant, both by the s.c. and 
i.m. route of immunization. A marked increase in antibody production was seen after 
secondary injection in week 4. Antibody levels in animals immunized with TiterMax 
were very low and only detectable from week 5 s.c. and from week 4 i.m. RIBI animals 
produced a detectable titre only in week 6 (i.m. immunized animals). Antibody 
responses were undetectable in our study when SPek15a without adjuvant was 
injected. 
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show any response. The initial serum dilution was 1 : 10 (point 0). Results are shown as the mean 
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Figure 2 ELISA antibody IiIres In rabbits Lm. Immunized and boosted with FA-, Specol-, RIBI-, 
TiterMax- or PBS/SPek15a mixtures. Sera of animals Immunized with PBS-mixtures did not show any 
response. The Initial serum dilution was 1 : 10 (point 0). Results are shown as the mean value for two 
rabbits. 
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When Mycoplasma pneumoniae was used as antigen (Fig. 3 and 4) a similar 
picture emerged for the antibody responses of animals immunized with FA or Specol. 
Because of the marked clinical findings in the animals s.c. immunized with 
Specol/Mycoplasma pneumoniae (see clinical observations and pathology) s.c. 
immunization was repeated with Specol and FA. In comparison with the first 
experiment ELISA antibody titres were somewhat higher for FA immunized animals 
and comparable for Specol immunized animals. Antibody levels in animals immunized 
with RIBI and TiterMax .were low. It should be noted that ELISA antibody titres 
decreased from week 5 for the RIBI and TiterMax immunized animals. For the RIBI 
adjuvant titres in Lm. immunized animals were higher than in s.c. immunized animals. 
On the contrary. TiterMax produced higher ELISA titres s.c. than Lm. 
In the determination of the titres of Mycoplasma pneumoniae group by 
immunofluorescence only the rabbits treated with Specol showed fluorescence three 
weeks after the first injection at the dilution 1 : 20. One week after the administration of 
the booster injection all rabbits showed a fluorescent reaction at dilution 1 : 80 with 
exception of those animals treated sUbcutaneously with FA and RIBI. which did not 
react at all. One week later the situation was the same except for the animals Injected 
subcutaneously with RIBI where reaction was observed at dilution 1 : 20. 
None of the animals immunized with galactocerebroside produced a detectable 
antibody response during the period of immunization. 
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Experiment 2 
The antibody titres after injection of different volumes of FAiSPek15a are shown in 
Fig. 5. After primary immunization the antibody responses were low. On day 21, the 
antibody response was detectable in all the sera (except for the control group). The 
titres increased until day 35 and reached a plateau on day 42. The antibody 
responses did not differ significantly between the animals injected with different 
volumes of FA. 
Clinical observations and pathology 
Locomotor activity was not affected by immunizations. Body weight and body 
temperature were within the normal limits for the post-immunization period for all types 
of adjuvant. In none of the samples taken for bacteriology growth could be 
demonstrated. Data of gross pathology are specified separately for Experiment 1, 2 
and 3. 
Experiment 1 
The adjuvants (FA, Specol, RIBI and TiterMax) were combined with the three different 
types of antigens in this experiment. On clinical observation, soft tissue swelling was 
found in animals subcutaneously exposed to FA, Specol, RIBI and TiterMax. 
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Figure 5 ELISA antibody tilres in rabbits s.c. immunized and boosted with FAlSPek15a mixtures 
(different volumes: 1 ml, 0.5 ml, 2 x 0.25 ml, 4 x 0.125 mil. FCA is used in primary and FIA in 
secondary Immunization. Antibody responses were not detectable in sera of week 0, 1 and 2. The 
Initial serum dilution was 1 : 10 (point 0). Results are shown as the mean value for two rabbits. 
Macroscopic examination revealed no abnormalities at the injection sites of control 
animals except some slight hyperaemia or haemorrhage at the secondary injection 
site of 4 animals. Inflammatory processes were found at most injection sites of animals 
injected with FA (70%) and RIBI (90%), while animals injected with Specol and 
TiterMax developed inflammation at 40% of the injection sites. As reasonable similarity 
existed between reactions of animals who received the same treatment, these data 
are taken together in Table 1. 
Enlargement of draining lymph nodes was observed in some animals with very 
severe lesions but otherwise occurred incidentally in all groups. Inspection of internal 
organs in animals with most severe lesions revealed no gross abnormalities, except 
for one RIBI-treated animal with multiple small subserous abdominal abcesses, which 
yielded Escherichia coli, Streptococcus faecalis and Staphylococcus aureus. 
Subcutaneous lesions varied in size, character and complexity. Dorso-ventral 
extension was larger than cranio-caudal, but no fistulous tracts as described by 
Broderson (1989) were observed. 
FCA treated animals mainly showed granulomatous nodules with central necrosis 
(6 of 8 primary sites), which were often hyperaemic or haemorrhagic. In one 
Mycoplasma-treated animal a flat yellow layer surrounded by severe hyperaemia and 
haemorrhage was observed. This animal showed the same severe abnormality at the 
secondary injection site, 2 weeks after FIA injection. Microscopically, the yellow 
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sUbstance appeared to be a necrotic layer within granulomatous inflamed connective 
tissue, very rich in capillaries near the necrotic areas. All FIA injections led to 
hyperaemic or haemorrhagic lesions 2 weeks after injection, that otherwise varied 
from slight to very extensive flat granulomatous processes, attached to superficial 
muscle. They showed less necrosis than FCA-induced granulomas. 
Specol, in combination with Mycoplasma pneumoniae, induced the same yellow 
caseous plaques as described for FCA, which were very extensive at both sides in 
both rabbits. After repeat of the latter combination, this time prepared according to the 
manufacturer's description, the lesions were confined to the secondary injection site 
and were milder, mainly resembling extensive fibrous proliferation of the subcutis. 
Table 1. Pathology findingsa at injection sites of rabbits immunized (s.c. or i.m.) with 
various adjuvants mixed with either SPek15a, galactocerebroside or Mycoplasma 
pneumoniae (Experiment 1) 
s.c. i.m. 
Adjuvant Antigen P' SO P S 
FA SPek15ad + ++ + ++ 
Galacto.· ++ + + 
M.pneu.f ++ ++ ++ 
Specol SPek15a + + 
Galacto. 
M.pneu. ++ + + 
RIBI SPek15a ++ + + + 
Galacto. ++ ++ ++ ++ 
M.pneu. ++ ++ + ++ 
TiterMax SPek15a ++ + + 
Galacto. + 
M.pneu. + ++ + 
SPek15a 
(no adjuvant) Galacto. 
M.pneu. 
, 
- = no lesion, + - moderate lesion, ++ = severe lesion; Lesions are described in detail in the results 
section; bP=primary immunization; cS=secondary immunization; deach line represents the average of 
two s.c. and the average of two I.m. Injected animats; egaJactocerebroslde; 'Mycoplasma pneumonlae, 
only results of repeat experiment of FA and Specol mixed with Mycoplasma pneumon;ae. 
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Microscopically the proliferation appeared to be granulomatous inflammation, in part 
around oil spaces, with minimal necrosis. In combination with other antigens, Specol 
induced only one lesion in a single animal. 
RIBI produced the largest number and the most severe lesions when compared 
with the other adjuvants. One secondary injection site (Mycoplasma pneumoniae) was 
ulcerated. In addition to one caseous plaque (as described above), in three animals 
spherical abscess-like processes were found, measuring up to 8 cm diameter. The 
caseous content was found microscopically to be necrosis of granulomatous 
inflammatory tissue. At most other injection sites, RIBI induced less voluminous 
necrotizing granulomas. 
Subcutaneous injection of TiterMax induced a few relatively severe changes. At 
one secondary injection site (SPek15a) ulceration occurred. In the Mycoplasmaijroup, 
yellow layers were found at one primary and two secondary injection sites (as 
described above). 
Intramuscular lesions were seen as irregular, grey, white, shining processes 
sometimes containing thick pale yellow pus, tending to spread parallel to muscle 
fibres. They measured up to 1.5 cm cross diameter and 5 cm in length. Skin lesions 
and muscle atrophy were not observed in Lm. injected rabbits. 
RIBI most conSistently produced lesions intramuscularly, 6 as well as 2 weeks post 
inoculation, and these lesions often showed hyperaemia and pus centrally. FCA and 
FIA produced changes less frequently and of less severity than RIB!. Specol and 
TiterMax produced few abnormalities intramuscularly 6 weeks post inoculation, but at 
2 weeks post inOCUlation most injection sites showed granulomas. At 6 weeks post 
inoculation, FCA induced more lesions than Specol and TiterMax. 
Experiment 2 
Gross examination of animals s.c. injected with different volumes of FA, revealed 
remarkable results. The two animals injected with 0.125 ml per injection site showed 
necrotizing granulomas, measuring up to 3 cm diameter, at 7 out of 8 FCA injection 
sites. Less severe granulomatous proliferations were found at 7 out of 8 FIA injection 
sites. Only one of the 1 ml FA injected rabbits showed impressive granulomas at both 
sides (Fig. 6). FCA lesions in animals injected with 0.5 ml were absent, while both 
animals injected with 0.25 ml (on two spots) showed two distinctive granulomas; FIA 
lesions were present at all sites injected with 0.5 and 0.25 ml. Both control animals 
showed no abnormalities at necropsy. 
Experiment 3 
On clinical observation, the animals injected with FCA and RIBI showed prominent 
nodules at both injection sites, measuring approximately 1 cm diameter. One FCA 
induced nodule was ulcerated centrally. Microscopically, intradermal granulomas 
around oil spaces were found, with focal necrosis. The RIBI-induced lesions (Fig. 7) 
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that appeared particularly tender on palpation, were composed microscopically of 
massive necrosis surrounded by a thin vital rim of granulomatous inflammatory tissue. 
Discussion 
In this study, Specel is being considered as a possible alternative to FA since Specol 
produced serum antibody titres comparable to FA but fewer adverse effects. 
Primary and secondary antibody response was elicited depending on type of 
antigen, adjuvant and route of administration. In order to discriminate between poor 
and potent adjuvants, the antigens used in this study were selected for their low 
immunogenic power. A dose range of 50-1.000 I1g is generally recommended for 
most protein, carbohydrate and nucleic acid antigens (Johnston et al., 1991). The 
dose of 200 I1g used for the SPek15a and galactocerebroside antigen should be 
sufficient to elicit an antibody response. The antibody tilre of the RIBIISPek15a-
injected animals was very low. This low antibody titre for RIBI adjuvant agrees wilh 
the observations by Johnston et al. (1991) who used a synthetic peptide as an 
antigen. However, Cantrell and Finn (1989) and Deeb et al. (1992) claim good 
antibody titres with the RIBI adjuvant. 1\ should be noted that the excellent antibody 
responses seen with Specel and SPek15a were also observed when the antibodies 
were tested in an <x,-antitrypsin (native protein) ELISA. This indicates that Specel is 
efficient not only in SPek15a antibody production but also in the production of anti-
native protein cross reactive antibodies (i.e. anti-peptide antibodies that also 
recognize the native protein). 
In the Mycoplasma pneumoniae group the antibody titres decreased from week 5 
for the animals injected with RIBI or TiterMax. This drop from week 5 after secondary 
injection was also found for RIBI by Deeb et al. (1992) who immunized rabbits i.m. 
with 0.25 mt RIBI with synthetic polypeptide antigen. In the study of Bennett et al. 
(1992) the antigen was conjugated to HEA or BSA which may have a positive 
influence on the immune response. In our study no such carriers were used and 
therefore a low immune responses may be expected. Our aim was not to examine the 
effect of a potent or less potent carrier protein; we wanted to discriminate between 
poor and potent adjuvants. The i.m. injections of RIBI seem to elevate the antibody 
titres more than the s.c. injection of the same adjuvant. 1\ is the other way around for 
the TiterMax adjuvant. The high antibody titres claimed for TiterMax adjuvant (Hunter 
and Bennett, 1984; Check et al., 1990) were not observed in this study. 
In the galactocerebroside group no antibody titres were detected after s.c. 
immunization or after i.m. immunization. 1\ remains obscure whether there is no 
antibody response at all or antibody response cannot be estimated for technical 
reasons. Fry et al. (1976) reported a study in rabbits when an antibody titre was 
measured by immunoprecipitation in agar and complement fixation. Fry et al. injected 
rabbits with 3 mg of galactocerebroside antigen mixed with 3 mg bovine serum 
albumine (in 0.3 ml PBS and 0.3 ml FA) by foot pad inoculations (each animal 
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Figure 6 Subcutaneous injection of 1 ml FCNSPek15a mixture. At necropsy after 42 days, an 
extensive subcutaneous area of oedema and hyperaemia; centrally irregular grey nodules attached to 
muscles. Superficial muscle layer removed. Microscopically, granulomatous inflammation with focal 
necrosis. 
Figure 7 Intradermal injection of 0.05 ml RIBI in two sites. At necropsy after 42 days, prominent 
yellow nodules covered with intact skin, measuring about 1 em diameter and containing thick pale 
yellow pus. Microscopically, intradermal granulomatous proliferations with central necrosis. 
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received 0.15 ml per foot pad). The galactocerebroside antigen used in our study was 
not coupled to a carrier protein. Further, FNgalactocerebroside used in mice in our 
laboratory resulted in high titres. This mice serum was used as a positive control in the 
antibody titrations for galactocerebroside. 
On macroscopic observation, lesions were seen after s.c. and. i.m. administration 
for most of the adjuvants. However, striking differences, both qualitative and 
quantitative, were seen. The small volume of 0.5 ml, as suggested by Herbert and 
Kristensen (1986), could not prevent the adverse effects of most adjuvants. The role 
of the antigen must be considered as having influenced the side effects after 
administration with an adjuvant. Specol and TiterMax in combination with 
galactocerebroside antigen hardly gave any side effects, while the RIBI adjuvant in 
combination with the galactocerebroside antigen showed an inflammatory reaction at 
all the injection sites. One severe lesion type, the extensive caseous layers with 
haemorrhagic borders in the subcutaneously injected animals, only occurred after 
administration of Mycoplasma pneumoniae as antigen in combination with four 
different adjuvants. After administration of the antigens in PBS no inflammatory 
processes were found at gross examination. 
The only difference between the repeat expariment (s.c. injection of FA or Specol 
with Mycoplasma pneumoniae) and the previous test was the procedure of antigen-
adjuvant mixing. The different side effects seen in the repeat experiment might be 
explained by this difference in mixing procedure. 
The results of Experiment 2 do not indicate that the injected volume of FA has 
any influence on lesions or antibody responses. Injection of 0.5 ml at one site seems 
to be preferable since adverse effects are less than after injection of 0.25 ml in two 
sites or 0.125 ml in 4 sites and no significant difference was seen in antibody titre. 
The number of animals used, however, is small (two). Broderson (1989) found that 
in rabbits, lesions were most severe when larger volumes (0.1-0.3 ml) of adjuvant 
were injected per site. 
After i.d. injection of 0.05 ml FCA or RIB I adjuvant, undesirable effects were found. 
Thus, the recommended volume (Canadian Council of Animal Care, 1991) of an i.d. 
injection of 0.05 ml adjuvant still leads to severe effects in animals injected with FCA 
or RIBI. As described by Broderson (1989) the inflammatory reaction with the i.d. 
injection route was localized. 
The rabbits did not appear to be severely or chronically impaired, since food intake, 
body weight and locomotor activity were within normal limits for the post-immunization 
period. The same results were observed in FA-immunized rabbits by Johnston et al. 
(1991) and in FA-immunized mice by Toth et al. (1989), while Wanstrup and 
Christensen (1965) observed decreased activity, dullness of the fur and loss of hair in 
mice when 0.05-0.2 ml FCA was s.c. injected weekly. 
The severe pathological changes observed In this study after immunization with FA 
confirm the data that it is a disagreeable formula. RIBI and, to a far lesser extent, 
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TiterMax adjuvants caused lesions and low antibody responses were produced. The 
adverse effects observed in animals injected with Specol were less severe than with 
FA. Immune responses produced by Specol were comparable to FA. Specol is 
therefore considered as being a possible alternative to FA for immunization purposes 
in rabbits. 
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Comparison of several types of adjuvants for 
immune potentiating properties and 
side effects in mice 
P.P.A.M. Leenaars, C.F.M. Hendriksen, M.A. Koedam, I. Claassen and 
E. Claassen, Vet. Immunol. Immunopathol., 1995,48, 123-138. 
Comparison In mIce 
Abstract 
Four types of adjuvants were evaluated as alternative to the use of Freund's 
complete adjuvant in mice. The adjuvants evaluated included a water-in-oil emulsion 
(Specol), a micro-organism (Lactobacillus), immune-stimulating complexes with 
incorporated rabies virus glycoprotein (RV-ISCOMs) and a saponin, Quil A. The 
adjuvants and saline were combined with three weak immunogens (a synthetic 
peptide, an autoantigen or a particulate antigen) and given by three different routes 
(intraperitoneal, sUbcutaneous or dorsal In the foot). The evaluation was based on 
clinical observations, behavioural studies, pathological lesions and capacity to 
support immunological responses to weak immunogens. Lesions were most severe 
after injection of antigen combined with Freund's adjuvant or Quil A, mild to 
moderate with Specol and minimal with Lactobacillus, RV-ISCOMs or saline. Despite 
pathological changes, no signs of prolonged pain or distress could be demonstrated 
based on clinical observations and behavioural studies. Minimal immunological 
responses were found after injection of antigen in combination with saline or 
Lactobacillus. T cell activation and high antibody responses were found after 
injection of antigen/RV-ISCOMs or antigen in Freund's adjuvant emulsions. After 
Specol/antigen immunizations T cell activation was demonstrated and high antibody 
litres were found except for Specol/autoantigen immunizations. Presented data 
suggest that Specol is a possible alternative to Freund's complete adjuvant for the 
induction of an immune response against weak immunogens except possibly 
autoantigens, for which RV-ISCOMs seem very well suitable. 
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Introduction 
To elicit effective Band T cell responses, Freund's complete adjuvant (FCA) has 
become the most widely used adjuvant in laboratory animals. However, besides the 
marked enhancement of the immune response, also a broad spectrum of unwanted 
side effects can be found (Toth et al., 1989). Pathological changes seen after 
injection of FCA are known to be very painful in humans (Chapel and August, 1976). 
Growing concern with respect to the severe side effects caused by FCA is leading to 
stricter regulations. In Canada (Canadian Council on Animal Care, 1991), the USA 
(National Institute of Health, 1988) and the Netherlands (Veterinary Public Health 
Inspectorate, 1993) for example, guidelines have been publised giving recommen-
dations on the use of adjuvant products in laboratory animals. One of the reasons 
for continuation of the use of FCA is a lack of information on possible alternatives to 
FCA, with regard to both side effects and immunological properties. Many products 
with adjuvant activity are available. Dependent on the type of immune response 
desired, an adjuvant may be applied. In an earlier study (Leenaars et al., 1994) we 
evaluated adjuvants for the production of polyclonal antibodies and side effects in 
rabbits. 
For the induction of a specific immune response it is important to know the mode of 
action of the adjuvant. To elicit immune responses efficiently the production of 
cytokines is required. Two major cytokines produced by activated helper T cells are 
IL-2 (Kuziel and Greene, 1990) and IFN-y (Gustafson and Rhodes, 1992). T cell 
activation can also be studied by revealing the 39 kDa membrane protein (gp39) 
expressed on activated helper T cells, this molecule is essential for the activation of 
resting B cells into antibody producing cells (Noelle et a/., 1992; Van den Eertwegh et 
al., 1993). 
Since mice are generally used in immunological research we conducted a study to 
compare side effects and Immunomodulating effects of alternative adjuvants to FCA in 
mice. The adjuvants, selected on their mechanism, low toxiticity and supposed 
immunological properties, included a water-in-oil emulsion, Lactobacillus strains, 
immune-stimulating complexes and saponin. To mimic normal laboratory problems in 
evoking immune responses and to ease discrimination between the adjuvants to be 
evaluated, the antigens used (a synthetic peptide, an autoantigen and a particulate 
antigen) were weak immunogens. 
Animals, materials and methods 
Animals 
Male and female BALB/c mice were bred specific pathogen free (SPF) at the RIVM 
breeding facilities, Bilthoven, the Netherlands and. were used at 10-14 weeks of age. 
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At the RIVM, animals were housed in groups of five under SPF conditions in 
polycarbonate cages, environmental temperature of 20-22'C, relative humidity of 
50-70% and with a 12 h day/night cycle. Mice were fed a commercial diet (Hope 
farms, Woerden, the Netherlands) and provided bottled water ad libitum. 
Adjuvants 
The following adjuvants were used: Freund's adjuvant (water-in-oil emulsion, Freund's 
incomplete adjuvant (FIA) containing mycobacteria (FCA); Difco Laboratories, Detroit, 
MI), water-in-oil emulsion (Specol described by Bokhout et al. (1981); Institute for 
Animal Science and Health (ID-DLO), Lelystad, the Netherlands), non-pathogenic 
micro-organism, Lactobacillus (Lactobacillus plantarum (ATCC 8014, 109 per ml), 
Lactobacillus casei (ATCC 393,109 per ml); Claassen et at., 1994), ISCOM matrix with 
incorporated rabies virus glycoprotein (RV-ISCOMs) (preparation described below; 
Claassen and Osterhaus, 1992) and purified saponin Quil A ('Spikoside', Iscotec, 
Lulea, Sweden). 
Rabies virus (RV-Pasteur strain) was propagated in Vero-cell monolayer cultures 
(van Wezel et at., 1978). Culture supernatant was cleared by filtration and 
concentrated by Amicon ultrafiltration (cut-off 106 Da). Virus was inactivated with 
B-propiolactone (BPL) and stored at -70'C at a concentration of 900 I-Ig per ml. This 
rabies virus antigen was used for the preparation of RV-ISCOMs as described earlier 
(Feduka et al., 1992). 
Antigens 
Synthetic peptide (SP215, an analogue of SP29) was synthesized as described by 
Boersma et al. (1989). SP215 is a sequence derived from the hinge region of human 
IgG2, comprising 21 amino acids. The autoantigen was myelin basic protein from 
bovine brain (MBP, Van Noort et a/., 1993; Sigma, SI. Louis, MO), consisting of 173 
amino acids (18.5 kDa). The particulate antigen Mycoplasma pneumoniae (MAC 
strain; M. pneumoniae) was a kind gift of Dr. A. Angulo (RIVM, Bilthoven, the Nether-
lands) and was prepared by culture into Chanock broth, concentrated by centrifugation 
and washed with phosphate buffered saline (PBS). Inactivation was done at 57'C 
during 30 min. Particles of Mycoplasma pneumoniae are 0.1 - 0.8 I-Im in diameter. 
Adjuvant/antigen preparation 
For the preparation of adjuvanVantigen mixtures, the antigens (amounts given in 
Table 1) were diluted in sterile physiological saline and mixed with the adjuvant, 
except when antigens were injected in combination wilh RV-ISCOMs. SP215 (2 mg) 
was coupled covalently to 120 I-Ig RV-ISCOMs using 1-ethyl-3-(dimethylaminopropyl) 
carbodiimide (EDC) as described previously (Deen et at., 1990). MBP (2.1 mg) was 
coupled to 80 I-Ig RV-ISCOMs using EDC. After coupling for 30 min. at room 
temperature (RT), RV-ISCOMs were dialysed against PBS overnight to remove 
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uncoupled antigens and EDC. Freund's adjuvant (FCA in primary and FIA in 
secondary immunization, abbreviated as FA) and Specol emulsions, containing 
antigen, were prepared as recommended by the manufacturer of the adjuvant. 
Lactobacillus/antigen mixtures were prepared by adding antigen in sterile 
physiological saline to Lactobacillus (I : 1) and mixing well. Quil A dissolved in water 
was added to the antigen and·mixed. Intraperitoneally (Lp.) injected animals received 
10 I1g Quil A per injection while animals injected subcutaneously (s.c.) or at the dorsal 
site of the hindfoot (d.f.p.) received 20 I1g Quil A per injection. 
Experimental design 
Adjuvants were evaluated in three experiments. In each experiment one type of 
antigen was combined with each of the adjuvants, with one exception: in combination 
with M. pneumoniae, RV-ISCOMs was substituted by Quil A. The size of this 
particulate antigen makes it unfeasible to couple to RV-ISCOMs. Per antigen and per 
injection route, a control group, injected with antigen in sterile physiological saline was 
included. Injected volume per route of administration and per type of antigen are given 
in Table 1. Five mice were used per group. 
Animals were given a primary injection with the adjuvanUantigen or saline/antigen 
preparations on day O. Identical secondary injections were given on day 42, except 
that FCA was replaced by FIA and the secondary injections of MBP/RV-ISCOMs were 
given on day 91 due to unavailability of the conjugated antigen. 
Blood samples were taken from the tail vein, on day -1 to determine preimmune titres, 
one week after primary immunization and at 7 day intervals thereafter. Sera were 
pooled per group except for sera collected at necropsy. These sera were collected 
and titrated individually. Sera were stored at -20'C. One week after secondary 
immunization mice were bled after being anaesthetized by intramuscular inoculation of 
0.1 ml KRA (mixture of Ketamine (50 mg per ml), Rompun (20 mg per ml) and 
Atropine (I mg per ml) in a 7 : 3 : 1 ratio). Animals were examined for gross lesions 
and relevant tissue samples were collected for histopathology. 
Table 1. Injected volumes per type of antigen and per route of administrationa and 
dose of antigen applied in this study 
Antigen 
SP215 
MBP 
M.pneub 
Dose (pg) 
50 
100 
15 
I.p. 
0.1 
0.2 
0.2 
Volume (m/) 
s.c. 
0.1 
0.2 
0.1 
a I.p., intraperitoneal; S.C., subcutaneous; d.f.p., at dorsal site of hind foot: 
b M.pneu = Mycoplasma pneumonlaa. 
d.f.p. 
2xO.04 
2xO.04 
2xO.04 
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Clinical observation and body weight 
Specific changes in common clinical signs to indicate pain, distress or discomfort in 
experimental animals were evaluated as described by Morton and Griffiths (1985). 
General condition was evaluated daily and mice were weighed twice a week, starting 
on day -1. Injection sites were palpated for signs of pain and swelling at least once a 
week. 
Behavioural and physiological state 
The behavioural changes and physiological state of the mice were studied in the 
Primary Observation Test (POT); a systematic quantitative procedure described by 
Irwin (1968) and modified by Prof. Dr. B. Olivier (Solvay-Duphar, Weesp, the 
Netherlands). 
The POT procedure involved an initial phase of undisturbed observation and a later 
manipulative phase during which the animal was subjected to different stimuli. Animal 
behaviour was studied before immunization, three days after primary immunization 
and weekly thereafter. 
The procedure started by placing a group of mice in a viewing jar followed by an 
adaptation period of 1 h. The observation study began by observing the animal's 
undisturbed behaviour within the viewing jar, i.e., dispersion in the cage, apathy, 
startle-reaction, restlessness, watchfulness and respiration. Thereafter, the animals 
were individually transferred onto the viewing arena for testing: arousal response to 
transfer, spatial locomotion, gait, slip resistance, righting reflex, exophthalmos and 
pilo-erection. Throughout individual handling, touch-reflex, provoked-freezing, 
provoked biting, skin colour, body tone, pupil size, urination-defecation and 
vocalization were studied. After handling, mice were again placed in the viewing jar 
and wash activity was observed. Behavioural changes and physiological state of each 
mouse were scored. 
Pathology 
Necropsy consisted of complete dissection and examination of injection sites and 
major organs. Tissue of lesions and organs showing macroscopic abnormalities were 
preserved in 4% buffered formaldehyde. A sample of the omentum was preserved of 
all i.p. injected animals. The size of the popliteal lymph node (PLN) of d.f.p. injected 
animals was scored. The left PLN was fixed in 4% buffered formaldehyde, while the 
right PLN was immediately frozen in liquid nitrogen fIJr immunohistochemistry for 
demonstration of cytokine-producing cells and gp39 expression. Frozen tissues were 
stored at -70"C in air-tight aluminium containers containing a small amount of ice to 
prevent dehydration on prolonged storage. For histopathological evaluation, a 
selection of fixed tissue samples was embedded in paraffin, sectioned at 5 ~m, and 
stained with haematoxylin and eosin. In the i.p. injected animals the extent of 
abdominal lesions was scored based on the relative amount of white plaques in the 
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visceral and diaphragmatic peritoneum. The severity of peritonitis in these groups was 
scored based on gross detection of adhesions and omentum retrahens and on 
microscopic evaluation of (peri)pancreatitis, fat necrosis and micro abscesses. In 
animals s.c. injected lesions were scored separately for primary and secondary 
injection site. The score was based on diameter of lesions and on microscopic 
evaluation of infiltrates and the presence of necrosis. In the d.f.p. injected animals 
swelling was scored grossly and severity of lesions was scored microscopically by 
involvement of deep layers and the presence of ulceration. Gross and histopathologic 
lesions were scored as follows: - = minimal; + = mild; ++ = moderate; +++ = marked. 
Immunoassays 
Serum antibodies to MBP, SP215 and M. pneumoniae were determined using a direct 
enzyme linked immunosorbent assay (ELISA). For animals immunized with SP215 
and MBP, ELISA procedures were performed essentially as described by Zegers et al. 
(1991). Sera were diluted 1:100, 1:300 and 1: 900. 
For M. pneumoniae antibodies, ELISA was performed as described in detail by 
Leenaars et al. (1994). The sera were diluted using three-fold dilutions from 1 : 270 to 
1 : 65610. 
Immunohistochemistry 
Detection of cytokine-producing cells and gp39+ cells in PLN were performed 
essentially as described by Van den Eertwegh et al. (1993). Cryostat sections (-20°C, 
8 f1m) were fixed for 10 min. in fresh acetone containing 0.02% H,O,. The murine 
monoclonal antibody (mAb) DB-1 (specific for rat IFN-y and cross-reacting with murine 
IFN-y) and the rat mAb S4B6 (specific for murine IL-2) both conjugated to alkaline 
phosphatase (AP) were used as cytokine-specific antibody conjugates. After washing 
the slides with PBS, AP activity (blue) was demonstrated by naphthol-substrate as 
described by Claassen et al. (1986a). Immunohistochemical demonstration of gp39 
was performed with MR-1 (a hamster mAb specific for murine gp39) horizontally 
overnight under high humidity at 4°C. Slides were washed three times with PBS 
followed by the murine mAb specific for rat/hamster-Igk (RG-7) chain conjugated to 
peroxidase (HRP) horizontally for 1 h under high humidity at RT. RG-7 HRP slides 
were washed three times with PBS and HRP activity (red) was demonstrated by AEC-
substrate as described by Claassen et al. (1986a). 
For both substrate types, the reaction was stopped by transferring slides to PBS. 
Sections were counterstained with haematoxylin, rinsed with tap water and embedded 
in glycerin-gelatin. Cytokine-producing cells (IL-2-PC and IFN-y-PC) and gp39+ cells 
were counted per cryostat section. 
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Statistical evaluation 
For statistical evaluation change in body weight was calculated as body weight on 
testday minus body weight on last measured day before. Differences between 
adjuvant and no-adjuvant groups were evaluated for significance using analysis of 
variance. Serum antibody responses at necropsy were analyzed by the two-sample 
Student's t-test for comparison of two empirical means in a normally distributed 
population. A probability of 0.05 or less was considered significant. 
Results 
Clinical findings 
After 7 days, the body weights of immunized animals were equal to or higher than 
body weights of control mice for the remainder of the post-immunization period. Pilo-
erection was observed two days after primary and secondary immunization, mainly in 
FA groups and when M. pneumoniae preparations were injected. Abnormalities 
(swelling, signs of pain etc.) after immunization are described below per injection 
route. 
i.p. injection 
Body weights decreased significantly in groups of mice (n=5) i.p. immunized with 
FCNantigen (3 out of 3 groups), Specol/antigen (2/3), Lactobacillus/antigen (1/3) or 
RV-ISCOMs/antigen (2/2). 
After primary immunization, Lp. injected animals showed no abnormalities at the 
injection site and palpation of the abdomen did not lead to any sign of pain such as 
vocalizing or struggling. Within one hour after secondary immunization (Lp.) with 
FINSP215 emulsion animals died. Within 2-3 days after secondary injection (i.p.) of 
antigen/RV-ISCOMs, some animals died (combined with SP215, 2/5 and .combined 
with MBP, 5/5). 
s.c. injection 
When mice were immunized subcutaneously, body weights significantly decreased 
after primary injection of FCNantigen (2 out of 3 groups), Specol/antigen (2/3), 
Lactobacillus/antigen (1/3) or RV-ISCOMs/antigen (1/2). At the s.c. injection site of 
F Nantigen emulsions, palpable nodules, varying in size between 1 and 5 mm, were 
found. One hour after secondary immunization (s.c.) with FINSP215 emulsion, one 
mouse died. In some animals s.c. injected with M. pneumoniae combined with Specol 
or Lactobacillus a yellow spot was found at the site of injection. Secondary injection of 
Quil NM. pneumoniae preparations (s.c.) resulted in nodules of 2-5 mm. 
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d.f.p. injection 
In animals injected with FCA, body weights were significantly decreased 2 days after 
immunization. An ulcerative lesion was found at the injection site in two animals 
injected with Quil AIM. pneumonlae 
Behavioural changes and physiological state 
Pilo·erection was observed in the first days after primary immunization (Lp.) with the 
FCAlSP215 or FCAlMBP emulsions. No significant changes in behaviour or 
physiological state of the mice were observed in other groups after primary 
immunization. After secondary injections, pilo·erection was observed in all groups Lp. 
or s.c. injected with M. pneumoniae preparations. Secondary injections resulted in 
mortality in some groups (specified above). 
Pathological findings at necropsy 
i.p. injection 
Table 2 shows gross and histopathologic lesions at necropsy. The most prevalent 
abdominal abnormality was white smooth shiny thickening of the peritoneum 
covering liver, diaphragm and spleen. Microscopically, these 'plaques' are 
granulomatous peritonitis. This was present in all FA and Specol treated animals. In 
animals that died immediately after FIAlSP215 injection (Lp.) the same plaques were 
found. Moreover they showed cyanosis of extremities and congestion of intestinal 
serosa. Animals that died after secondary injection (Lp.) of RV-ISCOMs/antigen 
showed a red nose and congestion of intestinal serosa and liver while no abdominal 
granulomatous lesions were found. Histology of the kidneys of three animals 
showed acute degeneration of convoluted tubules. Omentum retrahens was present 
in all groups treated with M. pneumoniaeladjuvant preparations. Intestinal adhesions 
were only found in FAlMBP (3/5 animals) and in RV-ISCOMs/antigen (1/3) injected 
animals. This last animal showed arteritis in the pancreas. 
s.c. injection 
FA injection sites most consistently showed lesions both 1 week after FIA as 7 weeks 
after FCA application. FCA injection resulted in white subcutaneous nodules 
measuring 1-9 mm, microscopically deSignated as fibrosing granulomas. FIA induced 
lesions grossly showed white fluid diffusely in the s.c. fat. Microscopy revealed oil 
spaces and fat necrosis surrounded by active fibrous tissue rich in granulocy1es. At 
the primary injection site of SpecoliM. pneumoniae in 3/5 mice thin-walled cysts 
(2-3 mm) with yellow fluid were present, microscopically diffuse pyogranulomatous 
panniculitis. Secondary injection of SpecoliM. pneumoniae induced subcutaneous 
white lesions which microscopically are granulomas around large oil spaces. A soft 
yellow mass was found after secondary injection of LactobacillusiM. pneumoniae and 
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Qui! AIM. pneumoniae, which microscopically appeared to be exudative panniculitis 
and diffuse necrotizing panniculitis respectively. 
Table 2. Score of gross and histopathologic lesions at necropsy (7 weeks after 
primary and 1 week after secondary injection) of mice injected with various 
adjuvanVantigen or saline/antigen mixtures via different routes· 
Pathological findings' 
i.p. s.C. d.f.p. 
Adjuvant Antigen extenf severity' primary" secondary" gross' histo' 
FA 
Specol 
Lactob.1 
RV-
ISCOMs 
QuilA 
Saline 
SP215 
MBP 
M.pneu. 
SP215 
MBP 
M.pneu. 
SP215 
MBP 
M.pneu. 
SP215 
MBPh 
M.pneu. 
SP215 
MBP 
M.pneu. 
d 
++ 
+++ 
+ 
+ 
++ 
+ 
+ 
++ • 
+++ +++ + 
+++ + ++ 
+ 
+ ++ + 
+++ ++ 
+ 
+++ ++ 
'Intraperitoneal (i.p.), subcutaneous (s.c.) 01 at the dOlsal site of the hind feet (d.f.p.); 
++ 
++ 
++ 
+ 
++ 
++ 
+ 
+++ 
b comparison of data is possible Intraroute and not Interroute because of anatomical differences; 
c _ = minimal; + = mild; ++ = moderate; +++ = marked; 
+ 
+ 
++ 
+ 
+++ 
d no data comparable since animals died within 1 h after secondary injection (see: Resulls section); 
e primary and secondary injection on the same site; 
f Lactoabacillus spp; 
gin 1/3 animals lesions were found (see: Pathological findings at necropsy, I.p. injection section); 
h 14 weeks after primary Injection; 
I no data comparable since animals died within 48 h after secondary injection (see: Results seclion). 
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d.f.p. injection 
Injection of FAiantigen or Specol/antigen preparations resulted in diffuse swelling of 
the metatarsal region and local swellings at the dorsal side just proximal to the 
metatarso-phalangeal joints and of the tarsal region. Histologically granulomatous 
inflammation in the subcutis was present. In the FA treated animals lesions also 
involved muscles, tendon sheaths and periost. Lesions were most severe after d.f.p. 
injection of Quil AIM. pneumoniae. Feet were swollen and hyperaemic and two 
animals showed an ulcerative lesion. Microscopically these lesions were extremely 
exudative and also involved the deep layers. The relative enlargement of the PLN 
after dJ.p. injection is shown in Table 3. 
Table 3. T cell activation, enlargement of popliteal lymph nodes (PLN), and anti-
body response of animals dJ.p. injected with various adjuvanVantigen preparations 
Antigen Adjuvant IL-2' IFN-y gp39 PLN' antibody response' 
SP215 FA + + + ++ 1.68±O.4 
Specol + + + ++ 1.78±O.2 
Lactab.d + O.19±O.2 
RV-ISCOMs + + + 1.97±O.O5 
Saline O.O4±O.5 
MBP FA + + + ++ O.15±O.2 
Specol + + + ++ O.O7±O.O3 
Lactob. 
RV·ISCOMs + + + ++ 1.83±O.5 
Saline 
M.pneu. FA + + + ++ 6 
Specol + + + ++ 6 
Lactab. + + + + 5 
OuilA + + + + 6 
Saline + + + 4 
a IL~2-PC. IFN-y-PC, gp39+ cells; - ;;: no staining observed, + ;;: staining observed; b PLN; - ;;: not enlarged, 
+ ;;: twice enlarged, ++ ;;: three times or more enlarged;C serum antibody responses one week after 
secondary injection; SP215 and MBP results are expressed as absorbance at 405 nm for diluted (1:300) 
sera. Values represent the mean ± SO of antibody responses of five mice. M. pneumonlae results are 
shown as 3109 serial dilutions with a serum dilution from 1 :270 (1) to 1 :65610 (6);0:1 Lacotabacl7lus spp. 
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Antibody response 
High serum anti-SP215 responses were found after injection of SP215 in combination 
with FA, Specol or RV-ISCOMs (Fig. 1). The d.f.p. injection resulted in antibody 
responses comparable to s.c. injection. Primary injection of SP215 emulsified in FCA 
or Specol resulted in high antibody responses which reached a plateau at week 5 
while secondary injection had limited effect on antibody responses. The secondary 
injection of RV-ISCOMs/SP215 had enhancing effect on the immune response. When 
RV-ISCOMs/SP215 were injected d.f.p., antibody responses were low until secondary 
immunization. A secondary injection (d.f.p.) of RV-ISCOMs/SP215 enhanced the 
antibody response to a level comparable to FAlSP215 or Specol/SP215 emulsions. 
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Figure 1 Serum anti-SP215 antibody responses In a direct ELISA. Mice were primary immunized and 
boosted (i.p. or s.c.) with different adjuvantlSP215 preparations. The results are expressed as 
absorbance at 405 nm for diluted (1:300) sera, collected 4 weeks after primary Immunization, one day 
before secondary injection and one week after secondary injection. ", no data available. Data from one 
week after secondary injection represent mean ± SO of antibody responses of five mice. 
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The i.p. injection of FNMBP emulsions resulted in high antibody titres (Fig. 2). After 
RV-ISCOMs/MBP injection (i.p.) serum antibody responses were still rising at the 
moment of secondary immunization. When MBP was s.c. injected (Fig. 2) antibody 
titres were similar to those produced after d.f.p. injection. Low anti-MBP antibody 
responses were found after injection of FNMBP emulsions via s.c. or d.t.p. route also 
after a secondary injection. After primary injection of RV-ISCOMs/MBP (s.c. or d.f.p.) 
anti-MBP antibodies increased till secondary immunization (week 13). Secondary 
injection (s.c. or d.f.p.) of RV-ISCOMs/MBP enhanced the immune response 
significantly. 
After primary injection of adjuvantiM. pneumoniae preparations minimal differences 
in antibody responses were observed between the adjuvants (data not shown). A 
secondary injection resulted in enhanced antibody responses in all groups. The effect 
of secondary injection of adjuvantiM. pneumoniae preparations on antibody responses 
was higher than in the salinelM. pneumoniae injected animals. 
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Figure 2 Serum anti~MBP antibody responses in a direct ELISA. Mice were Immunized and boosted 
(i.p. or s.c.) with different adjuvanUMBP preparations. The results are expressed as absorbance at 
405 nm for diluted (1:300) sera, collected 4 weeks after primary immunization, one day before 
secondary injection and one week after secondary injection. *, no data available. Data from one week 
after secondary injection represent mean ± SO of antibody responses of five mice. 
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T cell activation 
Cytokine production (IL-2, IFN-y) and gp39 expression were demonstrated by 
immunohistochemistry (Table 3). IL-2-producing cells (IL-2-PC) and IFN-y-PC cells 
were observed in PLN of animals injected with FNSP215 or Specol/SP215 emulsions 
or with RV-ISCOMs/SP215 (Fig. 3(a)). Gp39+ cells were demonstrated in PLN of all 
animals injected with different adjuvanVSP215 preparations. No gp39 expression or 
cytokine production were demonstrated in PLN of saiinelSP215 injected animals. 
In PLN of animals injected with FNMBP, Specoi/MBP, or RV-ISCOMs/MBP, IL-2-PC, 
IFN-y-PC and gp39+ cells were demonstrated. No cytokine-producing cells or gp39+ 
cells could be demonstrated in animals injected with LactobacilluslMBP or satine/MBP 
mixtures. IL-2-PC, IFN-y-PC and gp39+ cells (Fig. 3(b) - 3(d)) were observed in PLN of 
all animals injected with preparations containing M. pneumoniae as antigen. 
Discussion 
In a comparative study in mice we here show that RV-ISCOMs can be used as an 
effective adjuvant for the production of specific antibodies to autoantigen and small 
peptides while inducing minimal side effects when injected subcutaneously. In a 
previous study in rabbits (Leenaars et al., 1994) we concluded that Specol might be 
an acceptable alternative to FA. Based on data of this study with 3 antigens, we 
suggest that this conclusion can be extended to the mouse. An exception was 
autoantigen MBP, where only a very small amount of anti-MBP antibodies could be 
detected in serum of Specol/MBP injected animals. Cytokine-producing cells and 
gp39+ cells were demonstrated in PLN of animals d.f.p. injected with all three 
antigen/Specol emulsions while PLN were enlarged and many plasma cells were 
present (data not shown). The enlargement of the PLN can be explained by the 
aspecific immune-stimulating effects of Specol as described by Boersma et al. (1992). 
The low level of antibodies might be explained by the minimal presence of specific B 
cells for autoantigen (MBP). Furthermore, we were unable to induce Experimental 
Allergic Encephalomyelitis (EAE) in SJUJ mice with Specoi/MBP as opposed to 
FCNMBP (data not shown), indicating yet again that T cells were not antigen 
specifically activated by SpecoliMBP. High antibody responses found after 
immunization with Specol/SP215 confirm the data of Boersma et al. (1989) who found 
25 I1g of SP29 emulsified in Specol to be sufficient in mice to elicit an anti-peptide 
response. Specol can be a possible alternative to FCA; however, more research is 
needed to confirm that it is an alternative to FCA for a wide range of antigens. 
Pathological changes after i.p. injection of Specol emulsions were similar to those 
observed after injection of Freund's adjuvant emulsions, but the area affected was less 
extensive. 
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Figure 3 Immunohistochemical vlsualizalion of IL-2-produclng cells (IL-2-PC) and gp39' cells In the 
PLN after secondary Immunization with antigen/adjuvant mIxtures. Cryostat sections of murine 
lymphoid tissue were Incubated with specific Immuno-conjugates, followed by the appropriate 
substrates, as described in Animals, materials and methods section. IL-2-PC in a cryostat seclion of 
the PLN of a mouse, one week after secondary immunization with FIA combined with SP215 (a). 
Gp39+ cells In a cryostat sections of the PLN of a mouse, one week after secondary immunization with 
SpecoliM. pneumoniae (b), Laclobacl/luslM. pneumonia. (c) or Qui! NM. pneumonlae (d). 
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Only the injection of RV-ISCOMs/MBP induced high antibody responses to MBP 
after s.c. and d.f.p. injection. The responses exceeded those induced by Freund's 
adjuvant. The secondary injection of RV-ISCOMs/MBP was given in week 13 owing to 
the availability of the conjugated antigen. At week 7 anti-MBP antibody levels in the 
RV-ISCOMs/MBP were already higher than those found in the FNMBP group which 
received a secondary injection at week 6. Moreover, levels still increased in the period 
until the secondary immunization (at week 13) and had not reached a plateau at that 
time. 
For the coupling of antigen to RV-ISCOMs, the amounts of antigen given in Table 1 
were used per animal. However, possibly not all antigen was coupled to RV-ISCOMs 
and therefore the amount of antigen injected in combination with RV-ISCOMs may be 
lower than given in Table 1. It has been shown that when antigen is coupled to 
ISCOMs, immunization can be performed at reduced antigen concentra-tions (Morein 
et al., 1987). Coupling of haptens and peptides to ISCOMs is a laborious process and 
not all types of antigen can be coupled. These are disadvantages if ISCOMs are to be 
used as a ready-to-use product that serves as alternative to FCA. 
Besides the adjuvant, also the type of antigen and the route of injection influenced 
the severity of the lesions found after immunization with the adjuvanVantigen 
preparations. When different antigens were compared most severe lesions were found 
after injection of M. pneumoniae preparations. The nature of the antigen injected may 
be involved in the severity of induced lesions. When different injection routes were 
compared, i.p. injection resulted in relatively severe lesions (including intestinal 
adhesions, (peri)pancreatitis, abscesses) compared to s.c. injection and in some 
groups animals died after secondary i.p. immunization. Within 1 h after secondary i.p. 
injection of FINSP215 emulsions, animals most probably died as a result of 
anaphylactic shock as suggested by time course and observed circulatory 
disturbances (peripheral cyanosis and abdominal congestion). After the secondary i.p. 
injection of RV-ISCOMs/SP215, two animals died after 2-3 days (not suitable for 
microscopy). In one survivor arteritis was observed which suggests the possibility of a 
type III hypersensitivity reaction. Secondary i.p. injection of RV-ISCOMs/MBP resulted 
in death of the whole group within 48 h. No evidence of acute immune complex 
disease was found (i.c. no endothelial proliferation or polymorphonuclear infiltration in 
vessels or glomeruli) in these five mice. The presence of free Quil A in ISCOM 
preparations is not considered the cause of death. Quil A is known to have intrinsic 
haemolytic activity in vitro. When Quil A is incorporated in ISCOM, the haemolytic 
activity is ten times lower than observed with free Quil A (Kersten, 1990). 
Macroscopically, no signs of haemolysis were found and microscopically no 
haemoglobin was present in renal tubular epithelium. Morein et a/. (1987) and Speijers 
et al. (1988) observed minimal pathological effects after injection of ISCOMs. Speijers 
et al. (1988) injected 0.25 ml measles virus ISCOMs containing 90 I1g Quil A 
intramuscularly in rats and observed minimal local and no haematological effects. 
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Other immunopathologic events may have caused the death of these animals since 
these animals died within 48 h after secondary injection white circulatory disturbances 
were found as may be observed in shock state. Besides these immunopathologic 
events after i.p. injection, minimal pathological lesions were observed after injection of 
RV-ISCOMs. 
At necropsy severe pathological changes were found after injection of FA. Despite 
the severe lesions we could not demonstrate signs of prolonged pain or distress 
based on clinical observations, weight gain or several behavioural studies. This is in 
correspondence with results of Toth et al. (1989) who did not find prolonged signs of 
pain in mice after i.p. injection of 0.5 ml FNsaline (1:1). Van den Broek et al. (1994) 
however, suggest that i.p. injection of 0.1 ml FCA may lead to severe distress. The 
reasons for the fact that we could not demonstrate prolonged pain or distress white 
severe lesions were found could be that these lesions do not induce pain and distress 
in mice or the methods we used were not sufficient to detect prolonged animal 
distress. In order to control possible pain and distress, the induction of severe 
pathological changes need to be kept to a minimum. Amyx (1987) suggested that 
most of the undesirable side effects of the use of Freund's complete adjuvant can be 
eliminated by careful control of injection quantity and site selection. 
In conclusion, when alternative adjuvants are compared, the effect of the nature of 
antigen on immune responses and side effects, should be taken into account. We 
suggest that Specol is a possible alternative to FCA for the production of specific 
antibodies to small peptide and particulate antigen. We demonstrated that s.c. 
injection of RV-ISCOMs can be used for the production of specific antibodies to 
autoantigen or small peptide and cause minimal side effects. 
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Assessment of side effects induced by 
injection of different adjuvant/antigen 
combinations in rabbits and mice 
P.P.A.M. Leenaars, M.A. Koedam, P.W. Wester, V. Baumans, 
E. Claassen and C.F.M. Hendriksen, submitted. 
Adjuvant induced side effects 
Abstract 
In this paper, an evaluation is made of the side effects induced by injection of 
Freund's adjuvant (FA) and alternative adjuvants combined with different antigens. 
Freund's complete adjuvant was used in primary and Freund's incomplete adjuvant 
in secondary immunizations. This is abbreviated by FA. Rabbits and mice were 
injected subcutaneously (s.c.), intramuscularly (i.m.; rabbits) or intraperitoneally (i.p.; 
mice) with different adjuvants (FA, Specol, RIBI, TiterMax, Montanide ISA50, DDA, 
Gerbu, ISCOMs, Quil A, Lactobacilli) in combination with several types of antigens 
(synthetic peptides, autoantlgen, glycolipid, protein, Mycoplasma or viruses). 
Parameters used to evaluate the effect of treatment on animals' well-being included: 
clinical and behavioural changes (POT and LABORAS procedures) and gross and 
histopathological changes. In rabbits, no indications were found that injection of 
adjuvant/antigen mixtures induce acute or prolonged pain and distress. In mice, 
behavioural changes were observed immediately after (predominantly secondary) 
immunization. Injection of several adjuvant/antigen mixtures resulted in severe 
pathological changes, depending on adjuvant, type of antigen, animal species used 
and route of injection. In rabbits and mice, pathological changes were marked to 
severe after injection of FA while changes were variable, ranging from minimal to 
marked, after Specol and Montanide ISA50 injections. Pathological changes after 
RIBI injections were severe in rabbits while slight in mice. After TiterMax injections 
pathological changes were moderate in rabbits and severe in mice. ISCOMs, DDA, 
Lactobacillus or Gerbu induced minimal pathological changes as found at necropsy. 
Quil A1Mycop/asma pneumoniae induced severe pathological changes. In 
conclusion, injection of FA in accordance with existing guidelines resulted in most 
cases in severe pathological changes but in minimal clinical and behavioural 
indications of prolonged severe pain. From our data it appeared that Montanide 
ISA50 and Specol induce acceptable antibody titres and less pathological changes 
than FA. We therefore conclude that Montanide ISA50 and Specol can be an 
alternative to FA. 
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Introduction 
Immunization procedures are performed on a large scale in laboratory animals, often 
to produce specific polyclonal antibodies to different kinds of weakly immunogenic 
antigens. To enhance the immune response, an adjuvant is added to the antigen. In 
laboratory animals, Freund's complete adjuvant (FCA) is commonly used for this 
purpose since it evokes high-level and long-lasting humoral and cellular immunity to 
a wide range of antigens. However, the severity of the side effects induced by FCA 
has resulted in guidelines discouraging its use in laboratory animals (e.g. Canadian 
Council on Animal Care, 1991; Veterinary Public Health Inspectorate, 1993). The 
use of alternative adjuvants is recommended to reduce pain in immunized animals. 
Many products with adjuvant activity are available (reviewed in Claassen and 
Boersma, 1992; Vogel and Powell, 1995; Cox and Coulter, 1997). An alternative to 
FCA should be an adjuvant that induces minimal side effects and acceptable 
antibody responses and is easy to prepare, commercially available and inexpensive. 
Most evaluation studies on adjuvants emphasize the immunological properties of the 
product. Since the aim of replacing FCA is to reduce pain and distress, it is 
necessary to also evaluate the side effects upon administration. 
The severity of side effects can be evaluated based on clinical, behavioural, 
biochemical, and pathological parameters. Morton and Griffiths (1985) and Wallace 
et al. (1990) issued guidelines on the recognition of pain, distress and discomfort in 
experimental animals. The assessment includes general appearance, body weight, 
clinical signs, unprovoked behaviour, and responses to appropriate stimuli. Elevated 
levels of hormones or metobolites may be used as indicators of pain, however, 
problems may occur when interpreting these levels in pain and distress (Broom and 
Johnson, 1993). Irwin (1968) developed the Primary Observation Test to assess 
pain after injection of pharmacological agents. Jansen van 't Land and Hendriksen 
(1995) described a system to evaluate discomfort based on locomotion activity. 
Recently, a behaviour registration system LABORAS (Bulthuis et al., 1997; Van de 
Weerd, 1996) was developed which automatically records six different categories of 
behaviour (immobility, locomotion, climbing, grooming, eating, drinking) during 
prolonged periods of time. This system seems promising for extensive behavioural 
studies. Side effects of adjuvants can also be assessed based on gross- and 
histopathological changes. Many studies on side effects after administration of FCA 
have been published, while only limited data (Oeeb et al., 1992; Johnston at al., 
1991) are available on side effects induced by alternative adjuvants as compared to 
FCA. 
To obtain more information on side effects induced by Freund's adjuvant and 
alternative adjuvants, we performed comparative studies in which rabbits and mice 
were given different combinations of adjuvant and antigen via different routes. 
Besides antibody responses, clinical, behavioural, and pathological changes were 
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studied. Emphasis is put on five adjuvants (Freund's adjuvant, Specol, RIBI, 
TiterMax and Montanide ISA50) which are commercially available and easy to 
prepare; other adjuvants (DDA, Gerbu, ISCOMs, Quil A and LactobacillI) were 
studied in less detail. 
Animals, materials and methods 
Animals 
New Zealand White rabbits (Oryctolagus cuniculus) of both sexes were obtained 
from the specific pathogen free (SPF) breeding centre of the RIVM. The rabbits were 
about 6 months old and weighed between 3.5 and 4.0 kg initially. They were 
individually housed in stainless steel or plastic cages, environmental temperature of 
20-21°C and under a 12 h day-night light cycle. The relative humidity was between 
45 and 60%. The rabbits were fed rabbit chow (80 g/day, Hope Farms BV, Woerden, 
the Netherlands) and tap water was available ad libitum. 
BAlB/c/Rivm mice of both sexes were bred SPF at the RIVM breeding facilities 
and were used at 10-14 weeks of age. At the RIVM, animals were housed in groups 
of five mice (one sex) under SPF conditions in Macrolon type II cages, 
environmental temperature of 20-22°C, relative humidity of 50-70% and with a 12 h 
day/night cycle. Mice were fed a commercial diet (Hope Farms BV, Woerden, the 
Netherlands) and provided wilh tap water ad libitum. One exception is the 
behavioural experiment (lABORAS) at Utrecht University. For this experiment, 
female BAlB/cAnCrRyCpbRivU mice were maintained at the Central laboratory 
Animal Institute (GDl) of Utrecht University, the Netherlands, and were used at 10-
12 weeks of age. At the GDl (Utrecht), mice were housed individually in Macrolon 
type II cages, environmental temperature of 20-22°C, relative humidity of 50-70% 
and with a reversed 12 h day/night cycle. 
Adjuvants 
Freund's complete adjuvant (FCA; Difco laboratories, Detroit, MI) consists of 85% 
paraffin oil (mineral oil; Bayol F) and 15% emulsifier (mannide monooleate) with 
added heat-killed Mycobacterium butyricum (0.5 mg/ml). Freund's incomplete 
adjuvant (FIA; Difco laboratories, Detroit, MI) is the same product as FCA except 
that no Mycobacteria were added. The term Freund's adjuvant (FA) is used in this 
paper to indicate that FCA was used in primary and FIA in secondary immunization. 
Specol (ID-DlO, lelystad, the Netherlands; Bokhout et al., 1981; Boersma et al., 
1992) is 90% mineral oil (Marcol 52) and 10% emulsifier (Span 85 and Tween 85). 
RIBI (Sanbio BV, Uden, the Netherlands; Rudbach et al., 1995) consists of 
metabolizable 011 (squalene; 2% in final volume of adjuvant/antigen), emulsifier 
(Tween 80) and microbial components: 0.5 mg/ml monophosphoryl lipid A (MPl), 
0.5 mg/ml synthetic trehalose dicorynomycolate (TOM) and (when used in rabbits) 
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0.5 mg/ml cell wall skeleton (CWS). TiterMax (CytRx, Norcross, GA; Hunter et al., 
1995) consists of a metabolizable oil (squalene), emulsifier (sorbitan monooleate 
80), a patented block copolymer CRL-8941 and microparticulate silica coated with 
CRL-8941). Montanide ISA50 (Seppic, Paris, France; Ganne et al., 1994) consists of 
85% mineral oil and 15% emulsifier (mannide oleate). When mixed with aqueous 
antigen solution, FCA, FIA, Specol, Montanide and TiterMax form water-in-oil 
emulsions while RIBI forms an oil-in-water emulsion. ISCOM matrix with 
incorporated rabies virus glycoprotein (RV-ISCOMs) were kindly provided by Dr. I. 
Claassen (RIVM, Bilthoven, the Netherlands). Quil A ('Spikoside', Iscotec, Lulea, 
Sweden) is a purified saponin (Campbell and Peerbaye, 1992). Lactobacilli 
(Lactobacillus plantarum [ATCC 8014, 109 per mil, Lactobacillus casei [ATCC 393, 
109 per miD are non-pathogenic micro-organisms (Claassen et al., 1995) and were 
kindly provided by Dr. W. Boersma (TNO-PG; Leiden, the Netherlands). Gerbu 
adjuvant (Gerbu BIOTECHNIK GmbH, Gaiberg, Germany) contains GMDP (N-
acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine) in combination with 
natural synergists, supplied as a Iyophilisate. dimethyldioctadecylammonium 
bromide (DDA; Eastman Kodak Company, NY; kind gift from Dr. H. Snippe, Utrecht, 
the Netherlands) is a synthetic adjuvant which is surface active (Hilgers and Snippe, 
1992). 
Antigens 
Synthetic peptide (SPek15a, 27 amino acids, containing a Band T cell epitope) was 
synthesized as described by Zegers et al. (1993). Synthetic peptide (SP215, 21 
amino acids, a homologue to the hinge region of the human IgG2 molecule) was 
synthesized as described by Boersma et al. (1989). Myelin basic protein (MBP; 
Sigma, St. Louis, MO) is an autoantigen which is derived from bovine brain and 
consists of 173 amino acids, 18.5 kDa (Van Noort at al., 1993). Galactocerebroside 
(MBL-TNO, Rijswijk, the Netherlands; Gerritse et al., 1993) is a glycolipid. Bovine 
Serum Albumin (BSA) was obtained from Sigma, st. Louis, MO (A-9647). Measles 
virus (Edmonston strain; 107 CCID.ofml; van Binnendijk at al., 1994), rubella virus 
(HPV-77 strain; 107 CCID.ofml; Parkman et al., 1966) and mumps virus (Enderson 
strain; 107 CCID.ofml) was kindly supplied by Dr. N. Elzinga (RIVM, Bilthoven, the 
Netherlands). HIV peptides conjugated to tetanus toxoid were prepared by Dr. P. de 
Vries (RIVM, Bilthoven, the Netherlands). Mycoplasma pneumoniae (MAC strain) is 
a particulate antigen (0.1-0.8 ~m) and was a kind gift from Dr. A. Angulo (RIVM, 
Bilthoven, the Netherlands). The antigens (amounts per rabbit in Table 1 and per 
mouse in Table 2) were diluted in sterile phosphate buffered saline (PBS) except for 
galactocerebroside which was diluted in dimethyl sulphoxide (DMSO). 
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Adjuvant/antigen preparation 
Adjuvant/antigen and adjuvant/PBS mixtures, were prepared according to the 
manufacturers instructions. Freund's adjuvant emulsions (FCA in primary and FIA in 
secondary immunization, abbreviated by FA) were prepared by mixing FA and 
aqueous antigen solution (1 : 1), using two glass syringes with Luer Lock connector. 
The antigen was added to FA via the connector and mixed for 1 min. Specol 
emulsions were prepared by adding the aqueous antigen solution 
(Specol:antigen=5 : 4) dropwise to Specol while vortexing. RIBI emulsions were 
prepared by warming the RIBI vial to 40-45°C for 5 min., reconstituting a final 
volume of 2 ml with the aqueous antigen solution in the RIBI vial and vortexing for 3 
min. TiterMax was emulsified with aqueous antigen solution (1 : 1) the same way as 
FA, except that the aqueous antigen solution was added to the oil phase in two 
steps. Montanide ISA50 emulsions were prepared by pouring Montanide ISA50 in a 
glass tube, adding the aqueous antigen solution wilh a syringe and making 10 up 
and down strokes. Gerbu/antigen mixtures were prepared by adding antigen in PBS 
to the Gerbu powder and shaking carefully (per rabbit: 10 ~g Gerbu per injection). 
DDA was dis-solved in PBS and mixed with antigen (per rabbit: 400 ~g DDA per 
injection). When RV-ISCOMs were used as an adjuvant, the antigens (SP215 and 
MBP) were coupled to the RV-ISCOMs as described in Leenaars et al. (1995). Per 
injection mice received 3-4 ~g RV-ISCOMs. Quil A was dissolved in water, added to 
the antigen in PBS and mixed (per mouse: 10 ~g Quil A per intraperitoneal (Lp.) 
injection; 20 ~g Quil A per subcutaneous (s.c.) injection). Lactobacillus/antigen 
mixtures were prepared by adding antigen in PBS to Lactobacilli (109 per ml) in 1 : 1 
proportion and mixing well. 
Experimental design 
Comparative studies were performed in rabbits and mice. Adjuvant-antigen 
combinations inducing obvious problems were not unnecessarily repeated. 
Experimental designs are described in Table 1 for the studies in rabbits and Table 2 
for studies in mice. In rabbits, four experiments were performed, injecting animals 
s.c. on the flank or intramuscularly (Lm.) in the the posterior thigh. To discriminate 
between primary and secondary inoculations, single adjuvant/antigen injections 
were given on separate sites. This was not possible in rabbit exp nr. III and IV which 
were combined with routinely performed polyclonal antibody production 
experiments. Here, 4 injections were given (s.c.) due to concentration of antigen. In 
mice, three experiments were performed, injecting animals s.c. in the neck on 
primary injection and s.c. in the groin on secondary injection or Lp. Control rabbits 
and mice received antigen only. At selected time points blood samples were taken to 
determine antibody production, except for mice exp nr. III (see Table 2), which was a 
behavioural study only. Clinical and behavioural abnormalities occurring during the 
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experiment, and pathological changes at the end of each experiment were studied 
as described below. 
Table 1. Experimental design for immunization studies in rabbits 
Exp 
nr. Adjuvant 
I' -FA 
II 
-Specol 
-RIBI 
-TiterMax 
-none(PBS) 
-FA 
-Specol 
-Montanide 
ISA50 
-Gerbu 
-DDA 
'none(PBS) 
III -FA 
-Specol 
V -FA 
-Specol 
-Montanide 
ISA50 
-none(PBS) 
Antigen' 
(I'g per rabbit) 
-SPek15a (200) 
-Galacto (200) 
-M.pneu. (87) 
-Rubella' 
-BSA (1000) 
~Measlesi 
-Mumps' 
-HIV-pept/tt I 
-HIV-pept/tt II 
Route/ 
Volume (m/) #lb #2' 
-s.c.lO.5' 30 2 
-i.m.lO.5' 
-s.c.lO.1 24 2 
-Lm.lO.1 
-s.c.l4xO.25 4 5 
-s.c.l4xO.1 8 1 
Boost 
(day)' 
28 
28 
35 
28,M 
End 
(day)' Additional f 
42 W, T,L 
42 W 
49 
92 
, SPek15a = synthetic peptide; GalaclD = Galaclocerebroside; M.pneu. - Mycoplasma pneumonlae; 
BSA ::: bovine serum albumin; HIV-pepVIt ::: HIV peptides conjugated to tetanus toxoid; b number of 
combInations studied in experiment, combining one adjuvant, antigen, and route; (: number of animals 
injected per combination given in column #1; d day of secondary Immunization; e day of necropsy; f 
additional parameters studied to assess sIde effects; W= body weight, T ::: body temperature, L ::: 
locomotion activity; 9 also described in Leenaars et a/. (1994): h RIBI emulsions: 2 x 0.5 ml; TiterMax 
emulsions: 0.08 ml (as recommended by the manufacturers); I amount of ant1gen described In Antigen 
section of 'Animals, materials and methods'; J third immunization on day 84. 
Clinical and behavioural parameters 
General condition (appearance and clinical abnormalities) of the rabbits and mice 
was observed daily as described by Morton and Griffiths (1985). Abdomen of i.p. 
injected mice and s.c.lLm. injection sites were palpated to monitor signs of pain. 
Injection sites were examined for swelling the day after injection and weekly 
thereafter. Additional clinical or behavioural parameters were studied to evaluate 
side effects (see Table 1 and 2). These parameters are described below. 
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Table 2. Experimental design for immunization studies in mice 
Exp 
nr. 
I' 
Adjuvant 
-FA 
-Specol 
-RV-ISCOM8 
-Lactobac 
-none (PBS) 
I' -FA 
-Specol 
-QuilA 
-Lactobac 
-none (PBS) 
I' -FA 
-Specol 
-RV-ISCOM8 
-Lactobac 
-none (PBS) 
II -FA 
III 
-Specol 
-RIBI 
-TiterMax 
-Montanide 
ISA50 
-none (PBS) 
-FCA 
-none (PBS) 
Antigen' 
(Jig per mouse) 
Route/ 
Volume(ml) #1' 
-8.c.lO.2 
-MBP (100) -1.p.lO.2 10 
-8.c.lO.l 
-M.pneu.(15) -l.p.lO.2 10 
-8.c.lO.l 
-SP215 (50) -i.p.lO.l 10 
-SP215 (50) -8.c.lO.l" 24 
-none (PBS) -1.p.lO.2 
-none (PBS) -i.p.lO.2 2 
#:t 
5 
5 
5 
5 
4 
Boost End Add;-
(day)" (day)" tionaf 
42 49 W,P 
42 47 W.p 
42 47 W,P 
42 47 
18 L 
'MBP = myelin basic protein (autoanligen); M.pneu. = Mycoplasma pneumonlae; SP215 = synthetic 
peptide; b number of combinations studied in experiment, combining one adjuvant, antigen, and route; 
e number of animals Injected per combination given in column #1; d day of secondary Immunization; 
e day of necropsy; f additional parameters studied to assess side effects; W= body weight, P = Primary 
Observation Test, L = LABORAS. automated behaviour registration system; 9 also described In 
Leenaars at al. (1995); h TiterMax emulsions 0.05 mr (as recommended by the manufacturer). 
Body weight, body temperature, locomotion activity 
Rabbits were weighed (exp nr. I and II) weekly and mice (exp nr. I) were weighed 
before injection, 3 days after injection and twice weekly thereafter. Body temperature 
of rabbits (exp nr. I) was measured twice a week in a restraining box; after an initial 
acclimatisation of 30 min., the rectal temperature was recorded four times in 30 min. 
The average of these four temperatures was taken as the body temperature. 
Locomotion activity of rabbits was studied during the first week after primary and 
secondary injection by studying the animals moving freely in the animal room. 
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Primary Observation Test 
Behavioural changes and physiological state of the mice were studied (mice 
exp nr. I) in the Primary Observation Test (POT). POT is a systematic quantitative 
procedure described by Irwin (1968) and modified by Prof. Dr. B. Olivier (Solvay 
Duphar, Weesp, the Netherlands). The POT procedure was performed before 
injection, 3 days thereafter and then weekly. The POT procedure involved an initial 
phase of undisturbed observation and a later manipulative phase during which the 
animal was subjected to different stimuli. The procedure started by placing a group of 
five mice in an observation chamber followed by an adaptation period of 1 h. The 
observation study began by observing the animal's undisturbed behaviour within the 
observation chamber, i.e. dispersion in the cage, apathy, startle-reaction, rest-
lessness, watchfulness and respiration. Thereafter the animals were individually 
transferred onto the viewing arena to observe: arousal response to transfer, spatial 
locomotion, gait, slip resistance, righting reflex, exophthalmos and piloerection. Then, 
throughout individual handling, touch-reflex, provoked-freezing, provoked biting, skin 
colour, body tone, pupil size, urination-defecation and vocalisation were studied. After 
handling, mice were placed in the observation chamber and grooming was observed. 
Behavioural changes and physiological state were scored per mouse. 
Behaviour registration system LABORAS 
A newly developed behaviour registration system LABORAS (Bulthuis et al., 1997; 
Van de Weerd, 1996) was used to register behavioural patterns of individually 
housed mice (mice exp nr. III). The LABORAS system is a fully automated device 
which can deduce the behavioural categories: locomotion, immobility, climbing, 
grooming, eating, drinking. The animal is placed in a Macrolon type II cage which is 
located on a sensing platform. The mechanical vibrations caused by movements of 
the animal are transduced into electrical signals and recorded. The signals are 
translated into the six separate behavioural categories by a computer. On day 0, 
fifteen min. before the start of the dark period (= 15 min. before start of recording 
period), mice were injected with FCA or PBS (0.2 ml i.p.) and placed in the 
LABORAS system (i.e. in cage on sensing platform). Movements of the mouse were 
recorded during the first 4 hours of the dark period every other day during 16 days. 
Per day (i.e. first 4 hours of dark period) the relative time spent on each behavioural 
category was calculated and analysed. After a square-root transformation, data were 
statistically analysed using a t-test to detect significant differences in recorded 
behaviour between FCA and PBS injected mice. The level of statistical significance 
was pre-set at p < 0.05. 
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Pathology 
At the end of each experiment, rabbits were anaesthetized by intravenous injection 
of 2.5 ml sodiumpentobarbital (60 mglml) before bleeding via cardiac puncture. Mice 
were anaesthetized before orbital bleeding by Lm. injection of 0.1 ml of a mixture of 
ketamine (50 mglml), xylazine (20 mglml) and atropine (1 mglml) in a 7: 3 : 1 
volume ratio. Necropsy in rabbits and mice included dissection and examination of 
Injection sites and at least abdominal organs. For histopathological evaluation, 
tissue of injection sites, a sample of the omentum of all Lp. injected mice, and 
organs showing macroscopic abnormalities, were fixed in 4% neutral buffered 
formal-dehyde, embedded in paraffin, sectioned at 5 ~m, and stained with 
haematoxylin and eosin. Gross lesions were documented during necropsy and 
microscopy was performed in selected representative samples. In rabbits and In s.c. 
injected mice primary and secondary injection sites were scored separately, based 
on the area of Involvement and character of the lesions found. In individual rabbits 
the severity of lesions was scored according to Table 3. Microscopy was used to 
verify macroscopical observations (Fig. 1A-D). In individual mice, the severity of s.c. 
lesions was scored (macroscopically and microscopically) according to Table 4. In 
an attempt to grade pathological lesions, taking into account the supposed 
discomfort, categories were defined as shown in Table 3 and 4, which served as a 
general guideline for classification. In Lp. injected mice, the severity of abdominal 
lesions was mainly assessed macroscopically, based on the presence of abdominal 
effusions, adhesions, intestinal dilatation, presence of 'plaques' and omentum 
retrahens. Microscopical severity of peritonitis was determined to verify macroscopical 
observations. Examples of microscopic severity grade of lesions in mice are given in 
Fig. 1 E-H (s.c.) and Fig. 11-J (Lp.). 
Antibody responses 
During the experiments (except mice exp nr. III), blood samples were taken to 
determine antibody production. Since this paper emphasizes the side effects 
induced by adjuvants, only summarising results on antibody production will be given. 
More detailed information on antibody titres of rabbit exp nr. I and mice exp nr. I, can 
be obtained from Leenaars et al. (1994) and Leenaars et al. (1995), respectively. 
Antibody production after adjuvanVantigen injection was related to antibody 
production after FA/antigen injection. Antibody titre after FA/antigen injection was 
set on 100% and antibody titres after other adjuvanVantigen injections were 
expressed relative to the titre after FA/antigen. 
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Table 3. Pathological findings at injection sites of rabbits s.c. or Lm. injected with 
different adjuvant/antigen combinations; applied classification and gradinga 
grade 
8 
6 
4 
2 
o 
grade 
6 
4 
2 
Subcutaneous lesions" 
• extensive exudative lesions (generally accompanying granulomatous lesions) 
with severe haemorrhage. > 40 em' 
• abscess·like lesions, diameter> 2 cm 
• ulcus> 1 em 
• exudative lesions (generally accompanying granulomatous lesions) with 
haemorrhage < 20 cm' 
• extensive nodular granulomatous lesions 20-100 cm'; marked central necrosis 
in granulomas; minor signs of acute inflammation; 
• ulcus < 1 em 
• nodular granulomatous lesions 1 - 10 cm', without marked central necrosis 
and haemorrhage 
• nodular granulomatous lesions < 1 cm2 
• minimal diffuse opacity (flat granulomatous proliferation) andlor minimal or 
local hyperaemia or petecchial bleeding 5 - 25 em' 
• negative, or minimal local opacity or hyperaemia/petecchiae <5 cm' 
Intramuscular lesions" 
• granuloma(s) > 1 cm 0', with marked central necrosis 
• granuloma(s) > 2 cm 0', without marked central necrosis 
• granuloma(s) 0.5 - 2 em 0', without marked central necrosis 
• minimal white or red streaks in muscle, or slight hyperaemia or 
haemorrhage < 0.5 em 0' 
o • negative 
a In some cases lesions were given a score between the mentioned values; 
b when different lesions were present, highest scoring one was taken to classify the injection site; 
C transverse diameter, perpendicular to muscle fibres. 
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Table 4. Pathological findings at injection sites of mice s.c. injected with different 
adjuvanUantigen combinations; applied classification and grading" 
Primary Secondary 
gradeb macroscopy microscopy macroscopy microscopy 
3 • s.c. nodule • marked to • nodule externally • severe diffuse 
>4mm severe fibrosis, visible; s.c. nodule inflammation with 
diffuse > 5 mm or large marked cellularity 
inflammation amount of white (and generally 
and cellularity; tissue around thigh necrotising 
(epi)dermal muscles granuloma) 
abnormalities' 
2 • s.c. nodule • marked fibrosis • bulging white mass • marked diffuse 
2 -4 mm and slight to externally visible; inflammation with 
moderate s.c. marked moderate 
diffuse amount of white cellularity (and 
inflammation, tissue generally 
cellularity and necrotising 
granuloma granuloma) 
formation 
1 • s.c. nodule • slight to • white mass • moderate diffuse 
1 -2mm moderate externally visible, inflammation 
fibrosis, diffuse no swelling; s.c. 
inflammation. slight to moderate 
cellularity and amount of white 
granuloma tissue 
formation 
0.5 • s.c. nodule • minimal • negative externally; • minimal to slight 
< 1 mm fibrosis, diffuse s.c. minimal diffuse 
• s.c. inflammation. amount of white inflammation 
negative; cellularity and tissue 
hairless granuloma 
area <2 mm formation 
a In some cases scores were given In between mentioned values; 
b the macroscopic and microscopic severity grade of a lesion is not necessarily the same; 
(: exudative nature usually dominates granuloma formation. 
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Rabbit exp nr. III, s.c. FINmeasles virus, 2 weeks after secondary injection, score 8, Microscopical 
detail of palpable, extensive haemorrhaglc lesions, total surface 300 cm2• a: Necrosis of pre-existent 
tissue, as shown by pre-existent collagen fibres (arrows). between cellular debris and fibrin. b: 
Fibroangioblaslic proliferation with hyperaemia and haemorrhage. Considered primarily exudative, no 
granulomatous component present. HE, x11 O. 
B 
Rabbi! exp nr. IV, s.c. SpecollHIV-pepUIt II, 9 weeks after secondary injection, score 6. Microscopical 
detail of nodular complex, lesions, total surface 60 cm2• a: Marked central necrosis of granuloma, in 
which some oil spaces and no collagen fibres are present. b: Thin rim of vital granuloma. c: Fibroblast 
capsule. HE. x110. 
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Flgur.1 
C 
Rabbit exp nr. II, s.c. Montanide ISA50/BSA, 2 weeks after secondary injection, score 4. Microscopical 
detail of a palpable lesion, grossly described as faint pink tissue with central hyperaemia and slight 
haemorrhage, measuring 12 cm2 and maxImum width 0.5 cm. Epithelioid granulomas, partly around oil 
spaces, and Iympho-plasmacellular infiltrate between subcutaneous collagen fibres, Necrosis absent. 
HE, x110. 
D 
Rabbit exp nr. I, i,m. RIBllgaiactocerebroside, 6 weeks after primary injection, score 6. Microscopical 
delail of a lesion, described grossly as 1 cm 0 grey firm elongated mass, centrally containing thick 
yellow pus-like material surrounded by a red zone. a: Centrally in the lesion cellular debris and oil 
spaces. b: Necrotic muscle fibres. c: Reactive fibroblast capsule. Considered primarily exudative, no 
evidence for granulomatous component. HE, x110. 
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Mouse exp nr. II, s.c. TiterMaxlSP215, 7 weeks after primary injection. Grossly hairless area, s.c. 
pale-yellow nodule 5 mm with slight haemorrhage, score 3. Microscopical detail shows acanthosis, 
severe fibrosis and diffuse inflammation, with marked cellularity and an occasional small granuloma 
(9) with central necrosis, score 3, HE, xii O. 
F 
Mouse exp nr. II, s.c. SpecollSP215, 7 weeks after primary injection. Grossly white nodules < 2 mm 
and slight petechial bleeding In interscapular brown fat, score 1. Microscopically slight granuloma 
formation around oil spaces, moderate diffuse inflammation (not observable in this detail) and 
moderate fibrosis, score 1. HE, x110. 
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Figure 1 
G 
Mouse exp nr. II. s.c. TiterMaxlSP215. 5 days after secondary injection, Grossly promInent nodule. 
white viscous material inside thin capsule in s.c. fat. score 3. Microscopically fairly circumscribed 
lesion, essentially composed of large amount of cellular debris within reactive capsule, score 2.5. HE, 
x44. 
H 
Mouse exp nr. II. s.c. RIBllno anligen (PBS). 5 days after secondary Injection. Grossly minimal amount 
of white tissue s.c. in the groin, not externally visible. score 0.5. Microscopically moderate diffuse 
inflammation. score 1. HE. x44. 
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Mouse exp nr. II, I.p., omentum control: no adjuvant (PBS)/SP215. 5 days after secondary injecUon. 
Grossly negative, microscopically milky spots (physiological aggregates of lymphocytes and 
macrophages) and adipose tissue covered with Inconspicuous mesothelium. HE, x110. 
J 
Mouse exp nr.II, I.p., omentum Montanide ISA50/SP215, 5 days after secondary Injection. Grossly 
slight consolidation of omental edge, score 0.5 (see Table 7). Microscopically in contrast 
granulomatous inflammation, mesothelium prominent or absent, score 3. Also unaffected omentum 
present (not shown). HE, x110. 
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Results 
Clinical and behavioural signs 
Rabbits 
Both after s.c. and Lm. injection, no significant differences in body weight or body 
temperature were observed between the control (antigen injected) and experimental 
(adjuvanUantigen injected) groups. After injection, no clinical abnormalities were 
observed, except for one rabbit Lm. injected with RIBI/M. pneumoniae, which 
showed discomfort during locomotion activity the first 4 days after primary injection. 
Exp nr. I + II At s.c. injection sites in rabbits, tissue swelling was observed (see 
Table 5). Swelling at primary injection sites was mainly observed when FCA was 
injected. At secondary injection sites, swelling was observed more often than at 
primary injection sites. FA and RIBI injection most frequently resulted in swelling. 
Swelling, if present, increased the first 3-4 weeks after primary injection and 
decreased thereafter. After secondary immunization swelling increased during the 
first week post injection. 
In Lm. injected rabbits, no swelling was observed at the site of injection, except 
secondary Lm injection site of Specol/BSA. Upon palpation of s.c. and Lm. injection 
sites, no signs indicating pain were observed. 
Table 5. Tissue swelling after s.c. of injection adjuvanUantigen mixtures in rabbits 
Adjuvant 
Montanide 
Exp FA Speeal RIBI TiterMax ISA50 
nr. Antigen' primc secc prim sec prim sec prim sec prim sec 
SPek15a -d n.d. 
I Galaeto ++ ++ n.d. 
I M.pneu. ++ + ++ + n.d. 
II Rubella ++ + n.d. n.d. 
II BSA ++ + ++ n.d. n.d. + ++ 
a Antigens described under Table 1; 
b antigen conlrole (PBS + antigen injection): no abnormalities; 
C maximum swelling at primary (prim) or secondary (sec) injection site; 
oj - = no abnormalities; + = swelling < 2 cm; ++ swelling» 2 cm; n.d. = nol done. 
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Exp nr. III + IV Swelling was observed at most injection sites of rabbits given 
measles- or mumps antigen combined with FA or Specol, especially after secondary 
injection (5·20 cm2). Swelling after injection of mumps antigen combined with Specol 
was less extensive than combined with FA. Injection of HIV-peptide conjugates 
combined with FA resulted in severe swelling, persistent till the end of the 
experiment while injection of HIV-peptide conjugates combined with Specol resulted 
in swelling immediately after injection and minimal palpable swelling 4 weeks later. 
In rabbits injected with Montanide/HIV-peptide conjugates minimal swelling was 
observed. 
Mice 
Exp nr. I Body weight decreased in mice the first days after primary injection of 
FCNantigen (5 out of 6 groups; 5/6), Specol (4/6), RV-ISCOMs (3/4) and 
Lactobacillus (2/6). Within one week, body weights were back to normal. The first 
days after adjuvanUantigen injection, some clinical abnormalities were observed in 
mice. Piloerection was observed in mice the first two days after i.p. primary and 
secondary immunization with FNSP215 or FNMBP emulsions. After secondary 
immunization, piloerection was observed in all groups i.p. or s.c. given M. pneumoniae 
combined with an adjuvant. At s.c. injection sites of FCNSP215 and FCNMBP a 
nodule (1-4 mm) was palpated. Nodules were also observed when mice were given 
s.c. M. pneumoniae with FA, Specol or Quil A. The FA induced nodules were present 
from one week after injection till the end of the experiment. Quil A and Specol nodules 
had disappeared 4 weeks after injection. In exp nr. I, secondary i.p. injection resulted 
in mortality of mice when injecting FINSP215 (5 out of 5), RV-iscom with coupled 
SP215 (2/5) and RV-ISCOMs with coupled MBP (5/5). It should be noted that these 
deaths were antigen but not adjuvant related, probably related to the persistent high 
antibody titres observed in these animals. Palpation of injection site did not result in 
signs of pain. 
Exp nr. II Mice showed piloerection and hunched posture the first day after priming 
i.p. with FCA or TiterMax emulsions. The same clinical changes were found after 
secondary immunization with FA, TiterMax, Specol or Montanide emulsions. At 
necropsy (5 days after secondary injection) FA, TiterMax and Specol injected mice still 
showed piloerection. After primary s.c. injection nodules were palpable in mice 
injected with FNSP215 (4·8 mm) or TiterMax (5 mm). Two mice died after secondary 
i.p. immunization with FNSP215 (2/5). Palpation of the abdomen of i.p. injected mice 
or nodules at the s.c. injection sites did not lead to any sign of pain such as vocalising 
or struggling. 
Using the POT procedure, we did not observe changes in behaviour and 
physiological state of the mice (besides piloerection as described above). Assuming 
that lesions induced by i.p. FCNantigen injection are painful, we compared activity of 
mice at three weeks after i.p. injection of FCNSP215 or PBS/SP215. No differences 
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between these two groups were observed (data not shown), indicating that, at that 
time, mice were minimally disturbed in their locomotion activity by FCA injection. 
Behaviour registration system LABORAS 
In mice exp nr. III, no clinical abnormalities were observed. Using the LABORAS 
system, significant differences in behavioural patterns between FCA and PBS 
injected animals were observed. On the day of injection, locomotion, climbing, 
grooming, eating and drinking were significantly (p < 0.01) decreased in FCA 
injected mice while immobility was significantly (p < 0.01) increased in FCA injected 
mice as compared to PBS injected mice (Fig. 2). Two days later immobility was still 
significantly (p < 0.01) increased in FCA injected mice. Four days post immunization, 
no significant differences in recorded behaviour were observed. 
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Figure 2 Results of LABORAS behaviour registration system (mice exp nr. III). Behavioural patterns 
of FCA and PBS injected (0.2 ml J.p.) mice (n = 4) are shown. Relative mean time (± SD) spent on 
behaviour per day during 4 hours measuring period. * p < 0.01. 
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Pathological changes 
Rabbits 
Despite the absence of changes in clinical and behavioural parameters in rabbits 
after injection of adjuvant/antigen mixtures, severe pathological changes did occur in 
some of these animals. Pathological changes in rabbits of exp nr. I and II at primary 
and secondary injection sites of different adjuvant/antigen mixtures are summarized 
in Table 6. 
Gerbu injections induced no and DDA injections moderate lesions; as Gerbu and 
DDA gave negative immunological results, these adjuvants are not considered 
relevant and therefore are not included in Table 6. 
S.c. route rabbits RIBI and FA induced most and more severe lesions compared 
to other adjuvants. Lesions were often extensive (up to 100 cm2) and voluminous, 
combining proliferative and exudative features. Abscess-like lesions were only 
observed in RIBI treated rabbits. Specol, TiterMax and Montanide resulted in lesions 
at secondary injection sites mainly (Fig. 1 C). Their presence and severity depended 
on the antigen added. For the overall severity score of s.c. lesions per 
adjuvant/antigen combination (Fig. 3), the sum of the mean primary and secondary 
lesion score was taken, after applying a multiplication factor of 1.5 for the former 
score, to take into account possible reduction over time and longer duration of 
primary lesions. 
Pathological changes of rabbit exp nr. III and IV are not summarized in Table 6, 
since in these studies four injections, instead of one at a time, were given. When 
Specol was introduced to replace FA in routine polyclonal antibody production, for 
measles- and mumps antigen unexpected severe lesions were found. In the next 
series Specol and FA were compared, and with both antigens extensive (with 
measles antigen: more than 200 and more than 300 cm2 respectively and with 
mumps antigen almost 100 and more than 200 cm2 respectively) haemorrhagic 
lesions were induced (exp nr. III) (Fig. 1A). Measles antigen without adjuvant (n = 7) 
did not induce gross lesions, while mumps antigen (n = 1) induced an abscess-like 
lesion (60 cm2 totally). Injection of 4 x 0.25 ml FA without antigen (n = 1) induced 
extensive necrotising granulomas. The same amount of Specol without antigen 
(n = 1) resulted in (extensive: 100 cm2) primarily exudative lesions, while after a 
single dose of 0.1 ml (n = 1) minimal reaction was found (data not shown). In 
exp nr. IV, Specol and Montanide combined with antigen at relatively low doses 
(4 x 0.1 ml) were shown to induce eXUdative lesions (Fig. 1 B), which at the most 
recently injected sites were more severe than those induced by FlA. 
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Table 6. Pathological findings at injection sites of rabbits s.c. or i.m. injected with 
different adjuvanVantigen combinations 
s.c. injectionc i.m. injection 
Adjuvant' Antigenb primal}' secondal}' primal}' secondal}' 
FA SPek15a 4' 6 2 5 
Galacto 6 4 2 0.5 
M.pneu. 6 6 5 0 
Rubella 4 5 6 3.5 
BSA 5 6 6 5 
Specol SPek15a 0 3 0 6 
Galacto 0 0 0.5 0.5 
M.pneu. 2 6 2 4.5 
Rubella 0 0 0 0 
BSA 4 6 4 6 
RIB I SPek15a 7 4 5 3 
Galacto 7 7 6 6 
M.pneu. 5 8 5 6 
TiterMax SPek15a 1 5 2 5 
Galacto 2 0 2 
M.pneu. 3 6 0 3 
Montanlde Rubella 0 0 0 1 
ISA50 BSA 2 4 2.5 4.5 
a Antigen controls (PBS + antigen): all primary injection sites negative; secondary Injection sites: 
Galacto (i.m.), M.pneu. (Lm.) ~ severity score 1; Galacto (s.c.) ~ severity score 2; b SPek15a ~ 
synthetic peptide; M.pneu. ::: Mycoplasma pneumoniae; Galacto ::: Galactocerebroslde; BSA::: bovine 
serum albumin; e comparison is not possible between routes; d mean of severity score at injection site 
of two rabbits; score as described in Table 3 in 'Animals, materials and methods' secUon. 
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I.m. route rabbits Intramuscular lesions generally consisted of granulomas 
spreading parallel to muscle fibres and showed less variation in size and character 
than s.c. ones. Maximum cross diameter was 4 cm and in general length was 2 to 4 
times the cross diameter. RIBI and FA induced more and more severe lesions than 
the other adjuvants, resulted in lesions mainly at secondary injection sites. The 
presence and severity of lesions depended on the antigen used. Necrosis in I.m. 
granulomas was most common after RIBI injections. Necrosis of pre-existent tissue 
was restricted to 4 RIBI cases (Fig. 1 D) and 1 exceptionally severe Specol (BSA) 
case. The overall severity score of i.m. lesions is given in Fig. 3; the same 
calculation was applied as described for s.c. lesions. 
Freund's Speco! RIBI TflerMax MonlanJde ISMa 
(s.c,) SPI5a 
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Mpneu. 
"'. 
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'SA 
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overall severity score 
Figure 3 Overall pathological severity score of lesions after s.c. Of I.m. Injection of different 
adjuvanUantigen mixtures in rabbits (n = 2). For the overall severity score of lesions per 
adjuvanVanligen combination per route of injection, primary and secondary lesion scores were 
summed after applying a multiplication factor of 1.5 for the former score (see Pathological changes of 
'results' section. Antigen controls (PBS + antigen) are described under Table 6. 
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Mice 
Pathological changes in mice after injection of FA, Specol, RIBI, TiterMax and 
Montanide ISA50 are described later in this paragraph per route of injection. Data of 
RV-ISCOMs, Lactobacillus and Quil A are not included in Fig. 4 or Table 7, because 
of limited availability (RV-ISCOMs), negative immunological results (Lactobacillus) 
and limited immunological and pathological data (Quil A). When RV-ISCOMs were 
used, lesions (adhesion between omentum and mesorchium after Lp. inoculation) 
were found only in one mouse; however, 7 out of 20 mice died after secondary Lp. 
inoculation of RV-ISCOMs with coupled antigen. Lactobacillus induced pathological 
abnormalities only when combined with M. pneumoniae. (s.c.: exudative panniculitis; 
Lp.: omentum retrahens and fat necrosis). Quil A with M. pneumoniae resulted in 
comparable lesions (s.c. necrotising panniculitis; Lp.: marked omentum retrahens 
and peritoneal microabscesses). 
S.c. route mice Gross lesions found at the primary injection site varied slightly 
within groups, while lesions at secondary injection sites were almost identical within 
groups. At most primary injection sites of FA, TiterMax and Montanide, white or 
yellow nodules (2-10 mm) were observed. Microscopically, granuloma formation, 
exudative diffuse inflammation and fibrosis were present at varying degrees 
(Fig. 1 E-F). Specol resulted only in marked lesions at the primary injection site when 
it was combined with M. pneumoniae. After secondary injection of 
Specol/M. pneumoniae and in some animals after secondary injection of TiterMax, 
circumscribed and/or hyperaemic nodules (up to 10 mm) were found. At most 
secondary injection sites of other adjuvant/antigen combinations, grossly white shiny 
tissue attached to muscles was found. Depending on the amount of this apparently 
innocuous reaction, it was visible externally as a white s.c. area after moistening the 
coat and caused bulging of the skin in the groin. Microscopically, diffuse exudative 
inflammation usually dominated (Fig. 1 G-H), the severity of which was mostly 
uniform within groups and did not always parallel the gross findings. To come to a 
mean severity score of lesions per injection site, the sum of macroscopic and 
microscopic score was taken. To obtain an overall severity score per injected 
adjuvant/antigen combination, the sum of the mean primary lesion score (multiplied 
by 1.5) and the mean secondary lesion score was taken (as described for s.c. 
lesions in rabbits). The overall severity scores obtained in mice exp nr. II are 
visualized in Fig. 4. The score of FA in this figure (± 12) is representative for other 
antigens when combined with FA. The score of Specol when combined with 
M. pneumoniae was higher (10), and when combined with SP215 (exp nr. I) or MBP 
lower (± 2) than the depicted overall severity score of ± 5 for Specol/SP215. 
Injection of FA and RIB I in combination with antigen resulted in lesions comparable 
to those observed after injection of FA and RIBI without antigen. Specol and 
Montanide ISA50 without antigen induced lesions that were slightly milder than 
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those found after s.c. inoculation of the same adjuvant combined with antigen. 
TiterMax lesions were milder when s.c. injected without antigen compared with 
TiterMaxlantigen injection. All antigen controls (antigen+PBS) were grossly negative. 
Microscopically, M. pneumoniae/PBS and SP215/PBS (mice exp nr. II) injection 
resulted in minimal or slight diffuse inflammation at the secondary injection site. 
lop. route mice Injection of FA and TiterMax resulted most consistently in severe 
pathological abnormalities. Severity of lesions in the case of Specol depended on 
the antigen used. Pathological changes in Lp. treated mice are summarized in Table 
7. Findings were very homogenous within groups. Adhesions, often extensive, were 
seen between small and large intestine, spleen and abdominal wall or in the 
hypogastrium, with shortening of the ligamentum latum. The pattern of adhesions 
was strikingly comparable within groups. Other signs of peritoneal irritation were 
milky effusions and dilatation of the small intestine. In less severe cases, white 
smooth, shiny thickening of the peritoneum covering liver, diaphragm and spleen 
(designated plaques), and/or omentum retrahens were obselVed. Microscopically, 
severity of peritonitis was determined evaluating mesothelial alteration, volume and 
character of peritoneal infiltrate, hyperaemia and fibrosis. When no omentum could 
be recognized due to severe omentum retrahens, peritoneum covering the pancreas 
was analysed instead. Marked gross signs of active peritonitis were judged severe, 
regardless of microscopical score. In some groups gross abnormalities were minimal 
or slight, while microscopy revealed peritonitis of unexpected severity. When this 
was the case, the total score was increased when compared to the macroscopic 
overall score. Mice in exp nr. III (LABORAS experiment) showed no pathological 
changes after injection with PBS (0.2 ml Lp.) while FCAlPBS injection (0.2 ml Lp.) 
resulted in marked adhesions and plaques (Table 7). 
(s.c.) 
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Figure 4 Overall pathological severity score of lesions after s,c. injection of adjuvanVSP215 mixtures 
in mice (n = 2-4). The overall severity score was calculated as described under Figure 3. 
101 
Adjuvant induced side effects 
Table 7. Pathological findings in mice i.p. injected with different adjuvanVantigen 
combinations 
Adjuvanr Anliged' 
FA MBP 
M.pneu. 
SPil' 
- (PBS) 
Specol SPI 
MBP 
M.pneu. 
SPII 
- (PBS) 
RIBI SPII 
- (PBS) 
TiterMax SPII 
- (PBS) 
Montanlde SPII 
ISA50 - (PBS) 
FCA - (PBS) 
Macroscopv 
effu-
sions 
o 
o 
2 
o 
0.5 
o 
o 
o 
o 
o 
2 
2 
o 
o 
o 
adhe- intestinal pla- omenfu 
sions dilata- que m retm-
tlon S hens 
2 o 2 2 
o o 2 1.5 
2 o o 2 
o 0.5 0.5 
o o o 
o o 0.5 o 
o o 1.5 
2 2 o 2 
2 o 
o o 0.5 o 
o o o o 
o 2 
0.5 
o o 0.5 
o o 0.5 0.5 
2 o o 
Macro-
scop'; 
overall 
score 
4 
2 
4 
3 
2 
4 
4 
o 
o 
4 
4 
4 
Micro-
scoPY' 
severity total 
perito- scored 
nitis 
4.3 4 
4 2 
3 4 
3 3 
2 
3 
3 2 
4.5 4 
n.d. 4 
1.7 
1.8 
2.8 4 
n.d. 4 
3.3 2 
1.7 
n.d. 4 
a Antigen controls (PBS + antigen): grossly and microscopically negative; 6 SPI - synthetic peptide 
(mice exp nr. I); MBP::: myelin basic protein (autoantigen); M.pneu.::: Mycoplasma pneumoniae; 
SPII ::: synthetic peptide (mice exp nr. II): - ::: PBS, no antigen; cmean macroscopic severity score 
(n ::: 4-5): 0::: absent; 1::: moderate; 2::: marked; dO::: negative-minimal; 1::: slight; 2::: moderate; 
3 ::: marked; 4 = severe; e mean microscopic severity score (n = 3-5): 0::: negative; 1::: minimal; 
2 = slight; 3::: moderate; 4::: marked; 5::: severe; f two out of five mice died after secondary 
immunization. 
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Antibody responses 
This paper emphasizes the side effects induced by adjuvants. Consequently, only 
relevant results on antibody production are given. In Figure 5, mean relative 
antibody titres (FA = 100%) of five commercially available adjuvants (Freund's 
adjuvant, Specol, RIBI, TiterMax and Montanide ISA50), injected in rabbits (s.c. or 
i.m.) and mice (s.c. or i.p.) combined with different antigens, are shown. Injection of 
FA/antigen resulted in high titred specific antibody responses independent of the 
antigen combined with it. RIBI did not induce acceptable antibody responses in our 
studies in rabbits and mice. TiterMax was not effective in inducing antibody 
responses in rabbits and mice, except when i.p. injected in mice. Specol and 
Montanide ISA50 induced antibody responses which were comparable to those 
induced by FA in rabbits and mice. Except for Specol/autoantigen injection in mice 
which did not result in detectable antibody responses; Montanide ISA50 and also 
RIBI and TiterMax were not injected in combination with autoantigen. RV-ISCOMs 
with coupled antigen (autoantigen or synthetic peptide) induced very high specific 
antibody titres but this very potent and promising adjuvant is not (yet) commercially 
available and therefore can not readily replace FCA. Antibody titres were low when 
DDA, Gerbu or Lactobacillus were used as adjuvant when compared with FA. 
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Figure 5 Relative antibody mre in serum of rabbits and mice after injection of different 
adjuvanUantigen combinations. Antibody titre in serum of FA/antigen Injected animals was set on 
100%. 
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Discussion 
In this paper, FA and alternative adjuvants were evaluated on their side effects to 
select an alternative which combines minor side effects with high antibody titres for a 
broad range of antigen types. Injection of FA resulted in moderate to severe 
pathological changes (Fig. 3 and 4; Table 6 and 7), confirming data of Broderson et 
al. (1989), Toth et al. (1989) and Wiedemann et al. (1991). Literature data on side 
effects induced by alternative adjuvants compared with FA are very limited. 
Information of side effects is often only obtained from clinical observations. We 
consider necropsy necessary to determine the side effects induced by adjuvant 
injection (e.g. intramuscular lesions cannot properly be monitored in the living 
animal). Sometimes, we observed extensive lesions at necropsy while no swelling or 
nodules were found upon palpation. Lesions in rabbits after RIBI injection were more 
severe than those induced by FA (Fig. 3). Johnston et al. (1991) compared FA, RIBI 
and Montanide ISA50 and observed no differences in macroscopical abnormalities 
induced by these adjuvants. In contrast, Deeb et al. (1992) observed mild lesions 
after RIBI injection in rabbits. In our studies in mice, RIBI induced minimal 
pathological changes (Fig. 4 and Table 7). After i.p. injection of RIBI in mice Lipman 
et al. (1992) observed lesions (adhesions and white plaques on organs) which were 
less extensive than FA induced lesions. After injection of TiterMax in rabbits (Fig. 3) 
we observed slight lesions while injection of TiterMax in mice resulted in severe 
lesions (Fig. 4 and Table 7). Bennett et al. (1992) studied histopathological changes 
after i.m. injection of 2 x 40 ~I TiterMaxiLHRH-BSA and found mild lesions. 
Montanide ISA50 injections resulted generally in less severe lesions when 
compared to FA injections, both in rabbits and mice (Fig. 3 and 4; Table 6 and 7). As 
described above Johnston et al. (1991) injected rabbits wilh Montanide ISA50 and 
observed similar lesions as those induced by FCA. This may be explained by the 
fact that different antigens were used in both stUdies. 
Pathological investigation was performed at the end of each experiment. 
Consequently, continuous monitoring of the lesions by macroscopy and microscopy 
was not possible. The monitoring time point generally was 2 weeks or 5 days after 
secondary injection in rabbits and mice, respectively, lesions at primary injection 
sites being at least 6 weeks old at that time. To discriminate between primary and 
secondary injection, these injections were given on separate sites. Primary injection 
sites were negative more often than secondary ones. Besides healing of the 
inflammation, a role for immunopathological phenomena (as a result of repeated 
introduction of antigen) in secondary lesions is likely. Due to the one point of 
monitoring, rapidly resolving inflammatory reactions may have been missed, 
especially in rabbits (lesions at least 2 weeks old). A certain lesion, found at the 
primary injection site (at least 6 weeks old), is supposed to have impaired the animal 
more than an identical lesion found at the secondary injection site. To compensate 
for this, scores of primary injection sites were augmented by a factor 1.5 before 
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summing up primary and secondary scores to reach an overall severity score per 
adjuvanVantigen combination (Fig. 3 and 4). 
Microscopy was performed since this adds useful observations to gross data. 
Lesions at s.c. injection sites in mice showed some remarkable differences in 
macroscopic and microscopic findings. At the s.c. primary injection site in mice, 
grossly observed impressive nodules occasionally appeared to exist only of one or 
several large 'oil spaces' surrounded by slight or moderate (fibro)granulomatous 
proliferation. On the other hand macroscopically identically scored lesions, 
histologically could display marked diffuse and granulomatous inflammation and 
fibrosis around variably sized 'oil spaces'. Microscopical examination of s.c. 
secondary injection sites in mice revealed grossly unexpected severe inflammation 
in some groups. Why these microscopically marked exudative lesions are seen 
macroscopically as not remarkable, remains obscure. Haemorrhage was absent in 
lesions of mice but was present in lesions of rabbits, that showed marked 
hyperaemia in exudative lesions despite exsanguination. When upon macroscopical 
examination of s.c. and i.m. injection sites no pathological changes are found, 
additional information from microscopy depends on successful sampling. The i.p. 
route can always be monitored microscopically and mild or resolving peritonitis 
(missed grossly) can be assessed in a more sensitive way. Since in rabbits 
macroscopical severity correlated well with microscopical severity, microscopy was 
only used to verify gross findings. The same holds true for the i.p. route in mice. In 
s.c. treated mice macro- and microscopical findings were taken together, because 
the latter were unpredictable from the former. 
Besides the adjuvant, other factors determine the severity of lesions, e.g. antigen 
type and injection route. The importance of the antigen in induction of pathological 
changes was observed when M. pneumoniae was used as antigen. Lesions were 
relatively severe after injection of this antigen combined with all tested adjuvants in 
rabbits and mice while negligible lesions were observed when this antigen was 
injected without an adjuvant. In combination with measles or mumps antigen, Specol 
induced extensive lesions (less extensive than FA) in rabbits while in combination 
with other antigens (e.g. synthetic peptide, glycolipid) lesions were minimal to mild. 
This may be explained by the volume injected (4 x 0.25 ml) or the particulate 
character of the antigens. It is tricky to compare severity of lesions between injection 
routes. In our opinion the i.p. injection route should be rejected, due to the extensive 
surface of the peritoneum, its high susceptibility to physicochemical damage and its 
intimate contact with various vital organs. Especially the acute phase of peritonitis Is 
supposed to be painful. In abdominal tissue of mice, acute exudative inflammation 
was observed 2 to 96 h after i.p. FCAlTNP-KLH injection (0.2 ml) (data not shown). 
Jansen van 't Land and Hendriksen (1995) showed decreased locomotion activity 
the first day after i.p. injection of 0.2 ml FCA. In an experiment in the automated 
behavioural system LABORAS, locomotion, climbing, grooming, eating and drinking 
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were significantly reduced after i.p. injection of FCAlPBS (Fig. 2). The i.p. route also 
yielded some deaths after booster immunization, probably due to systemic 
reactions. From the pathology results in rabbits, a preferential route is difficult to 
select. The i.m. route is more prone to injection error (i.e. wrong localization of 
adjuvant/antigen mixture) and more painful than the s.c. one and i.m. lesions are 
more difficult to monitor clinically. The s.c. loose areolar tissue will permit spread of 
inoculum and inflammation more easily than the rigid muscle compartment, indeed 
resulting in larger s.c. lesions. 10m. lesions probably exert more pressure on the 
surrounding tissue. So, when considering the s.c. and i.m. route, pain experienced 
by the animal is not only a function of lesion size and character. Although s.c. 
lesions sometimes were very extensive, we prefer the s.c. route to the i.m. route. 
An effective adjuvant (Fig. 5) that induces minimal pain in the animals is preferred 
for immunization. In rabbits, no clinical or behavioural changes indicating pain and 
distress were observed. In mice, indications of acute pain and distress (e.g. weight 
loss, decrease in activity and piloerection) were found the first days after injection. 
Although no signs of prolonged severe pain and distress were observed, marked to 
severe pathological changes did occur after injection of several of the 
adjuvant/antigen mixtures (Fig. 3 and 4; Table 6 and 7). It is not possible to give an 
estimation of pain associated with the observed pathological changes, because we 
did not observe indications of prolonged pain and distress, in mice, only acute 
distress was found. The available methods may be inadequate to monitor prolonged 
pain and distress, or there was no significant pain and distress despite the severe 
pathological changes. To monitor pain and distress in rabbits, the methods may not 
be sufficient to detect all possible signs of pain, because rabbits do not readily 
exhibit pain signs (Wallace et a/., 1990; Griffiths, 1991). In mice, signs of acute pain 
were found while later in time pain is not detectable by clinical and behavioural 
changes, indicating that the animals can cope with the induced pathological 
changes or that these changes are not or less painful than excepted. Devices like 
the LABORAS system (Bulthuis at a/., 1997; Van de Weerd, 1996) enable the 
registration of behavioural changes in mice very accurately, suggesting adequate 
possibilities to monitor severe pain and distress. We injected animals, in accordance 
with the Dutch guidelines for immunization of laboratory animals, e.g. small volumes 
of FCA and FCA in primary and FIA in secondary immunization. This may declare 
that minimal pain and distress were found. Johnston et at. (1991) did not observe 
indications for pain in rabbits while marked pathological changes were found. Amyx 
(1987) suggested that most undesirable effects of FCA can be eliminated by careful 
control of injection quantity and site selection. The pathological changes induced by 
FCA are thought, based on the analogy principle with humans, to be (potentially) 
very painful. Reports on accidental and intentional human injections provide another 
source of information on pain induced by FCA. Chapel and August (1976) reported 
severe pain after accidental injection in humans. However, all persons who suffered 
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severe pain were positive to the tuberculin test prior to the accidental injection, 
indicating that the reaction was a result of repeated exposure to Mycobacteria (Stills 
and Bailey, 1991). Wanstrup and Christensen (1965) injected mice weekly with FCA 
and observed decreased activity, dullness of fur and loss of hair. 
In conclusion, to minimize pain and distress in immunization experiments, it is 
essential to use the adjuvant properly, I.e. in accordance with existing guidelines. 
When doing so, in our studies no clinical and behavioural changes indicative for 
severe prolonged pain and distress (acute distress was observed) were found, 
despite severe pathological changes observed with some adjuvants. Pathological 
changes are considered an essential parameter to study side effects of adjuvants. 
The s.c. route should be preferred above Lm. (rabbits) or Lp. (mice) route. When an 
adjuvant is sought that induces less pathological changes than FA and acceptable 
antibody responses, we suggest, based on our data, to use Montanide ISA50 and 
Specol as alternatives to FA. 
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Immune responses and side effects of five 
different oil based adjuvants in mice 
P.P.A.M. Leenaars, M.A. Koedam, C.F.M. Hendriksen and E. Claassen, 
submitted 
Properlles of oil adjuvants in mice 
Abstract 
In this study, five different oil based adjuvants were compared to assess efficacy 
and side effects. Mice were injected subcutaneously (s.c.) or intraperitoneally (Lp.) 
with a weak immunogen (synthetic peptide; SP215) emulsified in Freund's adjuvant 
(FA; Freund's complete adjuvant on primary and Freund's incomplete adjuvant on 
secondary injection), Specol, RIBI, TiterMax or Montanide ISA50. Control groups 
received antigen in phosphate buffered saline (PBS) or PBS emulsified in adjuvant. 
Side effects were evaluated based on clinical and behavioural abnormalities and 
(histo )pathological changes. Efficacy of adjuvants was evaluated based on their 
properties to induce peptide specific IgG1, IgG2a and total IgG antibodies, native 
protein cross reactive antibodies and cytokine production. Pilo-erection and hunched 
posture developed in mice after primary i.p. injection of TiterMax and after 
secondary injection of FIA, TiterMax, Specol or Montanide ISA50. Based on 
histopathological data, severity of lesions induced by adjuvant injection can be 
ranked as: (s.c. injection) FA = TiterMax > Montanide ISA50 > Specol = RIBI and 
(Lp. injection) FA = TiterMax = Specol > Montanide ISA50 > RIB!. Although marked 
differences in isotype profile and height of titre are observed among the different 
adjuvants used, we found that FA, Montanide ISA50 and Specol worked equally well 
in the s.c. and Lp. route, TiterMax functioned only when given Lp. and RIBI did not 
perform up to par. When comparing the number of cytokine producing cells 
(interferon-gamma, interleukin-4) in spleen sections of mice, RIBI yielded 
significantly higher numbers of positive cells compared with the other adjuvants 
used in this study, five days after secondary injection (Lp.). Combined with the low 
antibody responses after RIBI injection, these data suggests that cytokine profiles 
after secondary injection of adjuvant/antigen, not necessarily correlate with desired 
antibody titres and isotype distribution of antibodies. 
In conclusion, from our data it appeared that high peptide specific antibody levels 
with minimal side effects can be obtained by s.c. injection of peptide combined with 
Montanide ISA50 or Specol as alternatives to FA. 
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Introduction 
Adjuvants are substances which stimulate the immune system. In experimental 
immunology, adjuvants are used to induce specific antibody responses to an 
antigen. In laboratory animals, Freund's complete adjuvant (FCA) is, because of its 
overall applicability, routinely used for this purpose. FCA consists of a non-
metabolizable mineral oil with added heat-killed Mycobacteria, which makes it a very 
effective but also a harmful adjuvant. Severe side effects in laboratory animals were 
observed when FCA was injected (Broderson, 1989; Toth ef al., 1989). The severity 
of the side effects induced by FCA, resulted in concern about its use in laboratory 
animals. Several adjuvants are developed as an alterrnative to FCA (Claassen and 
Boersma, 1992; Vogel and Powell, 1995). These alternatives should ideally be as 
effective as FCA but induce minimal side effects. The components and constitution 
of an adjuvant determine to a large extent the efficacy and side effects. To minimize 
side effects, adjuvants have been developed in which harmful components of FCA 
have been replaced (e.g. by synthetic analogues) or deleted. Since the quality of the 
mineral oil and Mycobacteria in FCA are an important inducer of side effects, 
selected mineral oil adjuvants were introduced which do not include Mycobacteria or 
any other microbial components. Examples of such mineral oil adjuvants, Specol 
(Bokhout ef al., 1981) and some products of the Montanide series (Ganne ef al., 
1994). Mineral oils can also be replaced by metabolizable oils to reduce the side 
effects (Scalzo et al., 1995). Metabolizable oils, however, are less potent. Alternative 
adjuvants were developed, consisting of metabolizable oil with an added 
immunomodulator. Examples of such adjuvants are: TiterMax (Hunter ef al., 1995) 
and RIBI (Rudbach et al., 1995), which contain, a non ionic block polymer (CRL-
8941) and synthetic microbial products, respectively. 
The number of studies in which the side effects and efficacy of these alternatives 
to FCA have been compared is very limited. Side effects of adjuvants can be 
assessed by clinical, behavioural (Morton and Griffiths, 1985) and pathological 
changes. Evaluation of adjuvant efficacy can be based on antibody production by B 
cells. In the development of antibody responses, T-B cell interactions playa central 
role (Laman and Claassen, 1996). Upon activation, T helper (Th) cells express the 
ligand for CD40 (CD40L) and produce cytokines which are both essential for T cell-
dependent B cell activation. After the initial B cell activation, Th cell-derived 
cy10kines are thought to regulate the differentiation of B cells into antibody forming 
cells. The pattern of cy10kine secretion of Th cells is thought to be crucial in the 
selection of isotype produced by antibody-forming B cells. It is generally accepted 
that interferon-gamma (IFN-y; produced by Th1 cells) promotes antibodies of the 
IgG2a isotype, whereas interleukin (IL-4; produced by Th2 cells) promotes an 
immune response dominated by antibodies of the IgG1 isotype (reviewed by 
Finkelman ef al., 1990; Laman and Claassen, 1996). Consequently, cy10kine 
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production may be another indicator to study adjuvant efficacy. To evaluate the 
balance between efficacy and side effects of commercially available adjuvants, five 
different oil based adjuvants were injected (s.c. or i.p.) in mice combined with a 
weakly immunogenic antigen (synthetic peptide) and compared for their properties 
to induce antibody and cytokine production and side effects. 
Animals, materials and methods 
Animals 
Female BALB/c mice were bred specific pathogen free (SPF) at the RIVM breeding 
facilities, Bilthoven, the Netherlands and used at 10-14 weeks of age. Animals were 
housed under SPF conditions and had free access to pelleted food (Hope Farms, 
Woerden, the Netherlands) and tap water. The experiments were approved by the 
Animal Ethics Committee of the RIVM. 
Antigen 
The antigen used is a synthetic peptide of 21 amino acids (SP215), a homologue to 
the hinge region of the human IgG2 molecule, which was synthesized as described 
by Boersma et al. (1989). SP215 is weakly immunogenic, it does not induce a 
detectable antibody response when injected without an adjuvant or carrier. SP215 
was diluted in phosphate-buffered saline (PBS) and administered at a concentration 
of 50 ~g per mice for both the primary and secondary inoculation. 
Adjuvants 
Freund's incomplete adjuvant (FIA) and Freund's complete adjuvant (FCA) were 
obtained from Difco Laboratories (Detroit, MI). FIA is a non-metabolizable mineral oil 
(Bayol F) and an emulsifier. FCA is FIA with added heat-killed Mycobacterium 
butyricum (0.5 mg/ml). Specol (ID-DLO, Lelystad, the Netherlands) is a non-
metabolizable mineral oil (Marcol 52) and emulsifiers (described by Bokhout et al., 
1981). TiterMax (CytRx, Norcross, GA) contains a metabolizable oil (squalene), 
emulsifier and a patented block copolymer CRL-8941. When these oil adjuvants are 
mixed with aqueous antigen solution, water-in-oil emulsions are formed. Montanide 
ISA50 (Seppic, Paris, France) is a non-metabolizable mineral oil and emulsifier. RIBI 
(Sigma Immunochemicals, SI. Louis, MO) consists of a metabolizable oil (squalene), 
emulsifier and microbial components: 0.5 mg/ml mono phosphoryl lipid A (MPL) and 
0.5 mg/ml synthetic trehalose dimycolate (TOM). Mixing of RIBI with aqueous 
antigen solution results in an oil-in-water emulsion. 
112 
Chapier6 
Preparation of oil emulsions 
The oil emulsions were prepared by mixing oil and aqueous phase as recommended 
by the manufacturer. The adjuvants were mixed with either PBS/SP215 or PBS. 
Water-in-oil emulsions of FA (Freund's adjuvant; FCA in primary, FIA in secondary 
immunization) were prepared using two glass syringes. The aqueous phase was 
added to the oil phase (oil: aqueous phase = 1 : 1) and emulsified by mixing back 
and forth for 1 min. Specol emulsions were prepared by mixing the oil phase 
thoroughly on a vortex and adding the aqueous phase dropwise (oil: aqueous 
phase = 5 : 4). RIBI was prepared by warming the RIBI vial in a 40°C water bath for 
5 min., aqueous phase was added to the RIBI vial and vortexed for 3 min. TiterMax 
was prepared the same way as FA using two glass syringes, except that now the 
aqueous phase was added in two steps. Montanide ISA50 emulsions were made by 
transferring the oil phase into a plastic tube, adding aqueous phase, and emulsify by 
making 10 up and down strokes using a syringe (oil: aqueous phase = 1 : 1). 
Experimental design 
To evaluate the properties of oil based adjuvants to induce side effects, specific 
antibodies and cytokine production, mice were injected with SP215 emulsified in 
adjuvant (FA. Specol, RIBI, TiterMax or Montanide ISA50). Control groups received 
antigen in PBS or PBS emulsified in adjuvant. Per combination, five mice were 
injected subcutaneously (s.c.) and five intraperitoneally (Lp.). Mice were injected s.c. 
at the base of the neck in primary and in the groin in secondary immunization to 
distinguish between injection sites for pathological studies. The s.c. injected volume 
was 0.1 ml per injection except for TiterMax injections when 0.05 ml was injected (as 
recommended by the manufacturer). The Lp. injected volume was 0.2 ml per 
injection. Animals were given a primary injection on day 0 and an identical secondary 
injection on day 42, except that FCA was replaced by FlA. Blood samples were taken 
on day -3, 7, 14, 28 and 41 via orbital punction under ether anaesthesia. Five days 
after secondary immunization, mice were bled after being anaesthetized by 
intramuscular injection of 0.1 ml of a mixture of ketamine (50 mg/ml), xylazine 
(20 mg/ml) and atropine (1 mg/ml) in a 7:3:1 volume ratio. Animals were examined 
for gross lesions and relevant tissue samples were collected for histopathological 
study. Spleens were removed and immediately frozen in liquid nitrogen and stored 
at -70°C for immunohistochemistry. 
Clinical obse/vation and pathology 
General condition of the mice was evaluated daily, based on general appearance and 
clinical signs. Injection sites were palpated for signs of pain and examined for swelling 
once a week. Diameter of swelling was measured in s.c. injected animals. Five days 
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after secondary immunization, animals were bled and necropsy consisted of 
examination of injection sites and major organs. 
For histopathological evaluation, tissue of s.c. injection sites, a sample of the 
omentum of all i.p. injected animals and organs showing macroscopic abnormalities 
were preserved in 4% buffered formaldehyde, embedded in paraffin, sectioned at 
5 ~m, and stained with haematoxylin and eosin. Lesions were scored macro-
scopically and microscopically. In s.c. injected animals, lesions were scored 
separately at primary and secondary injection site. The score was based on diameter 
of lesions and on microscopic evaluation of infiltrates and the presence of necrosis 
and fibrosis. In the Lp. injected animals the severity of lesions was mainly assessed 
macroscopically, based on abdominal effusions, adhesions, intestinal dilatation, 
presence of 'plaques' and omentum retrahens. Microscopic severity of peritonitis 
(volume and character of peritoneal infiltrates) was added to correct for macroscopic 
underscoring. Gross and histopathologic lesions were scored and finally classified as 
follows: 0 = negative/minimal; 1 = slight; 2 = moderate; 3 = marked; 4 = severe. 
Immunoassays 
Peptide specific /gG1 and IgG2a antibody levels 
In serum samples, SP215 specific IgG1 and IgG2a antibody levels were determined 
by enzyme-linked immunosorbent assay (ELISA). Plates were coated with SP215 
(10 flg/ml) and blocked with PBT. Diluted serum samples were incubated and then 
plates were incubated wilh peroxidase-conjugated goat antibodies specific for 
mouse IgG1 (0.4 flg/ml) or IgG2a (0.4 flg/ml) antibodies (Nordic, Tilburg, the 
Netherlands). TMB (3,3',5,5'-tetramethylbenzidine), 100 mg/ml in 0.11 M 
CH3COONa (pH 5.5), was used as a substrate. After 10 min. the reaction was 
stopped by adding H2S04 (2M). The absorbance was read at 450 nm against the 
signal from preimmune serum as a blank. A pool of sera from mice (of this 
experiment) producing high levels of specific antibodies served as a standard and 
was used for calibration of both isotypes. The level of SP215 specific IgG1 and 
IgG2a antibodies are related to this standard and expressed as relative titre (% of 
standard). 
Peptide specific and native protein cross-reactive IgG antibody levels 
In serum samples, peptide (SP215) specific and native protein (hulgG2) cross-
reactive IgG antibody levels were determined by ELISA. Plates were coated with 
SP215 (10 ~g/ml) or hulgG2 (10 ~g/ml) and blocked wilh PBT (PBS containing 0.5% 
BSA and 0.05% Tween 20). Diluted serum samples were incubated and then plates 
were incubated with alkaline phosphatase {AP)-conjugated goat antibodies specific 
for mouse IgG (Kirkegaard & Perry Laboratories, Gailhersburg, MD){4 ~g/ml). PNPP 
(p-nitrophenyl phosphate) in 10 mmol diethanolamine and 1 mmol of MgCI2 per litre, 
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was used as substrate. The absorbance was read after 30 min. at 405 nm against 
the signal from preimmune serum as a blank. A pool of sera from mice producing 
high levels of specific antibodies served as a standard and was used for calibration. 
The level of IgG antibodies Is related to this standard and expressed as relative titre 
(% of standard). 
Immunohistochemistry 
Cryostat sections of spleen (-20·C, 8 ~m), three of every mouse for each staining, 
were picked up on glass slides and kept overnight under high humidity. Slides were 
fixed in fresh acetone, containing 0.02% H20 2 and then air dried. Detection of 
activated T cells and cytokine producing cells was performed as described 
previously (Van den Eertwegh et a/., 1993). Slides were incubated overnight with 
monoclonal antibodies (mAb) to detect activated T cells and cytokine producing 
cells. The mAb used were: biotinylated hamster mAb MR-1 (specific for murine 
CD40L; expressed on activated T cells), the biotinylated rat mAb 11 B11 (specific for 
murine IL-4; Ohara and Paul, 1985), the biotinylated murine mAb DB-1 (specific for 
rat IFN-y and cross-reacting with murine IFN-y; Van der Meide et al., 1989). Incubation 
with biotinylated mAb was followed by incubation with avidin conjugated to 
horseradish peroxidase (HRP). Histochemical revelation of HRP (red) activity was 
demonstrated as previously described (Claassen and Adler, 1988). Sections were 
counterstained with haematoxylin, and embedded. Activated T cells and cytokine 
producing cells were counted per cryostat section and calculated per mm2• 
Results 
Clinical findings 
To evaluate induced pain or distress, condition of the animals was studied based on 
general appearance and clinical signs. 
s.c. injection 
After s.c. primary immunization no clinical changes were observed while, after s.c. 
secondary immunization, mice showed piloerection and a hunched back when given 
SP215 in FA, Montanide ISA50 or TiterMax. One day after s.c. injection, clinical 
changes were no longer seen. When examining s.c. injection sites during the 
experiment, we observed swelling measuring 4-8 mm at primary injection sites in 
mice given FCA or TiterMax emulsions. Palpation of nodules or swelling at the s.c. 
injection sites did not lead to signs of pain such as vocalizing or struggling. One 
mouse died after secondary injection of TiterMaxlSP215. 
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i.p. injection 
The first hours after primary immunization (Lp.), mice given FA- or TiterMax-
emulsion showed piloerection and hunched back. These changes were also found 
after secondary immunization with FA-, TiterMax-, Specol- or Montanide ISA50-
emulsion. During five days after Lp. secondary immunization with SP215 combined 
with FA, TiterMax, or Specol, piloerection was observed. Within a few hours after 
secondary immunization with FAlSP215 two mice died. These phenomena are 
probably related to the persistent high antibody titres in these animals. Palpation of the 
abdomen of Lp. injected mice did not lead to signs of pain. 
Pathological findings at necropsy 
To obtain more data on side effects of the evaluated adjuvants, pathological 
changes were studied at the end of the experiment (summarized in Fig. 1). 
s. c. injection 
Primary s.c. injection sites showed some variation within groups while secondary 
injection sites were almost identical within groups. At most primary s.c. injection sites 
of FAlSP215 and TiterMaxlSP215, white or yellow nodules from 2-10 mm were 
observed. Microscopically, marked to severe granuloma formation, diffuse exudative 
inflammation and fibrosis were present at these injection sites, as well as 
(epi)dermal signs of inflammation. Some primary s.c. injection sites of Montanide 
ISA50/SP215 showed nodules (around 3 mm in diameter), which microscopically 
were less severe (mainly fibrosis) than forementioned groups. Secondary s.c. 
injection sites grossly showed white shiny tissue attached to muscles, the amount of 
which was most abundant in FAlSP215 and TiterMaxlSP215 injected groups. 
Microscopically, impressive diffuse inflammation dominated in all groups, whereas 
cellularity was highest in TiterMax groups. When the adjuvants were combined with 
PBS (instead of antigen), lesions found were comparable (FA, RIBI), slightly milder 
(Specol, Montanide ISA50), or milder (TiterMax). 
i.p. injection 
In Lp. injected mice findings were very homogenous within groups. Milky abdominal 
effusions were present in FA and TiterMax treated animals. These two adjuvants 
and Specol, resulted in intestinal adhesions, while Specol and TiterMax caused 
dilatation of the small intestine. These signs of active peritonitis were judged severe. 
Marked omentum retrahens was present in the three forementioned groups. 
Intraperitoneal inoculation of Montanide ISA50 and RIB I resulted in slight and 
minimal white shiny plaques in the peritoneum respectively, accompanied by 
minimal omentum retrahens in the case of Montanide ISA50. Microscopical 
examination confirmed the severity of peritonitis and absence of unaffected 
omentum in FA, TiterMax and Specol injected groups. In Montanide ISA50 and RIBI 
injected animals normal parts of omentum were present but affected parts 
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microscopically showed obvious peritonitis (Montanide ISA50 moderate, RIBI slight). 
When the adjuvants were combined with PBS (instead of antigen), the peritoneal 
lesions were somewhat milder in Specol, TiterMax and RIBI groups and markedly 
milder in FA and Montanide ISA50 groups. 
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Figure 1 Severity score of pathological changes at necropsy 5 days after secondary injection (day 47) 
of different adjuvants combined with SP215 or PBS (-) via s.c. or Lp. route; n=5. Severity score: 
o = negative/minimal; 1 = sllghl; 2 = moderate; 3 = marked; 4 = severe. 
Peptide specific /gG1 and /gG2a antibody production 
To study antibody responses and isotype distribution of peptide specific antibodies 
after adjuvanUSP215 immunization, SP215 specific IgG1 and IgG2a antibody levels 
were determined in serum of day -3, 7, 14,28,41,47. On day -3 peptide specific 
antibodies were not detectable while on day 7 and 14 antibody levels were low but 
detectable after i.p. or s.c. immunization with SP215 combined with FCA, Specol, 
TiterMax or Montanide ISA50 (data not shown). 
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After s.c. injection, SP215 specific IgG1 antibody levels were of comparable 
height when mice were given SP215 combined with FA, Montanide ISMO or Specol 
and minimal when given with TiterMax or RIBI. SP215 specific IgG2a antibody levels 
were highest after FNSP215 injection and slightly lower in serum of mice s.c. given 
SP215 combined with any of the other adjuvants used (data not shown). 
After i.p. injection, SP215 specific IgG1 antibody levels were very high in serum of 
mice injected with Montanide ISA50/SP215, high when SP215 was i.p. injected 
combined with FA, TiterMax, somewhat lower with Specol, and minimal when 
injected with RIBI (Fig. 2). A clear booster effect in IgG1 response was observed 
when Montanide ISA50 was used as an adjuvant. SP215 specific IgG2a antibody 
levels were high after i.p. immunization with TiterMaxlSP215. These SP215 specific 
IgG2a responses were at least six times higher than after immunization with any of 
the other adjuvants. When SP215 was injected without an adjuvant or adjuvant 
without SP215, no SP215 specific IgG1 and IgG2a antibodies were detectable. 
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Figure 2 SP215 specific 19G1 and 19G2a antibody responses (day 28, 41 and 47) after i.p. injeclion of 
different adjuvants or PBS (-) combined with SP215, On day 42, mice were given a secondary 
immunization. Values are expressed as relative titre (% of standard) as detected in ELISA (arithmetic 
mean ± s.d.; n=5). 
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Peptide specific and native protein cross-reactive /gG antibody production 
To investigate cross-reactivity of peptide specific antibodies with the native protein 
(hulgG2). SP215 and hulgG2 specific IgG responses were determined in serum 
from mice given SP215 combined with different adjuvants. After s.c. injection. 
SP215 specific IgG responses were comparable when mice were given SP215 
combined with FA. Montanide or Specol. low when given with TiterMax and minimal 
with RIBI on day 47 (Fig. 3). HulgG2 specific IgG responses were low after s.c. 
injection of SP215 combined with each adjuvant. After Lp. injection. SP215 specific 
IgG responses were high when mice were given SP215 combined with Montanide or 
TiterMax (Fig. 3). 
Figure 3 SP215 specific 19G and native protein (hulgG2) cross-reactive 19G antibody responses on 
day 47 after s.c, and i.p. injection of different adjuvants or PBS (-) combined with SP215. On day 42, 
mice were given a secondary injection. Values are expressed as relative titre (% of standard) as 
detected in F.LlSA (arithmetic mean ± SD; n=5). 
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These responses were twice as high as those observed after i.p. injection of 
SP215 combined with FA or Specol. SP215 specific IgG responses were low when 
mice were i.p. given SP215 combined with RIBI. HulgG2 specific IgG responses 
were high (twice as high as after FA) after i.p. injection of SP215 combined with 
TiterMax, while low levels of hulgG2 specific IgG antibodies were observed after Lp. 
injection of SP215 combined with Specol, Montanide or RIBI. Injection of SP215 
without an adjuvant resulted in undetectable SP215 or hulgG2 specific antibody 
production. 
Activated T cells and cytokine producing cells in spleen sections of i.p. injected mice 
To investigate whether isotypes distribution (lgG1 and IgG2a) could be correlated 
with cytokine production (IL-4 and IFN-gamma respectively) the number of IL-4 and 
IFN-gamma producing cells in spleen sections was assessed 5 days after secondary 
Lp. injection. T cell activation was studied by CD40L-expression (Th cells expressing 
the ligand for CD40). As shown in Fig. 4, relatively high frequencies of positive cells 
were observed in spleen sections of mice given RIBI combined with SP215 or with 
PBS. This was also observed when IL-2 and IL-5 producing cells were studied (data 
not shown). Immunization with FA (with or without antigen) resulted in low numbers 
of positive cells. These low numbers were comparable to those observed in spleen 
sections of mice given SP215 without an adjuvant. The number of positive cells was 
higher after Specol/SP215 injection than after Specol/PBS injection. 
Discussion 
In this study, efficacy and side effects of five commercially available oil adjuvants 
were compared in mice. We showed that Montanide ISA50 and Specol are suitable 
alternatives to FA preferably when given by the subcutaneous route. 
FCA (mineral oil and Mycobacteria) was used as a 'gold' standard since this 
adjuvant is very effective in Inducing a specific immune response to antigens. The 
effective immune-stimulating properties of FCA (Lipman et al., 1992) as well as the 
induction of severe pathological changes by FCA (Toth et al., 1989) were confirmed 
in our study. When Specol (mineral oil without Mycobacteria) was injected in 
combination with SP215, antibody levels were comparable to those observed after 
FAlSP215 injection. This confirms earlier findings (Leenaars et al., 1995) in which 
Specol/SP215 was injected Lp. or s.c. in mice. Specol induced mainly antibodies of 
the IgG1 isotype. This confirms earlier findings (Boersma et al., 1992). Anti-native 
protein antibodies were low after Specol/SP215 injection. This may be explained by 
the dose of antigen used. Boersma et al. (1989) described that the required dose of 
peptide is higher when an anti-native response is needed (200 ~g) than is strictly 
required for an anti-peptide response only (50 ~g). 
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Figure 4 Number of activated T cell (CD40L expression) and cytokine producing cells (tFN-gamma 
and IL-4) In spleen sections, five days after secondary Lp. injection (day 47) of different adjuvants or 
PBS H combined with SP215 or PBS (-). Values represent mean ± SO of number of positive cells per 
mm2;n=5. 
After s.c. injection of Specol. slight pathological changes were observed while Lp. 
injection resulted in comparable pathological changes as those observed after FA 
injection. The data after Lp. injection are in contrast with our earlier findings 
(Leenaars et 8/ .• 1995). when we observed minimal pathological changes also after 
Lp. injection of SpecollSP215. This may be due to the difference in the injected 
volume (0.1 ml earlier experiment; 0.2 ml in this study). Antibody responses after 
injection of Montanide ISA50 (mineral oil without Mycobacteria) combined with 
SP215 were comparable or even higher than when FNSP215 was injected. These 
data confirm findings of Jones et 8/. (1990). who observed higher antibody 
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responses when Montanide ISA50 was i.p. injected in mice compared with FA 
injection. Montanide ISA50/SP215 injection resulted in antibodies of IgG1 isotype, 
predominantly. Less severe pathological changes were found after Montanide ISA50 
injection as compared wilh FA injection. Our findings indicate that the balance 
between efficacy and safety of these Montanide ISA50 injections is better than of FA 
injections. After s.c. injection of TiterMax, antibody responses were much lower than 
after FA, while i.p. injection of TiterMaxlSP215 was observed to be effective (higher 
antibody levels than with FAlSP215) in inducing, peptide specific IgG, IgG1, IgG2a 
antibodies and native protein cross-reactive antibodies. Comparable antibody 
responses after TiterMax and FA injection were also observed by Bennett et a/. 
(1992) and Daly and Long (1996). We observed IgG2a antibody responses that 
were much higher after i.p. injection of TiterMax than after any of the other 
adjuvants. These high IgG2a levels are in accordance with findings that TiterMax 
induces cell-mediated immunity (Kast et al., 1993). Zhou and Afshar (1995) 
observed comparable anti-isotype antibody levels when mice were s.c. given 
pseudo rabies virus in FA or in TiterMax, but did not observe anti-idiotype antibodies 
when TiterMax was used as compared with FA. Claims, that TiterMax is safe for use 
in laboratory animals, could not be confirmed in our study. Both after i.p. and s.c. 
injection, pathological changes were comparable after TiterMax and FA injection. 
Therefore, despite high antibody responses after i.p. injection, TiterMax is not 
considered the ultimate alternative to replace FA. After injection of mice with 
RIBI/SP215, antibody levels were very low and minimal pathological changes were 
observed. Intermediate and low antibody responses after RIBI injection were 
observed by Tiong et al. (1993) and Kenney et al. (1989), respectively. These and 
our data conflict with findings of Geerligs et al. (1989), Lipman et al. (1992) and Daly 
and Long (1996), who observed comparable antibody responses after injection of 
FCA and RIBI. This may be explained by the antigen to which an immune response 
is required. A relatively high level of IgG2a antibodies was observed after RIBI 
injection. This confirms earlier findings that MPL and TDM stimulate production of 
antibodies of IgG2a isotype (Rudbach et al., 1995). 
Despite low antibody responses after RIBI/SP215 injection, significantly higher 
numbers of activated T cells (= CD40L expressing cells) and cytokine producing 
cells were observed in spleen sections of mice 5 days after secondary i.p. injection 
of RIBI compared with the other adjuvants. Based on data of Van den Eertwegh et 
al. (1993), we studied spleen sections 5 days after secondary injection. Van den 
Eertwegh et al. (1993) showed a peak in CD40L expressing cells and KLH specific 
antibody forming cells 4-5 days after secondary i.v. injection of KLH, suggesting that 
CD40L expression plays a role in the specific antibody production. Grun and Maurer 
(1989) observed preferential stimulation of phenotypically different T helper cell 
subsets and found corresponding IgG1 and IgG2a antibodies in serum after injection 
of FCA and Alum in mice. Our findings, however, suggest, that antibody levels in 
122 
Chapter 6 
serum and the numbers of activated T cells and cytokine producing cells in spleen 
sections do not necessarily correlate 5 days after secondary immunization. Fox 
(1992) detected differences in antibody titres and isotypes following injection with 
different adjuvants but did not find differential affects of adjuvants on Th1 and Th2 
cells. Valensi et al. (1994) observed that it was difficult to identify a consistent 
relationship between systemic cytokine responses measured and the antigen 
specific circulating antibody subclasses induced with different adjuvants. In our 
study, injection of adjuvant combined with or without antigen, resulted in comparable 
numbers of activated T cells and IFN-y and IL-4 producing cells, indicating non-
specific immune stimulation by the adjuvant. The induction of cytokines by the 
adjuvant may overrule the specific response to the antigen. We studied the immune-
stimulating effects 5 days after secondary immunization. Maybe the antigen specific 
antibodies are generated at later time points after secondary immunization. 
Antibody responses were comparable after injection via s.c. or Lp. route, except 
for Montanide ISA50 and TiterMax where higher antibody responses were found 
when these adjuvants were injected Lp. compared to s.c. Contradictory results were 
observed by Bennett et al. (1992) when injecting TiterMax in mice: Considering the 
severe pathological changes after Lp. injection, s.c. route should be preferred above 
Lp. route. 
From the data of our study, it can be concluded that s.c. injection of Montanide 
ISA50 or Specol are alternatives to induce acceptable antibody titres to synthetic 
peptide with less pathological changes than FCA. 
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Model to test efficacy of immunization 
procedures by early cytokine production 
in mice 
P.P.A.M. Leenaars, L. Nagelkerken, C.F.M. Hendriksen and E. Claassen. 
In: Animal Alternatives Welfare and Ethics, L.F.M. van Zutphen and M. Balls 
(Eds.), Elsevier Science, Amsterdam, in press 
Predictive value of cytoklne profiles 
Abstract 
To investigate the possibilities for efficacy prediction of immunization procedures in 
laboratory animals, we studied cytokine production shortly after adjuvant/antigen 
injection in mice using immunohistochemistry and in vitro cell cultures. A weak 
immunogen, SP215 (peptide of human IgG2 molecule) was studied. Cytokine 
producing cells (IL-4, IL-5, IL-2 and IFN-y) were counted in spleen sections 0, 2, 4, 
6, 96 hours after intraperitoneal (i.p.) injection of Freund's complete adjuvant (FCA) 
combined with SP215. Numbers of cytokine producing cells were low and 
comparable to unimmunized mice at these time points. At 5 and 14 days after i.p. 
injection of FCAlSP215, spleen cells were stimulated in vitro with SP215. Minimal 
antigen specific proliferation and cytokine production (IL-4 and IFN-y) were 
observed. At 14 days after subcutaneous (s.c.) injection of FCAlSP215, draining 
lymph node cells were stimulated in vitro with SP215. Significant levels of antigen 
specific IFN-y production were observed. To study adjuvant effect on antigen 
specific cytokine production (IL-4 and IFN-y) and isotype induction, mice were s.c. 
injected with FCAlSP215, FIAlSP215, Specol/SP215 or PBS/SP215. Two weeks 
later mice were bled and draining lymph node cells were cultured. Levels of antigen 
specific IFN-y production were comparable for all three adjuvants while IL-4 
production was below the detection limit of 5 pg/ml. SP215 specific IgG1 antibody 
levels were Significantly higher in Specol/SP215 compared to FCAlSP215 injected 
animals. IgG2a antibody levels were comparable in all adjuvant injected animals. 
Based on our data we conclude that early cytokine production measured by 
immunohistochemistry or in lymphoid cell cultures is not a useful model to predict 
the outcome of immunization procedures. 
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Introduction 
In immunization procedures, adjuvants are used to induce effective immune 
responses. In laboratory animals Freund's complete adjuvant (FCA) is often used for 
this purpose. The severity of the side effects induced by FCA, have resulted in 
guidelines discouraging its use in laboratory animals (Canadian Council on Animal 
Care, 1991; National Institute of Health, 1988; Veterinary Public Health Inspectorate, 
1993). Alternative adjuvants are recommended. A useful tool to choose an adjuvant 
is a model to predict the outcome of immunization procedures in which a weak 
immunogen is combined with an adjuvant of unknown efficacy for the particular 
combination under study. Cytokines are regulating glycoproteins which play an 
important role in the initial phase of an immune response and thereby can give 
information on the efficacy of an immunization. Several studies (reviewed by 
Finkelman et al., 1990) have shown that cytokines like interleukin-4 (IL-4) and 
interferon-gamma (IFN-y) direct the quality of immune responses after infection or 
vaccination. IL-4 promotes an immune response dominated by antibodies of the 
IgG1 and IgE isotypes while IFN-y promotes antibodies of the IgG2a isotype. The 
concentration of these two cytokines, IL-4 and IFN-y, shortly after immunization can 
give information on what type of immune response will be induced. Cytokine 
production can be measured on different levels, e.g. cytokine producing cells in 
sections of lymphoid organs, protein level (e.g. in serum), mRNA level. To make ILA 
and IFN-y production detectable, lymphoid cells may be stimulated in vitro and 
cytokine production measured in supernatants of cell cultures. We studied the 
possibilities to predict the immune response based on early production of cytokines 
(ILA and IFN-y) using a weak immunogen (SP215, synthetic peptide). 
Animals, materials and methods 
Animals 
Female BALB/c mice were bred specific pathogen free (SPF) at the RIVM breeding 
facilities, Bilthoven, the Netherlands and used at 10-14 weeks of age. Animals were 
housed under SPF conditions and had free access to pelleted food (Hope Farms, 
Woerden, the Netherlands) and tap water. The experiments were approved by the 
Animal Ethics Committee of the RIVM. 
Antigen 
Synthetic peptide (SP215, homologous to hinge region of human IgG2 molecule) 
was synthesized as described by Boersma et al. (1989). Per animal 50 ~g SP215 
was injected. 
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Adjuvants 
FIA and FCA were obtained from Difco Laboratories (Detroit, MI). FIA is a non-
metabolizable mineral oil. FCA is FIA with added heat-killed Mycobacterium 
butyricum (0.5 mglml). Specol (obtained from ID-DLO, Lelystad, the Netherlands) is 
a non-metabolizable mineral oil of which the constituents are approved for animal 
use by the USA Food and Drug Administration (described by Bokhout et al. 1981). 
When these 011 adjuvants are mixed with dissolved antigen, water-In-oil emulsions 
are formed. 
Experimental design 
To study the number of cytokine (IL-4, IL-5, IL-2, IFN-y) producing cells in spleen, 
twelve mice were injected intraperitoneally (i.p.) with 0.2 ml FCNSP215. After 2,4,6 
and 96 hours three mice were bled and spleens were removed and snap-frozen In 
liquid nitrogen for immunohistochemistry. From three unimmunized, mice spleens 
were also snap-frozen as control spleens. To analyse whether immunization of this 
weak immunogen (SP215) in FCA resulted in proper cytokine production, lymphoid 
cells were stimulated in vitro with SP215. Spleen cells were obtained from six mice 5 
and 14 days after i.p. injection of 0.2 ml FCNSP215. Alternatively to i.p. injection, 
sUbcutaneous (s.c.) injections were performed. Fourteen days after s.c. injection of 
4x50 III FCNSP215, draining lymph node and spleen cells were cultured in vitro with 
SP215. To study the effect of adjuvant on cytokine production and IgG isotype of 
antibodies, mice, each group consisted of 6 mice, were injected s.c. (4x50 Ill) with 
FCNSP215, FINSP215, Specol/SP215 or PBS/SP215. After 14 days, three mice of 
each group were sacrificed to study cytokine production of lymph node- and spleen 
cells in vitro. The remaining three mice were used to take blood samples to follow 
the immune response in time. 
Immunohistochemistry 
Cryostat sections of spleen (-20'C, 8 Ilm) were fixed in fresh acetone, containing 
0.02% H20 2 and then air dried. Slides were incubated overnight with monoclonal 
antibodies (mAb) to detect cytokine producing cells. These mAb were: DB-1 
conjugated to alkaline phosphatase (AP) for interferon-gamma producing cells (IFN-
y-PC), S.B6 conjugated to AP for interleukin-2-PC (IL-2-PC), TRFK-5 conjugated to 
AP for IL-5-PC and biotinylated 11 B11 followed by streptavidin conjugated to 
horseradish peroxidase (HRP) for IL-4-PC. Histochemical revelation of the AP and 
HRP activity was demonstrated as previously described (Claassen and Adler, 1988). 
Sections were counterstained with haematoxylin, and embedded. Cytokine 
producing cells were counted per cryostat section and calculated per mm2• 
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Cell cultures 
Single cell suspensions of spleens and lymph nodes were prepared in RPMI1640 
(Gibco, Paisley, Scotland) supplemented with penicillin (100 IU/ml), streptomycin 
(100 mg/ml), L-glutamine (2 gil), lI-mercapthoethanol (5x10-5 M), and 5% Fetal Calf 
Serum (FCS; Seralab Ltd., Sussex, Crawley Down, UK). In spleen cell suspensions, 
erythrocytes were lysed by incubation with ice cold lysis buffer (155 mM NH4CI, 
10 mM KHC03, 0.1 mM EDTA, pH 7.4) for 1 min. Spleen cells and draining lymph 
node cells (collected 5 or 14 days after immunization) were restimulated in vitro with 
SP215 (25 flg/ml), SP215+IL-2, IL-2 or immobilized anti-CD3 mAb (145-2c11) 
coated in 96-well plates overnight at 4°C (10 flg/ml). After 3, 4 and 5 days culturing, 
supernatants were collected and stored at -20°C until cytokine assays (IL-4 and 
IFN-y) were performed_ To study proliferation, the remaining cultures were pulsed for 
6 hours with 0.25 mCi [3H1TdR per well (RCC, Amersham, UK) and harvested onto 
glassfibre filler paper using a Micromate 196 multiple sample harvester. Radio 
activity was determined by using a Matrix 96 lI-counter. 
Cyfokine assays 
IL-4 and IFN-y were assayed by ELISA as described previously (Abrams et al., 
1992). For ILA, 11B11 mAb was used as capture and biotinylated BVD4 as 
detecting antibody. For IFN-y, R46A2 mAb was used as a capture and biotinylated 
AN18 as detecting antibody. The detection limits for IL-4 and IFN-y were 5 and 
10 pglml respectively. Standard curves were constructed with recombinant cytokines 
calibrated against DNAX standards. 
Determination of IgG1 and IgG2a 
In serum samples two isotypes (lgG1 and IgG2a) were determined by ELISA. Plates 
were coated with SP215, blocked with PBS containing 0.05% Tween 20 and 0.5% 
BSA. After washing, diluted serum samples were incubated, then plates were 
washed and incubated with peroxidase-conjugated goat antibodies specific for 
mouse IgG1 (0.4 Ilglml) or IgG2a (0.4 Ilg/ml) (Nordic, Tilburg, the Netherlands). 
After washing, 100 mg/ml TMB (3,3',5,5'-tetramethylbenzidine) in 0.11 M 
CH3COONa (pH 5.5) was added to the plates. The reaction was stopped after 
10 min. by adding H2S04 (2M). A pool of sera from mice producing high SP215 
specific antibodies levels served as a standard and was used for calibration of both 
isotypes. The level of 19G1 and IgG2a antibodies are related to this standard and 
expressed as relative titre (% of standard). The relative titre should only be used for 
comparison within that particular isotype. 
Statistical analysis 
Results were subjected to statistical analysis by using the Mann-Whitney U-test. 
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Results 
Cytokine producing cells in spleen sections 
At 2, 4, 6 and 96 hours after i.p. injection of FGNSP215, we observed low numbers 
of cytokine producing cells (IFN-y, IL-2, IL-4 and IL-5) in spleen sections using 
immunohistochemical techniques. These low numbers were not higher than in 
unimmunized mice. 
Proliferation and cytokine production by spleen cells in vitro, after i.p. priming with 
FCAlSP215 
To analyse whether immunization of this weak immunogen (SP215) in FCA results 
in detectable cytokine production, we stimulated spleen cells in vitro with SP215 at 5 
and 14 days after i.p. injection of FCNSP215, and studied whether proper antigen 
specific proliferation or cytokine production could be found. Plate-bound anti-GD3 
was used as a positive control. Whereas this mitogenic stimUlation resulted in a 
proliferation of about 3000 counts per min. and in about 100 pg/ml IL-4 and 6000 
pg/ml IFN-y, no antigen specific proliferative response or cytokine production was 
detectable on day 5 after immunization. Two weeks after immunization, low levels of 
antigen specific IL-4 were detectable, provided that IL-2 was added to the cultures; 
IL-2 alone gave 10 pg/mllL-4 whereas SP215 + IL-2 resulted in 20 pg/mIIL-4. Also 
for IFN-y, exogenous IL-2 was required to show a modest antigen specific 
production. These data thus indicate that early antigen specific cytokine production 
is not easily detectable after i.p. immunization employing a weak immunogen. 
In a separate experiment, we found that two weeks after s.c. immunization of this 
weak antigen in FGA resulted in significant levels of antigen specific IFN-y 
production by draining lymph node cells provide that exogenous IL-2 was present. 
Therefore, additional experiments were performed to address the possibility that s.c. 
priming with adjuvantlSP215 is useful to discriminate different adjuvants with respect 
to cytokine induction. 
Effect of adjuvants on cytokine production in vitro and IgG isotype of antibodies in 
serum after SUbcutaneous injection 
To investigate whether FGA, FIA, Specol and PBS differ in their ability to induce 
antigen specific cytokine production in draining lymph node cells, these cells were 
cultured two weeks after s.c. immunization of SP215 combined with these adjuvants. 
Moreover, we determined the presence of SP215 specific IgG1 and IgG2a 
antibodies as a read-out of the activity of IL-4 producing Th2 cells or IFN-y producing 
Th1 cells in vivo. In lymph node cell cultures, IFN-y production was enhanced in an 
antigen specific fashion in the presence of exogenous IL-2 (Table 1). However, IFN-
y levels were comparable in all three adjuvant groups and low in the control group. 
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IL-4 production was below the detection limit of 5 pgtml in lymph node cell cultures. 
In spleen cell cultures, no antigen specific stimulation of either ILA or IFN-y 
production was found. None of the adjuvants enhanced proliferation of lymph node 
or spleen cell cultures in an antigen specific fashion. 
Table 1. SP215 specific IFN-y production of lymph node cell cultures and 
corresponding SP215 specific antibody production (lgG1 and IgG2a) in serum, 14 
days after s.c. injection of SP215 combined with FCA, FIA, Specol or no adjuvant (-) 
Adjuvant 
FCA 
FCA 
FCA 
FIA 
FIA 
FIA 
Specol 
Specol 
Specol 
Anima/to 
1 
2 
3 
.................................. 
4 
5 
6 
7 
8 
9 
10 
tgG2a /gG1 
/FN-y (pg/m/) (% of standard) (% of standard) 
40 
2970 
160 
30 
200 
160 
50 
190 
1.2 2.0 
2.2 2.2 
0.7 
0.7 
0.9 
1.5 
2.7 
0.6 
1.4 
2.4 
2.0 
5.1 
4.7 
3.2 
7.0 
4.5 
11 20 
12 
- - underdetecUon limit 
In serum of all adjuvanVSP215 injected mice, SP215 specific IgG1 and IgG2a 
antibodies were observed on day 14 (Fig. 1). When comparing different adjuvants in 
their ability to induce SP215 specific IgG1 or IgG2a antibodies, we observed 
significantly (p<0.05) higher SP215 specific IgG1 antibody levels in SpecoltSP215 
injected animals compared to FCNSP215 injected animals (Fig. 1). IgG2a antibody 
levels were comparable for all three adjuvants. These data indicate that antigen 
specific antibody levels can give more information on the efficacy of an immunization 
procedure than antigen specific cytokine production (Table 1). 
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Figure 1 SP215 specific IgG1 and IgG2a antibodies levels in serum, 14 days after s.c. injection of 
SP215 combined with FCA, FIA, Specol or no adjuvant (PBS). 
Discussion 
In this report we investigate the possibilities to predict the efficacy of 
adjuvanUantigen injections in mice. Using immunohistochemistry and in vitro cell 
cultures we could not predict the outcome of an immunization procedure shortly after 
immunization when testing a weak immunogen (SP215, synthetic peptide). When a 
strong immunogen (TNP-KLH) was used, we observed increased numbers of IFN-y 
producing cells and IL-5 producing cells in spleen sections four hours after i.p. 
injection of FCAfTNP-KLH (data not shown). This may be explained by the fact that 
TNP-KLH is a strong immunogen and has an adjuvant effect by itself (Van Ommen 
et al., 1994) while the antigen under study is a weak immunogen. Using a strong 
immunomodulator (50 fl9 LPS), Jotwani et al. (1994) found endogenous cytokine 
levels in the bloodstream (e.g. 2500 pglml IFN-y) of mice, 6 hours after i.p. 
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immunization. In our experiments, IL-4 and IFN-y levels in serum were below the 
detection limits (5 and 10 pg/ml respectively) 4 hours, 5 days and 14 days after 
FCNSP215 injection (data not shown). 
Fourteen days after s.c. immunization of adjuvantlSP215, we did not observe IL-4 
production in lymph node cell cultures while high IgG1 levels in serum were found. 
Indicating that in our test system, IL-4 production in vitro does not necessarily 
correlate with IgG1 production in vivo fourteen days after immunization. IL-4 induces 
the isotype switching from IgM to IgG1. A very small amount of IL-4 may be enough 
to induce this isotype switch. 
In conclusion, since we wanted a model for the very early prediction (hours) of 
immune responses, getting data 14 days after immunization is late, while. in our 
testsystem using a weak immunogen in BALB/c mice, IL-4 and IFN-y production in 
vitro did not correlate with IgG1 and IgG2a production in vivo respectively. From the 
results it appeared that isotype distribution in serum on day 14 can give information 
on the outcome of the immune response and therefore we suggest to use this as an 
read-out instead of cytokine production in vitro 14 days after immunization. 
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Increased adjuvant efficacy in stimulation of 
antibody responses after macrophage 
elimination in vivo 
P.P.A.M. Leenaars, H.F.J. Savelkoul, C.F.M. Hendriksen, N. van Rooijen 
and E. Claassen, Immunology, 1997,90,337-343. 
Role of macrophages in adjuvant efficacy 
Summary 
To investigate whether macrophages influence the efficacy of adjuvants, we locally 
eliminated lymph node macrophages with dichloromethylene diphosphonate 
containing-liposomes before primary immunization. After macrophage elimination, 
animals were immunized with a soluble antigen (TNP-KLH; 2,4,6-trinitrophenyl-
keyhole limpet haemocyanin) either in phosphate buffered saline (PBS), in Freund's 
complete adjuvant (FCA), or in Specol. Specol is a water-in-oil emulsion, considered 
to be less aggressive than FCA, but equally effective. A secondary immunization 
followed with TNP-KLH. In vivo macrophage elimination before SpecoliTNP-KLH 
immunization resulted in increased adjuvant efficacy as measured by (primary) 
antibody responses. This suggests that the activity of Specol is not primarily 
mediated through macro phages but rather through other antigen-presenting cell 
types (e.g. dendritic cells, B cells, fibroblasts). The overall quality of produced 
antibodies, in terms of isotype distribution and affinity maturation, remained the 
same. After primary injection, FCAiTNP-KLH immunization resulted in significantly 
higher antibody responses in macrophage-depleted animals and antibody 
responses did not increase significantly after secondary immunization. However, a 
booster effect was found when macrophages were not eliminated before FCAiTNP-
KLH immunization, suggesting that the presence of macrophages during the first 
weeks of the primary immune response is essential for the induction of an effective 
secondary response in FCA immunizations. In conclusion, macrophage depletion 
before immunization with a soluble T cell-dependent antigen combined with Specol 
may enhance specific antibody responses without changing isotype or affinity of the 
antibodies. 
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Introduction 
Adjuvants are used to enhance immune responses to antigen resulting in higher titred 
specific antibody formation of desired isotypes (Karagouni and Hadjipetrou-
Kourounakis, 1990; Kenney et al., 1989). Besides effective immune responses 
Freund's complete adjuvant (FCA) induces severe side effects (Broderson, 1989; Toth 
st al., 1989). In earlier studies we evaluated several adjuvants as possible alternatives 
to FCA. We found Specol (a well-defined and reproducible water-in-oil emulsion; 
Bokhout st al., 1981) to be an animal-friendly efficient replacement for FCA (Leenaars 
et al., 1994; Leenaars et al., 1995). The mechanism of action of Specol is largely 
unknown. One way in which water-in-oil adjuvants are thought to enhance 
immunogenicity is through the activation of macrophages (M<!l) (Allison and 
Gregoriadis, 1990). The induction of effective immune responses involves different 
types of cells, antigen-presenting cells (APC), T and B cells. The type of antigen 
influences the way in which B cells are slimulated. When the anligen is T cell-
independent, e.g. polysaccharides, B cells may be slimulated directly by interaction of 
the antigen with the B cells, in those cases an adjuvant is not always effeclive. 
However, when the antigen is T cell-dependent (TO), e.g. proteins, glycoproteins, APC 
are required for sufficient anligen processing and presentalion to T cells for the 
induction of anlibody responses (Van den Eertwegh et al., 1992). Several cell types 
can function as APC. Particulate anligens are taken up almost exclusively by M<!l (Van 
Rooijen, 1992) while soluble anligen are processed and presented to the immune 
system by B cells and dendrilic cells mainly (Ibrahim et al., 1995). The antigen-
presenling function of M<!l in generating an immune response has been studied in vitro 
(Lanzavecchia, 1990), however, in vitro studies do not necessarily renect actual 
events in vivo (Van den Eertwegh et al., 1992). 
The role of M<!l in vivo can be studied by seleclive depletion of M<!l from lissues in 
the live animal using dichloromethylene-diphosphonate (CI,MOP) containing-
liposomes (Van Rooijen and Sanders, 1994). These liposomes are phagocytosed by 
M<!l after injeclion and once digested release of CI,MOP kills the M<!l. Which M<!l 
subpopulations are depleted depends on the route by which CI,MOP-liposomes are 
injected. Injection of CI,MOP-liposomes in the footpad results in local depletion of M<!l 
in the popliteal lymph node while leaving other cell types like dendrilic cells, Band T 
cells intact (Oelemarre et al., 1990). 
In this report, we studied the role of macrophages in adjuvant efficacy by the 
induction of humoral immune responses to 2,4,6-trinitrophenyl-keyhole limpet 
haemocyanin (TNP-KLH), either given with phosphate buffered saline (PBS) or 
emulsified in adjuvant after local eliminalion of macrophage by CI,MOP-liposomes. 
The adjuvant properties of FCA and Specol were compared. In macrophage-depleted 
and control mice the efficacy of the adjuvants was judged by the level of antigen 
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specific antibodies elicited after primary and secondary immunization and the quality 
of the antibodies in terms of isotype-distribution and affinity maturation. 
Materials and methods 
Animals 
Female BALB/c mice were bred specific pathogen free (SPF) at the RIVM breeding 
facilities, Bilthoven, the Netherlands and used at 10-14 weeks of age. Animals were 
housed in groups of five under SPF conditions and had free access to pelleted food 
and tap water. The experiments were approved by the Animal Experiments 
Committee of the RIVM and were performed as described in the Law on Animal 
Experiments. 
Antigen 
TNP-KLH was prepared as previously described (Claassen et al., 1986b). The dose of 
antigen was 50 ~g TNP-KLH per injection and was diluted in PBS. 
Adjuvants 
Freund's complete adjuvant (FCA; Difco Laboratories, Detroit, MI) is an oil emulsion 
consisting of 85% paraffin oil (= mineral oil), 15% mannide monooleate, and heat-
killed Mycobacterium butyricum (0.5 mg/ml). Water-in-oil (w/o) emulsion of 
FCAlTNP-KLH, was prepared by emulsifying FCA with an equal volume of TNP-KLH 
in PBS using two syringes and a double hub connector. TNP-KLH was added to 
FCA via the connector and mixed for 1 min. 
Specol (ID-DLO, Lelystad, the Netherlands) is an oil emulsion consisting of mineral 
oil (Marcol 52, paraffin's and cycloparaffin's) and emulsifiers: Sorbitan trioleate (Span 
85R) and Polyoxyethylene-20 Sorbitan trioleate (Tween 85R) mixed in ratio of 9/1 (v/v) 
(Bokhout et al., 1981). The constituents of Specol are approved for animal use by the 
USA Food and Drug Administration. A wlo emulsion of SpecoIITNP-KLH, was 
prepared by mixing TNP-KLH and Specol in ratio of 9/11 (v/v). TNP-KLH was added 
dropwise to the Specol while mixing on the vortex. 
MtP elimination 
Large multilamellar liposomes encapsulating the drug dichloromethylene-
diphosphonate (CI,MDP-Iiposomes) were prepared as described earlier (Van Rooijen 
and Sanders, 1994). CI,MDP was a gift of Boehringer Mannheim GmbH, Mannheim, 
Germany. CI,MDP-Iiposomes were used to locally eliminate M<I> in the popliteal lymph 
node (PLN). Two days before immunization 50 ~I PBS (control as described by van 
Rooijen and Sanders, 1994) or 50 ~I CI,MDP-Iiposomes were injected subcutaneously 
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at the upper site of the right hind fool. M<D elimination in the PLN was confirmed by 
acid phosphatase staining as described by Claassen et al. (1988). 
Immunization of mice 
On day 0 mice were immunized by injection of 50 ~I FCAfTNP-KLH, 50 ~I 
SpecolfTNP-KLH or 50 ~I TNP-KLH without an adjuvant subcutaneously at the upper 
site of the right hind fool. Physiologically there is no difference between footpad 
injection and injection at the upper site of the fool. Injection at the upper site is 
preferred since it is less painful because the animal is not walking on the injection site 
and minimal infections occur. A second injection followed on day 35 by injection (right 
hind foot) of TNP-KLH (50 ~g), macrophages were not eliminated before secondary 
immunization and no adjuvants were used in any of the animals at this point in time. 
Blood samples were taken under ether anaesthesia by orbital puncture, on day -4, two 
times per week during the first 2 weeks after primary and secondary injection, and 
weekly thereafter. On day 75 animals were bled. Serum samples were stored at -20°C 
until required for analysis. 
Detection of serum TNP-lgG antibody levels 
TNP-specific IgG antibodies were determined in mice serum samples using a direct 
enzyme-linked immunosorbent assay (ELISA) as described earlier (Claassen et al., 
1987). In short, plates were coated with ovalbumin (OVA)-TNP (5 ~g/ml), blocked with 
0.2% gelatine in PBS, followed by diluted serum samples. Subsequent steps were 
goat anti-mouse IgG antibodies conjugated to alkaline phosphatase (2 ~g/ml; 
Kirkegaard & Perry Laboratories, Gaithersburg, MO) and the substrate 
p-nilrophenylphosphate (PNPP; Sigma, SI. Louis, MO) 1 mg/ml dissolved in OEA 
with MgCI2. The reaction was stopped by adding NaOH after 30 min. The absorbance 
was measured at 405 nm with a microplate reader (Bio-Rad Laboratories, Richmond, 
CAl. The amount of anti-TNP antibodies was determined by preparation of a standard 
curve with an anti-TNP monoclonal antibody (mAb) of mouse origin. From this curve, 
at 1 : 1600 dilution, the amount of anti-TNP antibodies was calculated and expressed 
as Arbitrary Units (AU). 
Isotype-specific ELISA 
TNP-specific IgG1, IgE, IgG2a and IgM were determined in mice serum by isotype-
specific ELISA as described previously (Van Ommen et al., 1994). The detection limits 
for the different isotypes were 0.2 ng/ml, 1 ng/ml, 0.3 ng/ml and 0.2 ng/ml, 
respectively. Purified TNP-specific mAb of the appropriate isotypes were used for the 
standard curves. 
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Determination of affinity distributions 
The affinity distributions of serum IgG1 anti-TNP antibodies were determined in a 
TNP-specific isotype specific competitive ELISA (Pathak et al., 1997) essentially as 
described by Rizzo et al. (1992). Briefly, serum samples were diluted and incubated 
overnight (4°C) with increasing concentrations of the monovalent hapten N-&-DNP-L-
lysine HCI (DNP-Iys; 10-12 to 10-4 M in PBS; Sigma). The mixtures were then 
transferred to ELISA plates coated with TNP-KLH (0.5 ~g/ml). After incubation for 
3 h the plates were washed and the amount of TNP-specific antibody was 
established by using biotinylated goat anti-mouse IgG1 (0.5 ~g/ml; Southern 
Biotechnology, Birmingham, AL), HRP conjugated streptavidin (Southern 
Biotechnology) and the substrate 2,2'-azino-bis(3-ethylbenz-thiazoline-6-sulphonic 
acid) (ABTS; A-1888; Sigma). In this type of ELISA, the high-affinity antibodies are 
inhibited from binding to the plates by low concentrations of free hapten. As the free 
hapten concentration increases by increments, lower affinity antibodies are inhibited 
until theoretically, at sufficiently high hapten concentrations, all TNP-specific 
antibodies are inhibited from binding. Sera with high affinity will have relatively more 
and/or higher bars in the right side of the diagram. 
Immunohistochemical staining 
The presence of M<f> and interdigitating cells in the draining PLN was studied 2 days 
after injection of 50 ~I PBS or CI2MDP-liposomes, on the day of immunization. PLN 
were removed and frozen in liquid nitrogen. Cryostat sections of PLN (-20°C; 8 ~m) 
were fixed in acetone containing 0.02% H20 2 for 10 min. at room temperature and 
then air dried. Acid phosphatase activity was demonstrated by incubation with 
naphthol-AS-BI-phosphate (N-2250; Sigma) for 30 min. at 3rC (Claassen et al., 
1988). Rat anti-mouse mAb, NLDC-145, which recognizes interdigitating cells in 
lymphoid organs of the mouse (Kraal et al., 1986), was a kind gift of 
Prof. Dr. G. Kraal, Free University, Amsterdam, the Netherlands. After fixation 
cryostat sections were incubated with optimally titrated NLDC-145 mAb diluted in 
PBS containing 0.1% bovine serum albumin (BSA) overnight under high humidity at 
4°C. After washing in PBS slides were incubated with a 1: 150 dilution of rabbit anti-
rat immunoglobulin conjugated to HRP (Dakopatts, Copenhagen, Denmark) in PBS 
containing 1% BSA and 1% normal mouse serum for 60 min. at room temperature. 
After washing in PBS, HRP activity (red colour) was demonstrated with the 
substrate, 3-amino-9-ethylcarbazole (AEC; A-5754; Sigma) as described by 
Claassen et al. (1988). Slides were rinsed with PBS, counterstained with 
haematoxylin and mounted in glycerin-gelatin. 
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Statistical evaluation 
Antibody responses were analysed by the two-sided Student's t-test for comparison 
of two empirical means in a normally distributed population. A probability of 0.05 or 
less was considered significant. 
Results 
Elimination of MtP in PLN 
Delemarre et al. (1990) showed that a single footpad injection of Cl2MDP-liposomes 
resulted in complete depletion of lymph node M<I> lining the subcapsular sinus and in 
the medulla a few days after injection. This depletion is of major importance for the 
validation of our study. We confirmed M<I> depletion by acid phosphatase staining on 
day 0, the moment of immunization. This is two days after Cl2MDP-liposomes or PBS 
injection. Popliteal lymph nodes (PLN) of control animals (PBS treated) showed large 
numbers of acid phosphatase-positive cells (mainly M<I» which were located lining the 
subcapsular sinus (subcapsular sinus M<I», in the cortex (cortical M<I» and in the 
medulla (medullary M<I» (Fig. 1a). Subcapsular sinus M<I> and medullary M<I> were 
eliminated from the PLN two days after injection of Cl2MDP-liposomes at the upper 
site of the hind foot (Fig. 1b). Macrophages in the cortex (main T cell area) or in the 
follicles (main B cell area) were not affected (red spots in Fig. 1 b) as found before by 
Delemarre et al. (1990). 
Demonstration of interdigitating cells 
Interdigitating cells (I DC) are non-phagocytic cells which are not affected by CI2MDP-
liposome injection (Delemarre et al., 1990). Since IDC playa crucial role in antigen 
presentation, the presence of these cells was confirmed with IDC-specific mAb 
NLDC-145. Similar numbers of IDC were found in the para/deep cortex unit in the PLN 
of mice 2 days after PBS injection (Fig. 1c) and Cl2MDP-liposome injection (Fig. 1d). 
Increased TNP-specific IgG antibodies after MtP elimination in TNP-KLH induced 
immune responses 
TNP-KLH is immunogenic without an adjuvant, depending on the injected dose. In 
preliminary experiments, we determined a dose of TNP-KLH (50 ~g) which was high 
enough to induce a detectable IgG response and low enough to be stimulated by an 
adjuvant (data not shown). To investigate the role of macrophages in antibody 
responses we injected mice with Cl2MDP-liposomes to eliminate M<I> before primary 
injection of TNP-KLH. As described by van Rooijen and Sanders (1994) control mice 
were injected with PBS instead of CI2MDP-liposomes. TNP-specific IgG titres were 
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Figural Locallzalion of acid phosphatase posilive cells (macrophages) in the PLN (a, b) and NLDC-
145-posilive cells (interdigitating cells) in the para/deep cortex unit of the PLN (c, d). Mice were 
injected with 50 ~I PBS (a, c) or 50 ~I CI,MDP-liposomes (b, d) and 2 days later PLN were coliected. 
This is the moment ~nlmals In experimental groups were immunized. Note the absence of 
macrophages in the subcapsular sinus of the PLN of mice depleted of macrophages by injection of 
CI,MDP·liposomes (b) compared to PBS injected mice (a). 
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consistently higher when Mt!> were eliminated before TNP-KLH injection compared 
to control animals (Fig. 2a). Note that the y-axis has a log scale. 
Involvement of macrophages in FCAlTNP-KLH induced TNP-specific IgG responses 
To investigate whether the presence of Mt!> influences the efficacy of FCA, we locally 
eliminated macrophages by Cl2MDP-liposome injection before primary FCAlTNP-KLH 
immunization. Control animals received PBS instead of CI2MDP-liposomes. Evaluating 
antibody responses after FCAlTNP-KLH immunization (Fig. 2b) we observed higher 
TNP-specific IgG antibody responses after primary immunization when Mt!> were 
eliminated compared to control animals. Secondary immunization (TNP-KLH only, no 
adjuvants) of depleted animals resulted in a booster effect while antibody responses 
were significantly enhanced to 200 AU in control mice (p < 0.05), suggesting a role for 
macrophages in secondary immune response when FCA is used as an adjuvant. 
To study the enhancing effect of FCA, we compared antibody responses in 
Fig. 2 (a) (TNP-KLH immunization without adjuvant) and Fig. 2 (b) (immunization with 
TNP-KLH emulsified in FCA). Mt!> elimination before primary immunization resulted in 
similar (primary) anti-TNP IgG antibody responses after FCAlTNP-KLH injection and 
TNP-KLH injection without an adjuvant. Secondary immunization of these animals 
resulted in almost fourfold higher antibody responses after FCAlTNP-KLH 
immunization compared to TNP-KLH immunization without an adjuvant. PBS injection 
(control animals) before immunization with FCAlTNP-KLH resulted in (not significantly) 
higher primary and significantly higher (p < 0.05) secondary TNP-specific IgG antibody 
responses compared to TNP-KLH immunization without an adjuvant, showing an 
immune-stimulating effect of FCA as expected. 
Involvement of macrophages in SpecolfTNP-KLH induced TNP-specific IgG 
responses 
To investigate whether the presence of Mt!> influences efficacy of Specol (a less 
aggressive adjuvant than FCA) we locally eliminated macrophages by CI2MDP-
liposome injection before SpecoIITNP-KLH immunization. Control mice received PBS 
instead of Cl2MDP-liposomes (Van Rooijen and Sanders, 1994). Comparing antibody 
responses between macrophage eliminated and control animals after 
SpecoIITNP-KLH immunization (Fig.2c) we observed consistently higher anti-TNP 
antibody responses in depleted animals. This suggested that Mt!> do not playa major 
role in enhancing anti-TNP responses when Specol is used as an adjuvant but the 
presence of Mt!> rather have a suppressive effect. In depleted animals primary 
immunization with SpecoIITNP-KLH resulted in five times higher antibody responses 
than those observed after injection of TNP-KLH without an adjuvant or injection of 
FCAlTNP-KLH. 
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Effect of macrophage elimination before TNP-KLH immunization on isotype of TNP-
specific antibodies 
We showed that macrophage elimination before TNP-KLH immunization resulted in 
higher TNP-specific IgG antibody levels. We next studied the effect of macrophage 
elimination on isotype distribution. We determined TNP-specific antibody levels of the 
IgM, IgG1, IgG2a and IgE isotype in serum at selected time points. Antibody levels of 
these isotypes were identical in M<I>-depleted and control animals (data not shown). 
Effecf of macrophage elimination on affinity maturation of TNP-KLH induced TNP-
specific IgG1 responses 
To investigate whether the absence of macrophages influenced affinity maturation, we 
compared the relative affinity distribution of TNP-specific IgG1 antibodies of control 
and macrophage-depleted mice. Minimal differences in affinity distribution between 
M<I>-depleted and control groups in primary responses were observed (data not 
shown). On day 15 sera from both M<I>-depleted and control animals contained a 
major fraction (38%) of antibodies that were inhibited only at the high free hapten 
concentration of 10-4 M DNP-Iys (low affinity). Affinity increased during the time after 
immunization: at day 26 of the secondary response the serum showed a smaller 
fraction of the lowest affinity antibodies (10-4), along with a population of antibodies of 
higher affinity (10-5 to 10-7 M DNP-Iys). 
Effect of macrophage elimination on affinity maturation of adjuvanVTNP-KLH 
induced TNP-specific IgG1 responses 
Macrophage elimination did not influence affinity maturation during immune responses 
induced by TNP-KLH immunization without the use of an adjuvant. We next studied 
whether macrophage elimination affected affinity maturation when the immune 
response was induced by TNP-KLH emulsified in adjuvant (FCA or Specol). Affinity of 
TNP-specific IgG1 antibodies at day 9 and day 26 after secondary immunization in 
macrophage-depleted and control groups are shown in Fig. 3 (FCNTNP-KLH (Fig. 3a) 
and SpecolfTNP-KLH (Fig. 3b)). 
The histograms clearly show that affinity maturation occurred after secondary 
immunization in macrophage-depleted and control groups as well as in FCNTNP-KLH 
and SpecolfTNP-KLH groups. At day 9 of the secondary response serum contained a 
major fraction (around 35%) of antibodies that were inhibited mainly at the high free 
hapten concentration of 10-5 M DNP-Iys (lOW affinity). Affinity maturation occurred 
thereafter as seen from the emergence of higher affinity subpopulations (more and 
higher bars at the right hand side of the graph; at 10-6 and 10-7 M DNP-Iys) at day 26 of 
the secondary response. When affinity distributions of macrophage-depleted and 
control groups were compared, similar pictures emerged (Fig. 3). This was also the 
case when immunizations with the two adjuvants (FCA and Specol) are compared. 
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Figure 3 Relative affinity distributions of serum TNP-specific tgG1 antibodies in adjuvantfTNP-KLH 
immunized mice. Mice were injected with Cl2MDP-liposomes (Mfl>-depleted) or PBS (control) on day -
2, immunized with FCAfTNP-KLH (a) or with SpecolfTNP-KLH (b) on day 0, and secondarily 
immunized with 50 I1g of TNP-KLH on day 35. Data are shown from sera collected on day 9 (sec. day 
9) and day 26 (sec. day 26) after secondary immunization. Relative affinity was determined in a 
competitive inhibition ELISA. The abscissa indicates the concentration of free DNP-Iys (-log M) used 
for inhibition. Affinity increases to the right, higher affinity is more and higher bars in the right side of 
the graph. The ordinate shows the percentage of antibody present in each affinity subgroup. 
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This shows that macrophage depletion does not change normal affinity maturation 
and that FCA and Specol induce similar affinity maturation patterns. 
Discussion 
This study shows that local macrophage depletion by administration of CI2MDP-
liposome injection enhances TNP-specific IgG antibody responses induced by 
TNP-KLH immunization. Isotype distribution and affinity maturation are not affected by 
macrophage depletion. 
We studied two adjuvants, FCA and Specol, which differ at major points. FCA is a, 
relatively variable animal unfriendly, water-in·mineral oil emulsion containing 
Mycobacteria butyricum (Stewart-Tuli, 1995a). Specol is a standardized (constituents 
FDA approved) oil without any particulate matter. The bystander effect (help in T celi 
priming; Wright et al., 1987) of the particulate matter in FCA (which is never used in 
the secondary immunization; cf FIA) is clearly dependent on macrophages as we here 
also show. Free antigen, administered subcutaneously, is phagocytosed by meduliary 
M<I> (Fossum, 1980). In vitro studies demonstrated that preprocessing of particulate 
antigens by M<I> was crucial for the generation of immune responses (Van Rooijen, 
1992; Wright et al., 1987). M<I> have a specialized phagocytic and lysosomal function 
in processing particulate antigens while having a scavenging but not APC function for 
soluble antigens (Claassen et al., 1991). By eliminating M<I>, immunization may be 
more effective because less antigen wili be phagocytosed and therefore more antigen 
will come in contact with other APC such as for example interdigitating celis (I DC), 
which are extremely potent (Steinman, 1991). Using a specific mAb (NLDC-145) we 
confirmed the presence of IDC in the draining PLN after Cl2MDP-liposome injection. 
M<I> elimination may result in more soluble TO antigen being available for IDC leading 
to a better induction of an immune response. Alternatively one might envisage that 
elimination of M<I> (and the subsequent release of mediators etc.) in itself results in 
adjuvanticity. However, in an adjuvant-free system Delemarre et al. (1991) did not 
observe higher primary antibody responses after M<I> depletion when immunizing 
animals in the footpad with 50l1g TNP-KLH, the number of antibody-forming celis 
(AFC) increased (but not significantly) and the peak of the AFC response was 
delayed, arguing against the latter view. The present results also show that the 
mechanism of action of oil emulsions as adjuvant is not exclusively dependent on 
macrophages in the draining lymph nodes. 
Consequently, when an antibody response is required to (smali amounts of) a 
soluble antigen, elimination of M<I> combined with Specol may be a way to induce an 
effective antibody response with minimal side effects. 
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A rapid and simple method to localize 
oil based adjuvants in vivo 
P.P.A.M. Leenaars, H.H.A. Oostermeijer, C.F.M. Hendriksen 
and E. Claassen, J. Immunol. Methods, in press 
Localization of fluorescent labelled oil emulsions 
Abstract 
In this study we show that water-in-oil and oil-in-water emulsions, often used as 
immunological adjuvants, can conveniently be labelled and detected with fluorescent 
carbocyanine dyes. The method is rapid and simple and analysis can be carried out 
with routine fluorescent microscopy equipment on frozen tissue sections. It enables 
kinetic stUdies of in vivo routing of hydrophobic adjuvants. After sUbcutaneous 
administration of labelled oil emulsion we observed the emulsion in draining lymph 
nodes. Within the nodes the emulsion was located in macro phages of the marginal 
sinus mainly. After intraperitoneal administration we observed the bulk of 
fluorescently labelled emulsion associated with the capsules of spleen and liver. 
Only 10-15% of the material was found in the marginal zone macrophages of the 
spleen (where antigens normally localize) and minimal amounts were seen in the 
phagocytic Kupffer cells of the liver. Double labelling of oil and antigen revealed that 
oil and aqueous phase (= antigen) do not separate but colocalize in the spleen. 
Intraperitoneal administration of emulsions, and subsequent capsule association, did 
not interfere with "normal" marginal zone localization of antigen (soluble or 
particulate) injected by the intravenous or intraperitoneal route thereafter. The 
results indicate a second depot, in addition to the depot at the site of injection, of 
antigen containing oil emulsions associated with the capsules of spleen and liver. 
This new method of oil and antigen localization provides a new tool to study tissue, 
cellular and subcellular distribution of oil emulsions in relation to their immune-
stimulating effects and chemicophysical composition. 
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Introduction 
Adjuvants are employed in immunological research and vaccines to enhance the 
immune response (Stewart-Tull, 1995b). Oil emulsions are efficient adjuvants and 
thus often used for this purpose, especially in laboratory animals. The mechanisms 
by which oil emulsions influence immunological responses remain obscure (Cox and 
Coulter, 1997). Suggested modes of action include: depot function at the site of 
injection, protection of antigen (Ag) from degradation, non specific stimulation of 
macrophages, cytokine release and vehicle (transport/routing) function (cf: Gupta 
and Siber, 1995; Cox and Coulter, 1997; Leenaars at al., 1997; Allison and Byars, 
1992). 
In addition to this, injection site and composition of the adjuvant determines tissue 
and cellular localization of the antigen (Ag) in lymphoid organs, factors which in turn 
dictate the outcome of an immunization. Ag localization studies (in adjuvant free 
systems), using monoclonal antibodies or radioactive labelling methods (Van den 
Eertwegh at al., 1992, Van Rooijen et al., 1989) revealed specific localization 
patterns of different types of Ag, associated with different antibody levels and 
isotypes (cf. Laman and Claassen, 1996; Cox and Coulter, 1997). However, to our 
knowledge no simple method for the study of localization patterns of antigen 
containing emulsions is available. 
Lipophilic carbocyanine dyes have been successfully used for membrane 
labelling of living neurones, lymphocytes, low density lipoproteins, viruses, bacteria, 
liposomes and iscoms (reviewed in: Claassen, 1992; 1996; Claassen and Van 
Iwaarden, 1997). This type of label is very stable (both in terms of fluorescence and 
membrane integration) and can not diffuse over any aqueous phase, which makes it 
exlremely suitable for long term tracking studies in vivo. The hydrophobic character 
of oil makes it a potential candidate for labelling with carbocyanine dyes. 
When studying oil emulsions used as adjuvant, two phases (oil and water) need 
to be labelled separately since oil phase may locate different from aqueous phase 
(usually containing the Ag). Localization of oil and Ag depends on route of injection. 
To stimUlate draining lymph nodes, adjuvanUAg is often injected subcutaneously. 
For a systemic stimulation, intravenous injection is the most suitable route, however, 
oil emulsions are not tolerated well when injected intravenously. A similar systemic 
stimulation can be achieved by intraperitoneal injection as shown for soluble 
TI-2 antigens (Van den Eertwegh et al., 1992) or particulate liposomes 
(cf. Claassen, 1996). In daily praclice, oil based adjuvants are preferentially given 
subcutaneously, intraperitoneally or by the intramuscular route (long term depot and 
lymph node stimulation). 
From a recent study we found that in some cases macrophages play a 
suppressive and in other cases rather a stimulating role in the immune response 
induced by antigen or antigen containing oil emulsions. Furthermore, and more 
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importantly, it became clear that the efficient immune-stimulating effect of oil 
emulsions was only partly macrophage dependent (Leenaars et a/., 1997). To 
investigate which other mechanisms and macrophages are involved (or bypassed) 
in the uptake and processing of such emulsions a method for in situ localization of 
these compounds was deemed necessary. 
In the present study oil emulsions were labelled with carbocyanine dye (oil phase) 
and amine active probe (aqueous phase = Ag/carrier), thereby allowing the study of 
their localization patterns in lymphoid organs in situ. 
Materials and methods 
Animals 
Male BALB/c mice, aged 10-12 weeks, were obtained from Harlan, Zeist, the 
Netherlands and kept in polycarbonate cages, at 20-22'C, relative humidity of 
50-80% and with a 12 h daylnight cycle. Mice were given acidified water (pH 3) and 
fed pelleted mouse food (Hope Farms, Woerden, the Netherlands) ad Jibitum. 
Experiments were performed under the auspices of the Dutch Veterinary Inspection 
according to the law on Animal Experiments. 
Chemicals and antigens 
Oil (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; D-282), DiD 
(3,3'-dioctadecyloxacarbocyanine perchlorate; D-275), DiA (4-}4-dihexadecylamino-
styryl}-N-methylpyridinium iodide; D-3883) and AMCA (6-«7-amino-4-methyl-
coumarin-3-acetyl}amino}hexanoic acid, succinimidyl ester; AMCA-X,SE; A-6118) 
were obtained from Molecular Probes, Leiden, the Netherlands. Bovine serum 
albumin (BSA; A-8022) was obtained from Sigma, SI. Louis, MD. Ficoll-AECM83 
was a kind gift from Van Dudenaren (Erasmus University Rotterdam, cf. Koch et a/., 
1982; Van den Eertwegh et al., 1992). All other reagents were analytical grade or 
better.Adjuvants 
Freund's Incomplete Adjuvant (FIA; Dilco Laboratories Detroit, MI) is an oil emulsion 
consisting of mineral oil (85%) and emulsifier (15%). FIA emulsion was prepared by 
emulsifying FIA with an equal volume of PBS using glass syringes and a double hub 
connector. Specol (ID-DLD, Lelystad, the Netherlands) is an oil emulsion consisting 
of a mineral oil (90%) and emulsifiers (10%) (Bokhout el al., 1981; Boersma et a/., 
1992). Specol emulsion was prepared by mixing PBS and Specol in ratio of 9/11 
(v/v). PBS was added dropwise to Specol while mixing on the vortex. Multilamellar 
liposomes were prepared and labelled as described earlier and recently reviewed 
(for protocols see: Claassen and Van Iwaarden, 1997). 
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Fluorochrome labelling of emulsions and antigens 
To investigate the effects caused by integration of the different carbocyanine dyes 
(Oil, DiA, and DiO) into the emulsion, we determined the dose dependency of 
emulsion stability and fluorescence intensity. Stock solutions of all three dyes were 
made in pure ethanol (2.5 mg/ml, alternatively OM SO can be used). For the 
fluorescence labelling of FIA different amounts of dye-stock (2.5 mg/ml) were added 
to FIA while vigorously mixing on the vortex. To check fluorescent labelling of oil 
phase in water-in-oil emulsions, FIA-dyes were mixed with PBS (in a 1 : 1 ratio) and 
studied with an Olympus (Tokyo) Van ox fluorescence microscope. Oil fluorescence 
was observed as red with green light (excitation filter BP545), DiO fluorescence as 
green with blue light (using FITC optics, excitation filter BP490 + EY455) and DiA 
fluorescence as red with green light (excitation filter BP545). Fluorescence intensity 
and the stability of the emulsion were studied 30 min. after addition of dye labels. 
The stability of the emulsion was studied by determining the (unwanted) formation of 
micelles. 
Besides localization of oil phase of emulsion, we studied localization of the 
aqueous phase (containing the Ag) of the emulsion by labelling carriers with the 
water-soluble fluorescence AMCA. Stock solution of AMCA was made in N,N-
dimethylformamide (DMF; BDH Laboratory supplies, Poole, England, UK) 
(10 mg/ml). AMCA was conjugated to BSA and Ficoll as described in manufacturer's 
protocol 'conjugation with amine reactive probes' (MP 0143 01/26/96) of Molecular 
Probes, Leiden. In short, the carrier (BSA or Ficoll) was dissolved in 0.1 M 
bicarbonate (10 mg/ml). While vortexing the carrier, AMCA stock was added. This 
product was incubated for 1 h with continuous stirring. The reaction was stopped by 
add'pg freshly prepared hydroxylamine in a final concentration of 0.15 M. This 
product was incubated for 1 h. Hydroxylamine and unreacted AMCA were separated 
from the conjugate product on a gel fill ration column equilibrated with PBS. The first 
fluorescent band to elute is the carrier/AMCA-conjugate used in our experiments. 
This product was stored in the freezer (-20·C). To check AMCA fluorescence in DMF 
and carrier/AMCA conjugates, we mixed them with FIA and observed blue label in 
the aqueous phase with UV light (excitation filter UG1). Double labelled water-in-oil 
emulsions (aqueous phase, AMCA labelled BSA and oil phase, FIA labelled with Oil) 
were checked for fluorescence after mixing 1:1 on a vortex. We observed a red layer 
(oil phase) with green light and blue droplets (aqueous phase) with UV-light. 
Liposomes were labelled with addition of carbocyanine dye Oil (1-50 pg/ml, 
2.5 mg lipid) and liposomes were separated from unentrapped dye with flotation 
centrifugation after the addition of an equal volume of Iymphoprep as previously 
described (cf. Claassen and Van Iwaarden, 1997). 
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Experimental design 
To study localization of oil emulsion in draining lymph nodes, mice were injected 
subcutaneously in the upper site of the hind foot with 50 ~I Oil labelled FIA mixed 
with PBS (FIA-OiI/PBS; ratio 1 : 1), killed after 6 h and draining popliteal lymph 
nodes were collected. To study localization of oil emulsion in murine spleens, mice 
were injected intraperitoneally (i.p.) with 0.1 ml FIA-Oil/PBS and killed after 6 h. To 
study localization of oil phase as well as aqueous phase, mice were injected 
intraperitoneally with 0.1 ml double labelled water-in-oil emulsion (FIA-Oil/BSA-
AMCA) and killed 3 h later. To study possible interference of oil localization in 
capsule on Ag clearance in the spleen, mice were injected with 0.2 ml FIA-Oil/PBS 
and after 3 h labelled antigen (either fluorescently labelled ficoll or liposomes) was 
given by the intravenous (i.v.) or i.p. route. Mice were killed 3 or 24 h later. Spleens 
and liver were removed from i.p. injected mice and immediately frozen in liquid 
nitrogen and stored at -70·C till further use. 
Fluorescence microscopy of tissues 
Cryostat sections of 8 ~m were cut of frozen tissues (spleen, lymph node and liver) 
at -20·C. Sections were examined and photographed immediately after cryo-
sectioning with an Olympus (Tokyo) Vanox fluorescence microscope. Oil 
fluorescence was observed as red with green light (excitation filter BP 545) and 
AMCA fluorescence as blue with UVoptics (excitation filter UG1). 
Results 
Fluorescent labelling of oil emulsions and liposomes 
To investigate whether labelled oil can be used efficiently in water-in-oil and oil-in-
water emulsions, we prepared emulsions by mixing the labelled oil with PBS and 
studied these emulsions using fluorescence microscopy. Using green light, red 
background of labelled oil (FIA) and black droplets of unlabelled aqueous phase can 
be observed in Oil labelled water-in-oil emulsion (Fig. 1A). This is the other way 
around in oil-in-water emulsion (Fig. 1 B), red droplets are Oil labelled oil phase and 
black background is unlabelled aqueous phase. To evaluate fluorescence intensity 
of Oil labelled emulsions (Fig. 1A and 1 B), we compared them with Oil labelled 
liposomes (Fig. 1 C; cf Claassen, 1992). The fluorescence intensity of Oil labelled oil 
emulsions is clearly less intense than that observed with Oil labelled liposomes, but 
still more than enough for localization studies in vivo. 
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Figure 1 Fluorescent labelling of adjuvant products. 011 fluorescence is red In: (A) oil phase (Freund's 
incomplete adjuvant) of water~jn-oil emulsion, (8) oil phase (Speeal) In oil-in-water emulsion. and (C) 
liposomal membrane. 
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Stability of fluorescence intensity and micelle formation 
In view of differential effects of different carbocyanine compounds on stability of 
biomembranes (including lymphocytes) observed before (Claassen, 1992) we 
compared different dyes. For fluorescent labelling of oil emulsions we used Dil, DiO 
and DiA in concentrations ranging from 0-156 ~g/ml. We studied the suitability of 
these dyes to label oil by determining: (i) the stability of the fluorescence intensity 
and (ii) amount of micelle formation. Fig. 2 shows these two parameters as a 
function of concentration of carbocyanine dye used for labelling oil (FIA). 
When Dil is used for labelling (Fig. 2a) fluorescence intensity is strong at a 
concentration of 12 ~g fluorochrome per ml oil, while no micelle formation revealed 
at any concentration used during the time of the experiment. When DiA was used for 
labelling (Fig.2b) the fluorescence intensity was acceptable at 25 ~g/ml and 
micelles were formed at 31 ~g DiA per ml oil. When DiO was used for labelling 
(Fig. 2c), fluorescence intensity was acceptable at a concentration of 46 ~g/ml but at 
this concentration of DiO, some micelle formation was already observed. 
Consequently, Dil is preferred for labelling oil emulsions (12 ~g Dil per ml oil) and 
used in this study for localization experiments in vivo. 
3.3 Localization of adjuvant in spleen after systemic administration 
We studied the localization of oil phase in spleen and liver of mice after 
intraperitoneal injection of 0.1 ml FIA-Dil mixed with PBS. Fig. 3A shows 2/3 of a 
total spleen section, 6 h after FIA-DiI/PBS administration. Almost all fluorescent 
material is observed at the periphery of the spleen associated with the splenic 
capsule and not taken up by any particular cell. A minor fraction of the fluorescent 
label is found within the body of the spleen, the minimal label that is found here is 
associated with the marginal zone (note semi-circular patterns). After i.p. 
administration of Dil labelled emulsions, label was also observed in the capsule of 
the liver and only minimal amounts were seen in the Kupffer cells. 
To compare this localization pattern of oil emulsions with other adjuvant products, 
we labelled liposomes with Dil and administered these intravenously or 
intraperitoneally and collected spleen and liver. Almost all labelled liposomes were 
seen in the body of the spleen, I.e. in the marginal zone macro phages (M) and on 
follicular cells (F) of the spleen (Fig 3B). Relatively few liposomes are taken up by 
the red pulp macro phages (R) and none by T-cells in the PALS (P). No liposomal 
material was associated with the capsule. After Lv. or i.p. administration of Dil 
labelled liposomes, label was observed mainly in Kupffer cells of the liver. 
Macrophages were identified by acid phosphatase staining as described before 
(Van Rooijen et al., 1989). 
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Figure 2 Fluorescence intensity (intensity) and emulsion stability (micelles) as function of 
concentration of carbocyanine dye used for labelling oil emulsion. Oil phase of water~in-oil emulsion 
was labelled utilizing Oil (a), DiO (b) or DiA (e). Fluorescence intensity expressed as 0 ::: no 
fluorescence observed; 1 ::: mInimal fluorescence; 2 ::: acceptable fluorescence; 3 = strong 
fluorescence. Emulsion stability expressed as the amount of micelle formation; 0 ::: no micelle 
formation; 1 ::: micelles are formed; 2 ::: abundant micelle formation. 
Double-fluorescent labelling studies 
To study localization of oil phase as well as Ag phase, mice were injected 
intra peritoneally with 0.1 ml double labelled water-in-oil emulsion (FIA-Dil/BSA-
AMCA). We observed minimal separation of Ag and oil phase in de spleen 6 h after 
administration. The major fraction of fluorescent material is observed in/under the 
splenic capsule, while minimal fluorescent label is found in the spleen. The minimal 
label that is found here is associated wilh the marginal zone (M) and oil and 
aqueous phase are not separated (Fig.4A). To investigate whether this newly 
observed and typical localization pattern of oil phase of emulsions associated with 
the capsule of the spleen interferes with 'normal' clearance of the Ag by marginal 
zone macro phages of the spleen, mice were injected Intraperitoneally with 0.1 ml 
FIA-Dil/PBS before 0.1 ml fluorescently labelled Ag (Ficoll-AMCA) was injected. 
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Fig. 4B shows localization of Ficoll-AMCA in a marginal zone macrophage of the 
spleen (AMCA fluorescence is blue (arrow). It was clearly shown that the normal 
localization of Ficoll-AMCA in the marginal zone was not changed by previous 
administration of the adjuvant. 
In addition to the soluble Ag (Ficoll) we also used a particulate Ag (liposomes) in 
a pulse chase manner to demonstrate the effect of an earlier administration of a 
water in oil adjuvant on the capacity of splenic macrophages to take up the Ag. As 
Figure 6 shows the water in oil emulsion does not interfere with the normal follicular 
localization and uptake by splenic macrophages of liposomes (irrespective of the 
route of administration). 
Localization of Dil/abel/ed oil in poplitea//ymph node after sc injection 
To check localization of the oil emulsion in primary draining lymph node after sc 
injection, we administered Oil-FINPBS s.c. in the upper site of the hind foot and 
studied the popliteal lymph node (PLN). A tangential section through the marginal 
sinus shows that fluorescent label is found in the marginal sinus macro phages 6 h 
after administration (Fig. 5A), creating a web like pattern of marginal sinus 
macro phages which have taken up oil in varying amounts. 
Efficacy of trapping of labelled oil by marginal sinus macrophages is clearly 
shown when observing a cross section through the PLN (Fig. 5B). No label was 
found in the follicles (F) while minimal label was found in the interfollicular T-cell 
areas. Increasing amounts of label can be observed in deep cortex and medulla, the 
major part of the fluorescent material stays in the marginal sinus. After s.c. 
administration of oil emulsion, Oil label eventually also localized associated with 
capsule of spleen and liver as found for the Lp route (data not shown). 
Discussion 
This study shows that carbocyanine dyes can efficiently be used to label oil, water-
in-oil and oil-in-water emulsions to enable kinetic studies on in vivo routing of oil 
adjuvants, hereby adding a new tool to the immunotechnological arsenal. 
A major new finding is that oil emulsions localize preferentially in association with 
the capsules of spleen and liver after intraperitoneal administration. It is not clear 
which cells, if any, are associated with this peculiar way of localization or how the oil 
emulsion exactly arrives at this site. In double labelling studies, in which we labelled 
both oil and Ag (in aqueous phase), we observed the majority of oil and Ag 
associated with the capsule and only minimal amounts in the marginal zone and 
follicles, indicating that no phase separation occurred. It seems that this small 
amount of Ag is effective in inducing an immune response. This is in agreement with 
earlier functional studies (Leenaars et al., 1995) where we established much higher 
antibody responses to peptides after administration of peptides emulsified in oil than 
peptides mixed wilh PBS. 
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Figure 3 Fluorescence microscope image of an 8 IJm spleen cryo-seclion. (A) 6 h after i.p. 
administration of FIA-Dil/PBS. (8) 24 h after Lv. administration of DII-liposomes. Oil fluorescence Is 
found: (A) mainly directly under splenic capsule not associated with cells after FIA-Dil/PBS and (6) in 
a ring like structure In the marginal zone macrophages (M) and on follicular cells (F) after Oil-
liposomes. Magnificalion: (A): 213 of spleen secllon; x20, (8): 1110 of spleen seclion; x100. 
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Figure 4 No separation of oil and Ag .> Fluorescence microscopic image of an 8 J..Im spleen cryo· 
section. (A) 3 h after Lp. administration of FIA-Oil mixed with BSA-AMCA. P = pals; M = marginal 
zone. Oil fluorescence is yellow; AMCA fluorescence is blue, note mostly double staining. (8) 24 h 
after I.p. administration of FIA-OIIIPBS and 21 h after i.v. administration of Ficoll-AMCA. AMCA 
fluorescence is blue (arrow). Magnification: 4A = x400; 8 = x800. 
Figure 5 Fluorescence microscopic image of an 8 J..Im popliteal lymph node cryo-section, 6 h after s.c. 
administration in upper site of hind foot of FIA-Oil/PBS. (A) Tangential section, showing web like 
structure through macrophages in marginal sinus; Oil fluorescence is yellow with blue light. (B) cross 
section, showing efficiency of trapping labelled oil in marginal sinus macrophages; F = follicles; Oil 
fluorescence is red with green light. Magnification: A = x400; B = x200. 
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Figure 6 Animals as under 3B. Sections showing normalliposomal locallzation patterns at 21 h after 
liposomes (i.v. in A and 8; I.p. in C and D) and 24 h after sham (PBS) or Freund's incomplete adjuvant 
treatment via the i.p. route. 
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Localization of oil associated with the capsule after administration of oil emulsions 
may function as a second depot, besides the depot at the site of administration, and 
herewith stimulate splenic antigen-presenting cells by continuous release of Ag. 
These results can very well explain the efficacy of oil emulsions in inducing immune 
responses, i.e. by keeping the bulk of the Ag away from the suppressive marginal 
zone macrophages (Leenaars et a/ .. 1997) and releasing Ag over time for uptake by 
follicular cells of the spleen or interdigitating cells in the interfollicular T-cell areas of 
the lymph node. The fact that the efficacy of bacteria containing oil emulsions as 
adjuvants was only partly macrophage dependent could also be explained by this 
macrophage independent mechanism. 
Preparation of emulsions can be done in many different ways with as many 
different results. Important aspects of emulsions are stability, reproducibility, droplet 
size and charge. The localization pattern can possibly change when the emulsion is 
prepared differently, since physicochemical characteristics may change, in a similar 
fashion as described for liposomes (Claassen, 1996). The method described here 
can be employed for every combination and the results found, apply to the particular 
adjuvant used in this study. Nevertheless, the advantages of carbocyanins are 
evident and similar as we found before for the labelling of lymphocytes, bacteria, 
viruses, iscoms or liposomes (reviewed in Claassen, 1996). Furthermore, some 
emulsions can be labelled after they are formed, as shown with liposomes 
(Claassen, 1992), enabling retrospective localization studies with only those 
emulsions that need further study. Advantages of the use of Dil are stability (both of 
integration and of fluorescence), ease of use, minimal interference with 
physicochemical properties, no modification of proteins (as for e.g. FITC and 
TRITC), low price and the use of normal laboratory eqUipment. From the present 
results it has become clear that this new method enables the study of oil containing 
(or otherwise hydrophobic) adjuvant emulsions. Use of this method for other 
adjuvants (also those commercially available, for a complete listing and details see: 
Vogel and Powell, 1995) should elucidate the relation between efficacy and 
tissue/cellular localization and aid in educated design of hydrophobic and emulsion 
type adjuvants. Finally, in the design of adjuvants which are both efficient and have 
low intrinsic toxicity (Le. side effects; Claassen and Boersma, 1992; Gupta et al., 
1993), the histopathological studies relating emulsions with local tissue reactions, 
will also be facilitated by this method. 
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General discussion 
The main goal of the studies described in this thesis was to generate data on FCA 
and alternative adjuvants to analyse and expand recommendations on the use of 
adjuvants in laboratory animals and herewith reduce pain and distress in immunized 
animals. Additional goals of the studies were to increase insight into the correlation 
between cytokine profiles and antibody production and the mode of action of some 
selected adjuvants. 
Immunizations of laboratory animals are widely performed in biomedical research, 
for instance, to prepare specific polyclonal antibodies, produce specific B cells for 
developing monoclonal antibodies, evaluate potential antigens for vaccine 
development or conduct fundamental immunological research. In immunization 
experiments, adjuvants (Latin: adjuvare = to help) may be used to induce an 
adequate immune response to an antigen. Adjuvants can influence the magnitude 
and the quality of the induced immune response (e.g. isotype of antibodies or 
cytokine profiles ofT cells). In laboratory animals, Freund's complete adjuvant (FCA) 
is often used for this purpose because it induces effective immune responses to a 
broad range of antigens. However, besides satisfactory immune responses, severe 
side effects can be induced by FCA. These side effects resulted in restrictions on 
the use of FCA in order to reduce pain and distress in immunized laboratory 
animals. In the Netherlands, these restrictions are formulated in the Code of Practice 
for the immunization of laboratory animals (Veterinary Public Health Inspectorate, 
1993), recommending restricted use of FCA. To adequately select an alternative to 
FCA, it is necessary to know efficacy and side effects of alternative adjuvants. 
However, comparative information on immune-potentiating properties and side 
effects of alternative adjuvants is often lacking. This thesis focusses on the use of 
adjuvants for the generation of polyclonal antibodies. To obtain data on efficacy and 
side effects of FCA and alternative adjuvants, we performed comparative studies in 
rabbits and mice and studied antibody responses and adverse effects induced by 
FCA and alternative adjuvants. Consequently, emphasis was also put on those 
references in literature where adjuvants were actually compared (APPENDIX 
A and B), as opposed to a mere description of their effects. In addition, cytokine 
production after adjuvant injection and the role of macrophages in adjuvant efficacy 
were studied. 
In this general discussion, first antibody responses and side effects induced by 
five commercially available, potentially interesting adjuvants (FCA, Specol, RIBI, 
TiterMax, Montanide ISA50) are discussed, followed by other factors such as type of 
antigen, route of injection, animal species used, influencing the efficacy and side 
effects. Next, the predictive value of cytokine profiles for eventual antibody 
responses and the mode of action of water-in-oil emulsions are discussed. 
Thereafter, the degree of pain and distress induced by adjuvants is assessed and 
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alternative methods to produce antibodies are described. Finally, recommendations 
on the use of adjuvants for immunization procedures are given. 
Antibody responses and side effects induced by adjuvants 
To select a proper alternative to FCA, adjuvant induced antibody responses and 
side effects have to be evaluated in one and the same experiment. In several 
evaluation studies, FCA and alternative adjuvants were compared for their 
properties to induce antibody responses and clinical, behavioural andlor 
pathological changes in rabbits and mice. To mimic normal laboratory problems in 
evoking immune responses, the antigens used were mainly weak immunogens (e.g. 
synthetic peptides, autoantigen, glycolipid) as opposed to 'model antigens' such as 
carrier-hapten conjugates which are frequently used in comparative studies (e.g. 
Bennett et al., 1992). Antigens were always given at a relatively low dose so as to 
visualize maximal adjuvant effects. FCA is universally applicable (Gupta et al., 1993) 
and therefore used as 'gold standard' i.e. alternative adjuvants are compared with 
FCA on their antibody responses and side effects. Since minimal clinical and 
behavioural changes were observed after adjuvant/antigen injection, side effects will 
concern mainly pathological changes after injection. The meaning of pathological 
changes in the induction of pain and distress will be discussed later in this chapter in 
section 'Assessment of pain and distress induced by adjuvant'. The results of our 
comparative studies are discussed below per adjuvant. Emphasis is put on FCA, 
Specol, RIBI, TiterMax and Montanide ISA50 because these products are 
commercially available and easy to use. 
Freund's complete adjuvant 
FCA used in this thesis consists of 85% mineral oil (Bayol F), 15% Arlacel , and 0.5 
mglml heat-killed Mycobacterium butyricum (Difco Laboratories, Detroit, MI; Freund 
et al., 1937; Freund, 1951; Stewart-TulI, 1995a). Commercially available FCA may 
differ in the added amount and type of Mycobacteria; e.g. Difco Laboratories also 
has FCA containing 1 mglml heat-killed Mycobacterium tuberculosis H-37. The 
comparison of M. butyricum versus M. tuberculosis was not part of this study. 
Secondary injection was performed using FlA. FA (FCA in primary; FIA in secondary 
injection) emulsified with aqueous antigen solution (1 : 1) results in water-in-oil (w/o) 
emulsions. 
antibody responses 
The overall applicability of FA to induce polyclonal antibodies to a wide range of 
antigens was confirmed in all our studies. Antibody responses after FA/antigen 
injection were also comparable or higher than any other tested adjuvant. In mice, 
exceptions were the induction of antibodies to autoantigen. Antibody responses 
were (4 times) higher after s.c. injection of autoantigen (MBP) coupled to 
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RV-ISCOMs, than MBP emulsified in FA. The longer period between primary and 
secondary immunization with RV-ISCOMs/MBP may explain these higher levels 
than FA. After Lp. injection of TiterMax/synthetic peptide, peptide specific IgG 
antibodies levels recognizing the native protein were higher than those observed 
after FA/synthetic peptide injection. 
side effects 
In rabbits, no clinical or behavioural changes, indicative for pain and distress, were 
observed. In mice weight-loss, piloerection and hunched posture were observed 1 to 
3 days after primary injection, which might be an indication of distress. These 
changes were most extensive in FA injected mice when compared with injection of 
other adjuvants. The pathological changes observed after administration of FA in 
rabbits and mice were at least moderate and often severe. Generally, gross and 
histopathological lesions after FA/antigen injection had highest severity grade 
compared with other adjuvants injected with the same antigen. An exception was 
injection of RIBI (s.c. or Lm.) in rabbits which resulted in more severe lesions with all 
three antigens tested, as compared with FA lesions. The observed pathological 
changes after FA injection (e.g. granulomatous lesions with exudative nature; 
intestinal adhesions) confirm data of other authors who studied lesions after injection 
of FCA (Broderson, 1989; Toth et al., 1989; Deeb et al., 1992; Smith et al., 1992). 
conclusion 
FA is a very effective adjuvant in inducing antibody responses in rabbits and mice. 
Generally, the induced pathological lesions are severe, but clinical and behavioural 
changes were minimal in rabbits and only observed the first 1-3 days after FA 
injection in mice. 
Specol 
Specol (lD-DLO, Lelystad, the Netherlands; Bokhout et a/., 1981; Boersma et al., 
1992; Vogel and Powell, 1995) consists of a mineral oil (Marcol 52) and two 
emulsifiers (Span 85 and Tween 85). Preparing Specol and aqueous antigen, in a 
5 : 4 ratio, results in a water-in-oil emulsion. 
antibody responses 
Immunization of rabbits or mice with Specollantigen resulted in specific antibody 
responses comparable to those induced by Montanide ISA50/antigen and 
FA/antigen. This confirms data of Boersma et al. (1993) who described that for the 
induction of peptide specific antibodies in rabbits and mice, Specol leads to good 
results in almost all cases. Zegers et al. (1993) found Specol to be effective in 
producing anti-peptide antibodies that recognize the native protein in rabbits and 
mice. In mice, we only observed native protein cross-reactive antibodies when the 
Specollpeptide was Lp. injected and not when s.c. injected. Specol did not induce 
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antibodies to autoantigen (MBP), confirming that Specol has limited properties to 
induce T cell-mediated immunity. This is supported by the finding that 
Specol/synthetic peptide injection in mice resulted mainly in peptide specific 
antibodies of the IgG1 isotype (cf Boersma et al., 1992). 
side effects 
No clinical and behavioural changes, indicative for pain or distress, were observed in 
rabbits immunized wilh Specol emulsions. In mice, we observed weight loss, 
piloerection and hunched posture the first 2 days after injection of Specol emulsions. 
These changes were less extensive than after FA injections. The pathological 
changes observed after injection of Specol emulsions were mostly minimal to 
moderate except for lesions observed after injection of Specol combined with 
measles virus, mumps virus or Mycoplasma pneumoniae. Lesions were then marked 
to severe and sometimes comparable to those after FA injection. The particulate 
character of these antigens may playa role in the severity of lesions. Particulate 
antigen may be released from the Specol emulsion slower than soluble antigens 
resulting in longer contact of particulate antigen with attracted cells, such as 
macro phages and neutrophils, resulting in more damage. Not all particulate antigens 
(e.g. Rubella-virus), however, were shown to induce severe pathological changes 
when emulsified in Specol. Bokhout et al. (1981) observed no tissue necrosis and 
only slight degeneration of muscular tissue after i.m. injection of Specol without 
antigen, while when antigen was added, lesions included granulomas of 1 cm. This 
again indicates that the (type of) antigen in Specol influences the induction of side 
effects. 
conclusion 
Specol induces comparable antibody titres to FA and Montanide ISA50, except for 
antibody responses to autoantigens, while the severily of lesions induced by Specol 
is variable, depending on the antigen. Generally, the severity of Specol lesions was 
comparable to Montanide ISA50 lesions and far less severe than FA lesions. 
RIBI 
RIBI adjuvant system (RIBI ImmunoChem Research Inc., Hamilton, MT; Ribi et a/., 
1982: Masihi et al., 1986; Rudbach et al., 1995) consists of highly purified microbial 
components contained in a metabolizable oil (squalene) and emulsifier (Tween 80). 
Two formulations of RIBI adjuvant were used in our experiments as recommended 
by the manufacturer; for rabbils, the RIBI containing three microbial components, 
0.5 mglml MPL (monophosphoryl lipid A), 0.5 mglml TOM (synthetic trehalose 
dicorynomycolate) and 0.5 mglml CWS (cell wall skeleton) and for mice, the RIBI 
containing 0.5 mglml MPL and 0.5 mg/ml TOM, were used. When RIBI is prepared 
with aqueous antigen solution, an oil-in-water emulsion is formed. 
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antibody responses 
Immunization of rabbits with RIBI, combined with synthetic peptide, resulted in low 
antibody titres when compared to FA. Antibodies were only detectable after 
secondary injection. These findings confirm data of Johnston et al. (1991) and Smith 
et al. (1992) who observed low antibody responses in rabbits even though they used 
carrier-peptide antigens Le. BSNpeptide and protein/polymer, respectively. Also 
Bennett et al. (1992) observed low antibody responses after injection of a carrier-
peptide (BSNLHRH) combined with RIB I in rabbits. Bennett et al. (1992) used RIBI 
which contains MPL and TOM and can therefore formally not be compared with our 
experiments. When RIBI/Mycop/asma pneumoniae was injected (s.c. or Lm.) in 
rabbits antibody responses were intermediate and transient compared to FA 
injections. Mallon et al. (1991) used RIBI containing MPL and TOM in rabbits and 
observed intermediate antibody titres after s.c. injection with a subunit enzyme (rat 
liver microsomal epoxide hydrolase). Oeeb et al. (1992) found transient antibody 
responses after Lm. injection of synthetic polypeptide combined with RIBI compared 
to FA in rabbits. 
When comparing immunological properties of RIBI with those of FA in mice, 
injection of synthetic peptide emulsified in RIBI induced low antibody levels 
compared with FA injection. Our findings are in contrast with those of Lipman et al. 
(1992) and Geerligs et al. (1989) who Lp. injected mice with RIBI combined with 
bovine gamma globulin/hapten and BSNsynthetic peptide respectively and 
observed specific antibody levels comparable to FA injection. This was also 
observed in mice after s.c. injection of a protein toxin (Hewetson et al., 1993) or 
fusion protein (Daly and Long, 1996) in combination with FA or RIBI. The type of 
antigen used (carrier-hapten in the former two and proteins in the latter two studies) 
may explain these higher antibody levels found. Kenney et al. (1989) observed 
intermediate antibody titres when RIBI/human serum albumin was injected in mice. 
Relative, to IgG1, we observed high levels of IgG2a antibodies were observed after 
secondary Lp. injection of RIBI/synthetic peptide. This confirms the expected 
induction of IgG2a antibodies by MPL and TOM (Van de Wijgert et al., 1991; 
Rudbach et al., 1995). RIBI might therefore be useful to induce cell-mediated 
immunity (Johnson and Tomai, 1990). 
side effects 
In rabbits and mice minimal clinical and behavioural changes, which might be 
indicative for pain and distress, were observed. After RIBI/antigen injection in 
rabbits, lesions were more severe (with all three antigens) than those found after 
injection of FNantigen, both after s.c. and Lm. injections. Johnston et al. (1991) 
injected BSA-peptide combined with RIB I or FA in rabbits and observed that RIBI 
and FA induced comparable pathological changes. In contrast, Oeeb et at. (1992) 
found lesions after RIBI injection that were less severe than those found after FA 
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injection in rabbits. The severity of the RIBI lesions in our rabbit studies exceeding 
those induced by FA; this may be explained by the volume injected (2xO.5 ml). The 
manufacturer of RIBI recommends 1 ml divided in ten inoculation sites per rabbit. As 
we wanted to perform all inoculations in a similar manner, the recommended volume 
of 1 ml RIBI was divided in two inoculation sites (as approved by the manufacturer). 
Another explanation may be the way in which we prepared the RIBl/antigen 
emulsions. In mice however, we used the same preparation protocol (described by 
the manufacturer) and observed minimal side effects. These findings in mice are in 
contrast with findings of Lipman ef a/. (1992) who injected RIBI and FCA in mice and 
observed pathological lesions which were comparable for both adjuvants but FCA 
lesions were more extensive than RIBI lesions. It is not clear why these considerable 
differences in pathological changes between rabbits and mice occur after RIBI 
injection. The fact that the RIBI used in rabbits contained, besides MPL and TOM, 
also CWS may playa role. 
conclusion 
RIBI has only limited value in rabbits and mice for induction of antibody responses. 
Pathological changes in rabbits after RIBI injection, exceeded those induced by FA. 
In mice pathological changes were minimal after RIBI injection. 
TilerMax 
TiterMax (CytRx Corporation, Norcross, GA; Hunter ef a/., 1981; Hunter and 
Bennett, 1986; Hunter ef a/., 1995) consists of a metabolizable oil (squalene), 
emulsifier (Sorbitan Monooleate 80) and a patented block copolymer CRL-8941. 
When TiterMax is mixed 1 : 1 with aqueous antigen, a water-in-oil emulsion is 
formed. 
antibody responses 
Intramuscular injection of TiterMaxiantigen in rabbits resulted in low antibody 
responses while injection via the s.c. route resulted in intermediate antibody 
responses. Smith ef a/. (1992) also observed low titres when TiterMaxiantigen was 
i.m. injected. The high antibody titres claimed for TiterMax in rabbits (Bennett ef a/., 
1992) were not observed in our study. Subcutaneous injection of mice with 
TiterMaxisynthetic peptide resulted in low antibody levels while after i.p. injection, 
these levels were high. In mice, we subcutaneously injected the recommended 
amount of 50 ~I TiterMaxiantigen per mouse while intra peritoneally 0.2 ml 
TiterMaxiantigen was injected. This may be an explanation for the difference in 
response after the s.c. and i.p. route of injection. Zhou and Afshar (1995) also 
observed low antibody titres after s.c. injection with TiterMax. However, Bennett ef 
a/. (1992) observed comparable antibody levels when injecting carrier-hapten with 
TiterMax or with FA. Also, Sjolander ef a/. (1996) and Daly and Long (1996) 
observed comparable antibody titres and isotype distribution of antibodies (lgG 1 and 
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IgG2a) after s.c. injection of influenza virus micelles or fusion protein, respectively, in 
combination with TiterMax or FA. Subcutaneous injection of whole killed parasite 
(Ten Hagen et a/., 1993) combined with TiterMax or FA resulted in comparable IgG1 
levels while IgG2a levels were lower when TiterMax was used. The high antibody 
levels observed by the authors above after s.c. injection of TiterMax combined with 
antigen, as opposed to our findings, may be explained by the type of antigen used. 
In our studies, we used a synthetic peptide while in the studies described above, 
relatively immunogenic particulate or carrier-hapten antigens were used. After Lp. 
injection with TiterMax/synthetic peptide, peptide specific IgG1 antibody levels were 
comparable to those observed after FA injection while antibodies of the IgG2a 
isotype were 4 times higher after TiterMax than after FA injection. These high IgG2a 
antibody levels are in accordance with the ability of TiterMax to induce cell-mediated 
immunity (Kast et al., 1993). Efficacy of TiterMax in T cell-mediated diseases was 
shown by Roberge et al. (1992) and Shenoy and Christadoss (1993) who 
successfully induced experimental autoimmune uveoretinitis and autoimmune 
myasthenia gravis, respectively, using TiterMax. However, induction of adjuvant 
arthritis in susceptible rats was not successful (Hunter et al., 1995). The level of anti-
peptide antibodies that recognize the native protein, was higher after Lp. injection of 
TiterMax/antigen than of FNantigen. 
side effects 
No clinical or behavioural changes, indicative for pain and distress, were observed in 
rabbits. In mice, piloerection and hunched posture was observed the first days after 
primary and secondary immunization with TiterMax, especially after Lp. injection. 
These changes were as severe as those observed after Lp. injection of FA. 
Pathological changes after TiterMax injection in rabbits were less severe than those 
observed after FA injection. Upon clinical observation, no lesions were observed by 
Smith et al. (1992) after Lm. injection of TiterMax in rabbits while after Lm. injection 
of FA small granulomatous lesions were observed. Bennet! et al. (1992) studied i.m. 
lesions after TiterMax injection histologically and observed mild reactions. In mice, 
we observed pathological changes after injection (Lp. or s.c.) of TiterMax which 
were as severe as those observed after FA injection. This was not reported by other 
authors. Hunter and Bennet! (1984) described that the nonionic block polymer 
surfactants differ in the generation of inflammation. The combination of our antigen 
(synthetic peptide) with TiterMax may have changed its inflammatory effects, and 
this may also explain the differences between lesions found in rabbits and mice. 
conclusion 
TiterMax was not shown to be an effective adjuvant for antibody production to weak 
immunogens in rabbits. In mice, s.c. injection of TiterMax was not effective while Lp. 
injection of TiterMax resulted in very high IgG2a and native-protein cross-reactive 
antibody levels. The pathological changes in rabbits observed after TiterMax 
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injection were less severe than after FA while in mice lesions of comparable severity 
were found. 
Montanide ISA50 
Oils of the Montanide series (Seppic, Paris, France; Ganne et al., 1994) are diverse, 
some of them are biodegradable. In this study, we used Montanide ISA50 which 
consists of 85% mineral oil and 15% emulsifier (mannide oleate). After mixing 
Montanide ISA50 with aqueous antigen in a 1 : 1 ration, a water-in-oil emulsion is 
formed. 
antibody responses 
Injection of Montanide ISA50lantigen in rabbits resulted in specific antibody 
responses comparable with those observed after FNantigen injection. This was also 
observed by Johnston et al. (1991) who used BSA-peptide as an antigen. In mice, 
'Montanide ISA50/synthetic peptide immunization resulted in antibody responses 
comparable to (s.c. injected) or even exceeding (Lp. injected) those induced by FA. 
These findings confirm the observations by Jones et al. (1990) who used carrier-
synthetic peptide as antigen in mice. Montanide ISA50 immunizations in mice 
resulted mainly in antibodies of the IgG1 isotype while minimal IgG2a antibodies 
were found. Antibodies of the IgG1 isotype are commonly observed after injection of 
water-in-mineral oil emulsions (Allison and Byars, 1991). This suggests that 
Montanide ISA50 is not very effective in inducing cell-mediated immunity. Minimal 
anti-peptide antibodies recognizing native protein were induced by Montanide 
ISA50/synthetic peptide injection. 
side effects 
Injection of Montanide ISA50 emulsions in rabbits and mice resulted in lesions which 
were less severe than those observed after FA injection. When Montanide ISA50 
was s.c. injected in rabbits, combined with HIV-peptide conjugated to tetanus toxoid, 
exudative lesions were found at the site of injection. These exudative lesions may 
be explained by the tetanus toxoid component in the antigen. Johnston et al. (1991) 
injected Montanide ISA50/BSA-peptide in rabbits and observed comparable 
pathological changes as those observed after FA injection. In mice, Montanide 
ISA50 injection (s.c.) resulted in comparable pathological changes as FA injection 
but lesions were less extensive. 
conclusion 
Montanide ISA50 was shown to be an effective adjuvant for the induction of 
antibodies in rabbits and mice while it induced variable lesions, depending on the 
antigen, the severity of lesions was comparable to Specol lesions and less severe 
than FA lesions 
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Other studied adjuvants 
Immune-stimulaling complexes (iscoms) are used as an experimental adjuvant 
(Morein et al., 1987; Barr and Mitchell, 1996) and are not (yet) commercially 
available. Basically, ISCOM is formed from cholesterol, saponin, phospholipid and is 
termed ISCOM matrix or empty ISCOMs. When viral envelope proteins (e.g. rabies, 
measles, influenza) are incorporated into the ISCOM matrix, it is called ISCOMs. In 
our studies, ISCOMs wilh incorporated rabies virus glycoprotein (RV-ISCOMs) were 
used. Other antigens can to be coupled to the RV-ISCOMs to induce effective 
immune responses (Lovgren and Larsson, 1994). Since ISCOMs are a relatively 
small structure (40 nm), it is therefore ill-adapted for coupling of particulate antigens. 
We studied a synthetic peptide and an autoantigen (MBP) coupled to RV-ISCOMs. 
Immunization of these RV-ISCOMs with coupled antigen was shown to be very 
effective in inducing antigen specific antibody responses. This confirms findings of 
Lovgren et al. (1987) who coupled biotin as an antigen to influenza virus ISCOMs. In 
our studies, anti-MBP antibody responses exceeded those found after FNMBP 
injection. Using another autoantigen (PLP-peptide) coupled to RV-ISCOMs in SJUj 
mice, we induced high peptide specific antibody levels but we were not able to 
induce experimental autoimmune encephalomyelitis in these mice as opposed to 
FCNPLP-peptide (unpublished data). At necropsy minimal gross and 
histopathological lesions were found after injection of RV-ISCOMs with coupled 
antigen. RV-ISCOMs is a very interesting adjuvant for the induction of antibody 
responses to small antigens. It can not easily replace FCA at this moment since it is 
not commercially available. 
The experimental Lactobacillus adjuvant was not effective in inducing antibody 
responses. Boersma et al. (1994) showed that peplides need to be coupled to 
Lactobacillus to generate acceptable levels of responsiveness. This makes it less 
useful as ready to use adjuvant to replace FA. We confirmed that Lactobacillus is 
not pathogenic upon administralion, but observed severe pathological lesions when 
it was injected in combination with Mycoplasma pneumoniae, suggesting a role for 
antigen/adjuvant interactions in the induction of pathological changes. 
Gerbu and DDA induced no and moderate lesions, respectively, after injection in 
rabbits while weak immune responses were found. Quil A was only injected in 
combination with Mycoplasma pneumoniae in mice. This resulted in severe 
pathological changes, probably due to combination with this antigen. Antibody titres 
after Quil N Mycoplasma pneumoniae injection could not be used since the antigen 
induced antibodies wilhout adjuvant. 
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Other factors influencing immunization result 
Besides the adjuvants, many other factors influence the outcome of an 
immunization, e.g. type of antigen, injection volume and route, and animal species 
(Chapter 2). The influence of these factors on our data is discussed below. 
As described in Chapter 2, the antigen greatly influences the immunological and 
pathological result of an immunization (Constant et al., 1995; HayGlass and Stefura, 
1991) depending on e.g. its source, chemical nature and size. Van Ommen et al. 
(1994) used the model antigen, TNP-KLH, in combination with adjuvant and 
speculated that the KLH part of the antigen was responsible for the outcome of the 
immunization and not the adjuvant. To allow discrimination between the potency of 
the alternative adjuvants, we generally used weak immunogens such as synthetic 
peptides and included a control group (injection of antigen only) in each experiment. 
Consequently, we found that M. pneumoniae induced an antibody titre without 
adjuvant in mice while in rabbits antibody titres were low. In rabbits and mice, M. 
pneumonlae induced severe lesions with all adjuvants tested while minimal lesions 
without adjuvant. The interaction between adjuvant and antigen may have caused 
the severe pathological changes. 
The injection route affects the nature and intensity of the response, probably due 
to distinct types of antigen-presenting cells that encounter the antigen (Hsieh et al., 
1992; De Becker et al., 1994). When an adjuvant is added to the antigen, 
adjuvanUantigen micelles may be formed, depending on the adjuvant. These 
micelles will be handled by a different type of antigen-presenting cells (Laman and 
Claassen, 1996) showing the importance of adjuvants in inducing an immune 
response. Minimal differences in antibody responses were observed between the 
injection routes used in rabbits (s.c. and Lm.) or in mice (s.c. and i.p.). An exception 
was TiterMax; antibody levels were high after Lp. injection of TiterMax While low 
after s.c. injection. In contrast, Bennett et al. (1992) found that the s.c. route of 
injection was superior to i.p. route in mice. The difference in injection volume, 
between s.c. and i.p. injections in our study, may explain our findings. 
The induction of pathological lesions, however, depends on the route of injection. 
Comparing s.c. and i.m. injection route for induced pathological changes in rabbits, 
lesions with comparable extent were found after s.c. and i.m. injection. The i.m. 
route, however, is more prone to injection error than the s.c. route since it is not as 
easy to verify the location of injection, i.m. lesions are also more difficult to monitor 
clinically and i.m. lesions are supposed to be more painful. Therefore, the s.c. route 
is preferred to the i.m. route in rabbits. In mice, s.c. and i.p. injection route were 
used. The severity of the lesions induced after these two routes is completely 
different. As opposed to s.c. injection where adjuvanUantigen is localized at one 
place, i.p. injections effect the extensive surface of the peritoneum and the inoculate 
is in close contact with various vital organs. Additionally, Walvoort (1991) studied the 
effectiveness of i.p. injections by different biotechnicians and showed variability in 
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effectiveness between biotechnicians and sometimes damage of organs. The s.c. 
route should therefore be preferred to the i.p. route. 
Different animal species and also different strains of animals, particularly mice, 
respond differently to adjuvanVantigen injection (Gupta and Siber, 1995). After 
injection of the same antigen (M. pneumoniae) in rabbits and mice, M. pneumoniae 
was found to be weakly immunogenic in rabbits, i.e. no antibody response without 
an adjuvant, while injection of M. pneumoniae without an adjuvant in mice resulted 
in antibody responses almost comparable to those induced by adjuvanUM. 
pneumoniae injection. BALB/c mice were used in the immunological studies 
described in this thesis. An inquiry under researchers in the Netherlands showed 
that BALB/c mice are most frequently used in immunization experiments to induce 
specific B cells (unpublished data). BALB/c mice are Th2 biased and consequently, 
immunological results may be different when, for example, C57BLl6 mice, a Th1 
biased strain, are used. Besides differences in immunological response, different 
animal species or strains may tolerate an adjuvanVantigen mixture differently. We 
observed differences in the induction of pathological changes between rabbits and 
mice, injected with the same adjuvants e.g. lesions after TiterMax injection in rabbits 
were mild while in mice severe pathological changes were found. Differences 
between mice strains are described by Boersma et al. (1992), in C3H/He and 
BALB/c mice, no or only mild irritation was observed upon i.p. injection of Specol 
while, NZB and C57BLl6 mice showed chronic mild to severe peritonitis. 
The preparation method of the emulsion can influence the immunogenic 
properties of antigen/adjuvant emulsions since it induces morphological changes in 
the emulsion structure e.g. droplet size (Bomford et aI, 1992; Audibert and Lise, 
1993). It is therefore important to pay attention to the preparation of proper water-in-
oil emulsions. To test stability of water-in·oil emulsions a drop emulsion was put on 
the surface of water; when the emulsion is stable, the drop does not spread. 
The number of injection sites also has influence on the outcome of an 
immunization. We injected 0.5 ml water-in·oil emulsion at one site and compared 
this with the same volume spread over 2 or 4 injection sites. This resulted in 
comparable antibody responses, suggesting that dividing antigen over more sites 
does not always improve the antibody response. In contrast, Bennett et a/. (1992) 
injected mice s.c. at 2 or 4 sites and observed higher antibody titres after injection at 
4 sites. They, however, used mice, different injection volumes, and another 
adjuvant. Since we observed pathological changes at all injection sites, injection at 
one site is suggested. 
Predictive value of cytokine profiles induced by adjuvants 
Murine T helper (Th) cell clones can be divided into different subsets based on their 
Iymphokine profile (Mosmann et al., 1986; Cherwinski et al., 1987). Th1 cells 
produce IfN-y and IL-2, whereas Th2 cells secrete IL-4 and IL-5. Several studies 
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(reviewed by Finkelman et al., 1990; Mosmann and Coffman, 1989; Mosmann and 
Sad, 1996) showed that cytokines such as IL-4 and IFN-y direct the quality of 
immune responses after infection and vaccination. IL-4 promotes an immune 
response dominated by antibodies of the IgG1 and IgE isotypes (Snapper and 
Mond, 1988; Swain et al., 1990) while IFN-y promotes antibodies of the IgG2a 
isotype (Stevens at al., 1988; Finkelman et a/., 1988b). The regulation of isotype 
immunoglobulin production by adjuvants has been described in vivo (Hadjipetrou-
Kourounakis and M611er, 1984; Kenney et a/., 1989; Karagouni and Hadjipetrou-
Kourounakis, 1990). Adjuvants can also modulate the immune response to different 
T helper cells (Cox and Coulter, 1997). Street et a/. (1990) described the important 
role of adjuvants in determining which Th cell subsets (Th1 or Th2) will be activated 
in vivo, and consequently, which cytokines are produced. Because cytokines playa 
crucial role in mediating immune responses, many of the activities induced by 
adjuvants may be mediated through cytokines. Van den Eertwegh at al. (1993) 
showed a peak in CD40L expressing cells (activated T cells) and KLH specific 
antibody forming cells 4-5 days after secondary i. v. injection of KLH and suggested 
that CD40L expression on activated T cells plays rola in the specific antibody 
production. Grun and Maurer (1989) observed preferential stimulation of 
phenotypically different T helper cell subsets and found corresponding IgG1 and 
IgG2a antibodies in serum after injection of FCA and Alum in mice. 
Using immunohistochemical techniques, we studied the number of activated T 
cells and cytokine producing cells in murine spleen sections 5 days after secondary 
i.p. injection of SP215 combined with FA, Specol, RIBI, TiterMax or Montanide 
ISA50. These data were correlated wilh antibody levels and isotype distribution in 
serum, 5 days after secondary immunization. Significantly higher numbers of 
activated T cells and cytokine producing cells (IL-4 and IFN-y) were observed in 
spleen sections 5 days after secondary injection of RIBI compared with any of the 
other adjuvants while RIBI injection resulted in lowest antibody levels. 
TiterMaxlSP215 injection resulted in very high peptide-specific IgG2a antibody 
levels (7 times higher than FAlSP215 injection) while no increased numbers of IFN-y 
producing cells were found. Injection of Montanide ISA50 combined with SP215 
resulted in, relatively to IgG2a antibody levels, very high SP215-specific IgG1 
antibody levels while the number of IL-4 producing cells was not significantly 
increased. Data of our study suggest that specific antibody titres and isotype 
distribution in serum not necessarily correlate wilh the numbers of activated T cells 
and cytokine producing cells in spleen sections 5 days after secondary 
immunization. Studying cytokine production at more time points and using other 
cytokine detection methods may provide information on when these levels are 
indicative, if at all, for isotype distribution in serum. The number of activated T cells 
and cytokine producing cells was also determined after injection of adjuvant without 
antigen. No significant differences in cytokine profiles (IL-4 and IFN-y) were 
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observed between adjuvant injection with or without antigen. This indicates that this 
cytokine production was not antigen specific stimulated but rather due to non-
specific immune stimulation by the adjuvant. This may be explained by the type of 
antigen used in our study. The antigen studied, SP215, is a weak immunogen 
(synthetic peptide), the influence of which may be overruled by the non-specific 
immune-stimulating effects of the adjuvants. Van Ommen et al. (1994) showed that 
the antigen (model antigen, TNP-KLH) has a major impact on the outcome of an 
immunization. They injected TNP-KLH in combination wilh Alum or FCA and 
observed comparable antibody responses independent of the adjuvant used. They 
speculated that the KLH part of the antigen was responsible for the type of immune 
response while the adjuvant enhanced this response without changing the type of 
response. 
The predictive value of cytokine profiles for isotype distribution of antibodies was 
also studied in the initial phase of the immune response. To obtain data on cytokine 
production following primary injection of FCAlSP215, we used immunohisto-
chemistry and in vitro cell culturing of lymphoid cells but cytokine profiles could not 
be measured because these levels were below the detection limits of our system. 
Using a strong immunogen (TNP-KLH), increased numbers of IFN-y producing cells 
were found in murine spleen sections 4 hours after FCAlTNP-KLH injection 
(unpublished data). Jotwani et al. (1994) injected a strong immunomodulator (LPS) 
and found IFN-y responses in the bloodstream 6 hours later. To analyse whether 
injection of the weak immunogen (SP215) in FCA results in detectable cytokine 
production, we stimulated spleen cells in vitro with SP215 at 5 and 14 days after Lp. 
injection of FCAlSP215, and studied whether proper antigen specific proliferation or 
cytokine production could be found. Our data indicated that early antigen specific 
cytokine production and proliferation of spleen cell cultures is not easily detectable 
after Lp. injection employing a weak immunogen. In vitro antigen specific stimulation 
of lymph node cells resulted in significantly enhanced IFN-y levels at 14 days after 
s.c. injection of FCAlSP215, FIAlSP215 or Specol/SP215. IL-4 production in these 
culture was below the detection limit. The ability of these three adjuvants to induce 
SP215 specific IgG1 and IgG2a antibodies was studied in serum 14 days after 
injection. IgG1 levels were significantly higher after Specol/SP215 injection while 
IgG2a levels were similar in all groups. A remarkable finding was that no IL-4 
production was detectable in vitro while considerable IgG1 antibody levels were 
observed in serum. This indicates that ILA production by lymph node cells in vitro 
does not necessarily correlate wilh IgG1 production in vivo at 14 days after s.c. 
immunization. Probably a very small amount of IL-4 is enough to induce the isotype 
switch from IgM to IgG1 (Le Gros et al., 1990). 
In our testsystem, cytokine profiles were not shown to have a predictive value for 
antibody responses to weak immunogens emulsified in oil adjuvants. Fox (1992) 
used a peptide antigen and could not find differential effects of adjuvants on Th1 
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and Th2 cells while differences in antibody titres and isotypes were observed after 
injection of different adjuvants. Difficulties to identify a consistent relationship 
between systemic cytokine production and antigen specific antibody isotypes in 
serum induced by different adjuvants were also described by Valensi et aJ. (1994). 
From our results it appeared that isotype distribution in serum can give more 
information on immunization result than cytokine profiles. More studies are needed 
to elucidate the correlation between cytokine profiles and isotype distribution in vivo. 
In vivo behaviour of water-in-oil emulsions 
Water-in·oil (w/o) emulsions comprise microdroplets of water stabilized by surfactant 
in a continuous oil phase. The mechanism of action of wlo emulsions is poorly 
known (Cox and Coulter, 1997). Wlo emulsions appear to improve and prolong 
antigen presentation by: depot function at the site of injection, protection of antigen 
from degradation, enhanced uptake of antigen by macrophages, activation of 
macrophages, and vehicle (transport/routing) function (Waksman, 1979). The 
preparation method of emulsions influences its structure (e.g. droplet size) which 
determines the antigen-presenting properties and thereby its efficacy (Harding et al., 
1991; Bomford, 1992; Ten Hagen et al., 1993). One way in which water-in-oil 
emulsions are thought to enhance the immune response is the conversion of the 
antigen to particulate matter. Since particulate matter is taken up almost exclusively 
by macro phages (Van Rooijen, 1992), this conversion would enhance the uptake of 
antigen by these cells. We studied the role of macrophages in adjuvant efficacy of 
wlo emulsions. Macrophages were eliminated in vivo by injection of dichloro-
methylene-diphosphonate (CI2MDP) containing-Iiposomes (Van Rooijen and 
Sanders, 1994) before injection of adjuvanUantigen preparations. Elimination of 
macrophages before injection of antigen combined with Specol or without adjuvant, 
resulted in increased antigen specific antibodies. Antibody responses were 
decreased, when macro phages were eliminated before FCAIantigen injection. This 
confirms that (pre)processing of particulate matter (FCA contains Mycobacteria) is 
dependent on macrophages. The importance of macrophages to process an antigen 
for the induction of an immune response, depends upon the type of antigen. In vitro 
studies demonstrated that pre-processing of particulate antigens by macrophages 
was crucial for the generation of immune responses (Wright et al., 1987; Van 
Rooijen, 1992). Delemarre et al. (1991) showed this phenomenon in vivo. Soluble 
antigens are processed and presented to the immune system by other types of 
antigen-presenting cells, such as B cells and dendritic cells (Ibrahim et al., 1995). 
We used TNP-KLH, which is a soluble antigen and therefore does not need 
macrophages (Laman and Claassen, 1996). By eliminating macrophages, 
immunization may be more effective because less antigen will be phagocytosed and 
therefore more antigen will come in contact with professional antigen·presenting 
cells such as interdigitating cells, which are extremely potent (Steinman, 1991; 
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Girolomoni and Ricciardi-Castagnoli, 1997). Our data showed that macrophages 
indeed playa role in the induction of the immune response with wlo emulsions, but 
that this can be a suppressive role. 
This suppressive role of macrophages was confusing in the light of macrophage 
involvement in adjuvant efficacy of wlo emulsions. To investigate which other 
mechanisms and macrophages are involved (or bypassed) in the uptake and 
processing of such emulsions, a method for in situ localization of these compounds 
was developed. The oil phase of wlo emulsions was labelled with a lipophilic 
fluorescent dye (DiI). This enabled kinetic studies on in vivo routing of wlo adjuvants. 
After i.p. administration of labelled oil emulsion, localization of oil was associated 
with the capsule of the spleen. This may function as a second depot, besides the 
depot at the site of administration, and herewith stimulate splenic antigen-presenting 
cells by continuous release of antigen. These results can explain the efficacy of oil 
emulsions in inducing immune responses, i.e. by keeping the bulk of the antigen 
away from the suppressive marginal zone macrophages (Leenaars et a/., 1997) and 
releasing antigen over time for uptake by follicular cells of the spleen or 
interdigitating cells in the interfollicular T cells areas of the lymph node. It can be 
concluded that efficacy of wlo emulsions is not exclusively dependent on 
macrophages. 
Assessment of pain and distress induced by adjuvants 
In the Dutch guidelines for immunization of laboratory animals (Veterinary Public 
Health Inspectorate, 1993), the use of FCA is classified as causing (very) severe 
distress. Under the USDA Guidelines, experiments are classified as Type C (some 
pain or distress of short duration) when FCA is injected intramuscularly and Type E 
(significant pain or distress) when FCA is injected in the footpad, intradermally or 
intraperitoneally. To reduce pain and distress in immunized animals, the use of FCA 
in immunization experiments was restricted in the Netherlands. The reduction of 
pain and distress in immunized animals was a clear motive for the studies 
underlying this thesis. The clinical signs and behavioural changes to recognize pain, 
distress and discomfort in laboratory animals have been described extensively by 
Morton and Griffiths (1985), Wallace et al. (1990) and Bateson (1991). Using these 
criteria, no indications for pain or distress were found in rabbits injected with FCA or 
any other adjuvanVantigen combination. Johnston et al. (1991) did not observe 
evidence of weight decrease or behavioural changes suggestive of chronic pain in 
rabbits after FCNantigen injection. Smith et al. (1992) injected rabbits s.c. and did 
not find indication of pain on palpation of inoculation site. At day 7, 14, 21 and 28 
after primary and 7 and 14 days after secondary injection of adjuvanVantigen (s.c. or 
i.m.) in rabbits, we measured creatinine kinase levels and did not observe a clear 
increase within a group of animals. Deeb ef al. (1992) observed elevated creatinine 
kinase levels in rabbits on day 2 after i.m. injection of FCNantigen or RIBI/PBS. This 
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might be indicative for muscle inflammation or necrosis and therefore associated 
with discomfort. The 7 days interval, between i.m. injection and blood sampling, may 
explain why we did not observe elevated creatinine kinase levels. Deeb et al. (1992) 
also observed muscle quivering upon palpation of the inoculation site two days after 
injection of FCA or RIBI emulsions, while some FCA injected rabbits showed muscle 
quivering through day 35. They did not observe differences in weight gain, body 
temperature and heart rate between the groups. 
To study the induced pain and distress after immunization more extensively, we 
used non-aversive behavioural tests in mice as recommended by Manser (1992). 
The behavioural tests included: (1) primary observation test, (2) activity 
measurement and (3) LABORAS. Using these additional tests and general criteria 
for pain and distress, only indications for acute pain and distress, 1 to 3 days after 
injection of FCA, were found and no indications for prolonged severe pain and 
distress. Toth et al. (1989) also demonstrated that mice were temporarily impaired 
after i.p. injection of FCNBSA (0.5 ml). These immunized mice developed unkempt 
haircoats, hunched postures, mild diarrhoea, decreased food intake and decreased 
body weights and returned to an apparently normal condition within one week. The 
injected volume (0.5 ml) of FCA may explain why these changes were present for 
one week, as opposed to the 1-3 days we found, to return to normal condition. 
Jansen van 't Land and Hendriksen (1995) observed decreased locomotion activity 
using an automatic system to measure locomotion activity during day and night. 
They injected mice i.p. with 0.1, 0.2, or 0.5 ml FCA and found a dose-dependent 
reduction in locomotion activity. When 0.5 ml FCA was i.p. injected, activity was 
decreased until day 5 after injection. Body weight was also found to be decreased 
until day 5 in the 0.5 ml FCA injected group. When the maximum volume allowed in 
the Dutch guidelines (0.2 ml) was injected, Jansen van 't Land and Hendriksen 
(1995) observed significantly decreased activity in FCA injected animals the first two 
days after injection. 
In accordance with Manser (1992), pathological changes were studied, resulting 
in obyious differences between adjuvant regimes without the need of invasive 
procedures during the animal's lifetime. These pathological changes can be 
indicative for pain, however, minimal clinical and behavioural changes were 
observed. This enigmatic finding may be explained in two ways; (1) the available 
methods to study clinical and behavioural changes to monitor pain and distress, are 
not adequate or (2) no severe prolonged pain and distress is induced as expected 
based on the pathological changes observed. 
A problem in recognizing signs of pain in rabbits may be that rabbits do not 
readily exhibit pain signs, rabbits may be masking their suffering instinctively 
(Wallace et al., 1990; Griffiths, 1991). In mice, behavioural measures indicated that 
the animals were temporarily impaired immediately after immunization. The 
availability of automated devices such as LABORAS makes it possible to monitor 
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subtle changes in the behavioural pattern of mice (locomotion, immobility, climbing, 
grooming, eating and drinking), providing adequate possibilities to detect severe 
pain and distress. 
Rabbits and mice were injected in accordance with recommendations given in the 
Dutch guidelines for immunization of laboratory animals (Veterinary Public Health 
Inspectorate, 1993), e.g. volume, injection route, and FCA injection only in primary 
immunization. This may explain why no prolonged impairment after injection of FCA 
was observed. Careful control of injection quantity and site selection was also 
suggested by Amyx (1987) to eliminate most undesirable effects of FCA. 
Based on analogy principle with humans, the pathological changes, observed 
after injection of FCA in laboratory animals, are suggested to be painful (Stafleu et 
a/., 1992). However, literature in which pain in humans is described after injection of 
FCA (Chapel and August, 1976; Hughes et a/., 1970) concerns papers in which 
lesions after FCA injection were painful in humans only when these persons were 
tuberculin-sensitized. This may indicate that the reaction was a result of repeated 
exposure to Mycobacteria (Stills and Bailey, 1991). Wanstrup and Christensen 
(1965) injected mice weekly with FCA (s.c. 0.05-0.2 ml) and observed decreased 
activity, dullness of fur, loss of hair in mice. We did not use FCA twice in the same 
animal. The assumption that FCA injection induces severe pain and distress may be 
based on studies prior to 1970 since these FCA stUdies often were completed with 
acid-treated mineral oil, while nowadays the production is done by the single or 
double hydrogenation process which results in a far less toxic product (Stewart-Tull, 
1995a). 
The next question is whether pathological changes found in humans, not induced 
by FCA but comparable to those found in laboratory animals after injection of FCA 
(e.g. peritonitis, adhesions), are painful. Based on the analogy principle with humans 
this may be expected. The amount of pain induced by lesions strongly depends on 
the location and extent. Walvoort (1991) showed that only a small number of 
pathological changes found in humans and in animals do correlate with respect to 
induced pain. This suggests that the pathological changes are not necessarily 
painful, but does not exclude the possibility that they are. 
Finally, we have to answer the question whether lesions induced by injection of 
FCA are painful in laboratory animals during a prolonged period. This question can 
not be answered since no indications of prolonged impairment were found. The 
development of lesions may have been painful since inflammatory mediators are 
released, which may lead to pain sensation. The first 1-3 days after i.p. injection of 
FCA, indications of pain were found, probably due to acute peritonitis. 
It can be argued that since there is no proof that the pathological changes 
observed after adjuvant injection do not induce pain, the benefit of the doubt should 
go to the animal (Morton and Griffiths, 1985), i.e. the adjuvant that induces the least 
pathological changes should be preferred. This implies the importance of 
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pathological studies when assessing side effects of adjuvants. Since, some 
alternative adjuvants also induce severe pathological changes, it may be disputed 
whether it is valid to claim that FCA is more harmful than alternative adjuvants. In 
rabbits, for example, pathological changes after RIBliantigen injection were found to 
be more severe than those induced after FA/antigen injection. This concept has 
consequences for the selection of an alternative adjuvant. This will be discussed 
below in 'adjuvant selection for immunization'. 
Alternative methods to produce antibodies 
Antibody production requires the use of live animals. In this thesis, we studied the 
possibilities to reduce pain and distress in animals used for antibody production by 
careful selection of the adjuvant used. Below, other ways to reduce pain and 
distress in the production of antibodies are described. 
Antibody production in the egg yolk (lgY) of chickens can be an alternative in vivo 
technique for production of polyclonal antibodies in mammals (McCafferty et a/., 
1990; Svedson Bollen et a/., 1996). The current status of immunoglobulin (Ig) Y 
production in the chicken is reviewed in Schade et al. (1996) and AL TEX (1996). 
The IgY structure and function were reviewed by Warr et al. (1995). Scientifically, 
IgY atibodies are interesting because of the phylogenetic difference between 
chickens and mammals. This results in less cross-reactivity in assays of mammalian 
proteins. The use of chickens for antibody production, as opposed to mammals, can 
represent both a refinement and a reduction in animal use. Refinement is achieved 
in that the second painful step, the collection of blood, is replaced by antibody 
extraction from egg yolk. It entails a reduction in the number of animals used 
because chickens produce larger amounts of antibodies than laboratory rodents. 
Major disadvantages of IgY technique to produce antibodies are: (1) the animals still 
have to be injected with adjuvant/antigen mixtures, and (2) standard immuno-
chemical assays for IgY antibodies are rarely available. The utility of chicken egg 
yolk as a realistic alternative source of polyclonal antibodies in mammals has to be 
questioned. 
Some authors (Ohlin and Borrebaeck, 1992; Wohlleben et aI., 1996) described in 
vitro immunizations for the production of antibodies. This method replaces the 
animal for in vitro cell cultures to produce antibodies, but it has not been very 
successful till now because antibodies produced in vitro include antibodies of the 
IgM isotype mainly. 
A very promising technique is the phage antibody display technology. This 
technology permits the selection of antibody fragments from large libraries 
constructed from the B cells of naive or immunized individuals (De Kruif et al., 1996). 
To create large libraries, animals may still need to be immunized (albeit only once). 
Phage antibody display technology is used to produce Fab fragments of purified 
antigens. By mimicking the affinity maturation of antibodies in vitro, phage display 
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strategies have the potential to reduce or eliminate the use of animals in antibody 
production protocols (Peterson, 1996). 
Adjuvant selection for immunization 
In the Dutch guidelines for immunization of laboratory animals (Veterinary Public 
Health Inspectorate, 1993), drafted by experts, the use of FCA is restricted and the 
use of alternative adjuvants is encouraged to minimize pain and distress in 
immunized animals. We followed these guidelines when comparing alternative 
adjuvants with FA and observed, with a number of clinical parameters and 
behavioural tests, no indications of pain and distress in rabbits and exclusively 
indications of acute pain and distress (1-3 days) after injection of FA in mice. This 
indicates that it is important to follow the guidelines for immunization procedures. 
Minimal clinical and behavioural changes were observed, while, severe pathological 
changes were found after injection of FA and some alternative adjuvants. Con-
sequently, the adjuvant that induces the least pathological changes combined with 
acceptable immune responses should be preferred (unless clinical or behavioural 
changes are found). The fact that minimal indications of severe pain and distress are 
obtained from clinical and behavioural studies stresses the importance of pathology 
studies when assessing side effects of adjuvants (cf Manser, 1992). 
From our studies, it is clear that severe pathological changes were also induced 
by some alternative adjuvants, while antibody responses with these adjuvants were 
not always acceptable. It may therefore not always be advantageous to use an 
alternative to FCA. Immunization with alternative adjuvants of which little information 
is available, may result in low antibody titres and severe pathological changes. As a 
result, additional animals may be needed and pathological changes induced in 
addition. Consequently, when an adjuvant is needed for only a single experiment, 
using small numbers of animals, and no analogous data on alternative adjuvants are 
present, we suggest not to test alternative adjuvants, but to use FCA, i.e. when no 
data are available on experiments using the same type of antigen, using the same 
animal species and strain, and with the same immunization goal. Testing alternative 
adjuvants is suggested in recurrent immunization experiments in which FCA is 
traditionally used. The selection of an adjuvant for combination with an antigen 
depends on the combined data available on efficacy and side effects of the 
adjuvanVantigen combination of interest. Several studies, described in this thesis, 
were performed to generate data on FA and alternative adjuvants. From these 
studies it can be concluded that when no data are available for adequate adjuvant 
selection, Specol or Montanide ISA50 can be used in pilot experiments. 
The pilot experiment should be performed taking the following into account: 
• inclusion of FA in the experiment as 'gold standard' 
• use of alternative adjuvant in accordance with guidelines for use of FCA 
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• clinical and behavioural parameters monitored every day during the experiment 
• necropsy at the end of the experiment and scoring of pathological changes. 
From the data obtained from the pilot study, the use of the alternative adjuvant in 
future research can be decided. The alternative adjuvant should only be used when 
satisfactory immunological results are obtained and the side effects are less severe 
than after FA injection. 
Concluding remarks 
The supposed severe side effects induced by FCA injection resulted in restrictions 
on its use and, consequently, in the need for alternative adjuvants. The selection of 
an alternative is not without problems since the combined information on efficacy 
and side effects of these adjuvants is often lacking. The studies described in this 
thesis were designed to generate data on FCA and alternative adjuvants. 
Comparative studies were performed in accordance with eXisting guidelines and 
data generated showed minimal clinical and behavioural changes indicative for 
prolonged severe pain. This implies that most severe side effects can be avoided by 
good biotechnical practice, including aseptic working, proper preparation of emulsion 
and injection technique. The use of additional behavioural tests for the assessment 
of pain and distress did not result in clear-cut differences with respect to unwanted 
side effects of the adjuvants tested. Pathological changes, however, were observed 
after adjuvant injection and are considered an essential parameter to study, also 
retrospectively, side effects of adjuvants. The antigen used and the route of injection 
were shown to greatly influence the induction of pathological changes. The 
subcutaneous route should be preferred over intramUSCUlar (in rabbits) and 
intraperitoneal route (in mice). 
The offensive altitude with respect to FCA and the suggested need to use 
alternative adjuvants, was not confirmed by the data underlying this thesis, i.e. 
severe pathological changes were also Observed after injection of alternative 
adjuvants without effective immune responses and minimal indications of prolonged 
severe pain and distress after FA injection were demonstrated by the clinical and 
behavioural tests performed. To minimize the number of animals used and the 
additional risk of inducing pathological changes, the use of FA is suggested when a 
single experiment is performed and no adequate data on alternatives are available. 
For recurrent experiments, a pilot experiment is suggested, using Montanide ISA50 
or Specol as an alternative, including FA as a gold standard, injecting alternative 
adjuvants in accordance with guidelines on the use of FCA, studying clinical and 
behavioural parameters, and evaluating pathological changes. More research is 
needed to elucidate the mechanism of action of adjuvants to predict immune 
responses and to develop a new generation of adjuvants, combining efficacy with 
minimal side effects. 
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In biomedical research, laboratory animals are immunized on large scale, e.g. for 
the induction of poly- and monoclonal antibodies or in vaccination experiments. To 
enhance and direct the immune response to an antigen, adjuvants (Latin: adjuvare, 
to help) are applied. Various sUbstances (e.g. mineral salts, oil emulsions, bacterial 
products, saponins) have been recognized as an enhancer of the immune response. 
In laboratory animals, immunization procedures are frequently performed with 
Freund's complete adjuvant (FCA; water-in-oil emulsion with added heat-killed 
Mycobacteria) because of its overall applicability to induce immune responses. 
However, besides the intended stimulation of the immune response, FCA can 
induce undesirable side effects. In many countries (e.g. the Netherlands), guidelines 
restricting the use of FCA in laboratory animals are developed. This resulted in a 
need for alternative adjuvants. An overall alternative to replace FCA is not available. 
Adequate selection of an alternative adjuvant is difficult because sufficient combined 
information on antibody responses and side effects of these alternatives is usually 
lacking, and the mechanism of action of adjuvants is largely unknown, which makes 
it difficult to predict the outcome of an immunization. 
The main goals of the studies presented in this thesis was to compare FCA and 
several commercially available adjuvants on immunostimulating properties and side 
effects, to provide a basis for recommendations on the use of adjuvants in 
immunization procedures and ultimately to reduce pain and distress in immunized 
animals. Emphasis is put on the use of adjuvants for the production of antibodies. 
Additional goals were to study the correlation between antibody production and 
cytokine profiles, and to increase insight into the mode of action of water-in-oil 
emulsions. 
Chapter 1, the introduction of this thesis, describes the aim of the stUdies and 
gives a short introduction to the chapters. 
In Chapter 2, adjuvants and other factors (e.g. type and amount of antigen, route 
of injection, animal species), influencing the outcome of an immunization, are 
described. Adequate selection of an adjuvant for antibody production is not possible 
from the literature overview in Chapter 2. To obtain information, comparative studies 
were conducted to evaluate FCA and alternative adjuvant (Specol, RIBI, TiterMax, 
Montanide ISA50, ISCOMs, Quil A, Lac/obacillus, DDA, Gerbu) on their properties to 
induce antibody responses and side effects in rabbits (Chapter 3 and 5) and mice 
(Chapter 4, 5 and 6). In Chapter 5, special attention is paid to the assessement of 
side effects induced by adjuvants. The use of FCA and some alternative adjuvants 
resulted in severe pathological changes, however, indications of prolonged pain and 
distress, were not found. Based on the studies described in Chapter 3, 4, 5, and 6, it 
was concluded that Montanide ISA50 and Specol are possible alternatives to the 
use of FCA for antibody production, and that the sUbcutaneous injection route is 
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preferred above the intramuscular route in rabbits and the intraperitoneal route in 
mice. 
Since many factors determine the outcome of an immunization, and the 
mechanism of action is not completely elucidated, prediction of the outcome of the 
immunization is difficult. The possibilities to predict the immunization result were 
studied by determining cytokine profiles and antibody responses after 
adjuvant/antigen injeclion (Chapter 6 and 7). No correlalion between antibody 
responses and cytokine profiles could be demonstrated. 
In Chapter 8, the role of macrophages in the mode of aclion of water-in-oil 
emulsions was studied by using a well·established macrophage elimination 
technique. Besides a stimulative role, macrophages were shown to play a 
suppressive role in the induclion of the immune response with water-in-oil 
emulsions. This suppressive role of macrophages was confusing in the light of 
presumed macrophage involvement in adjuvant efficacy of water-in-oil emulsions. 
Consequently, a new method was developed to label the oil phase of water-in-oil 
emulsions. Oil distribution in lymphoid organs after injection of water-in-Iabelled oil 
emulsion was studied (Chapter 9). Oil was found to be mainly localized associated 
with the capsule of the spleen. This localizalion may funclion as a second depot and 
partly explain the efficacy of water-in-oil emulsions. 
Chapter 10 presents a general discussion on the main points emerging from the 
experimental work. Finally, recommendations are given on the use and selection of 
adjuvants for immunization procedures in laboratory animals. 
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In het biomedisch onderzoek worden proefdieren voor diverse doeleinden gebruikt, 
bijvoorbeeld voor de productie van antilichamen voor onderzoek, diagnostiek en 
therapie. Proefdieren zijn hiervoor nodig omdat op dit moment geen geschikte 
methoden zonder dieren voorhanden zijn. am het ongerief bij proefdieren, 
veroorzaakt door het inspuiten van materiaal (immuniseren), te verminderen zijn 
richtlijnen opgesteld voor het uitvoeren van immunisaties. Speciale aandacht gaat 
hierbij uit naar de toepassing van adjuvantia. Adjuvantia (van het Latijnse woord 
adjuvare = helpen) worden gebruikt om het immuunsysteem te stimuleren en de 
Immuunrespons te sturen en kunnen daardoor helpen de gewenste immuunrespons 
op te wekken. Vele stoffen hebben een adjuvant werking zoals: aluminium zouten, 
bacteriale producten en water-in-olie emulsies (water druppels in olie fase). De 
structuur en samenstelling van een adjuvant zijn bepalend voor de immuun-
stimulerende werking maar ook voor mogelijke bijwerkingen. Het werkings-
mechanisme van adjuvantia is echter niet volledig bekend. V~~r de productie van 
antilichamen in proefdieren wordt veelvuldig gebruik gemaakt van Freund's 
complete adjuvant (FCA). Oit adjuvant is een water-in-olie emulsie waaraan 
Mycobacterian zijn toegevoegd. FCA is een zeer effectief adjuvant voor een groot 
aantal antigen en (= materiaal waartegen een immuunrespons wordt opgewekt), 
maar het kan ernstige bijwerkingen veroorzaken. Het gebruik van FCA wordt 
daarom sterk ontmoedigd in de bestaande richtlijnen voor immunisatie procedures. 
Het seleeleren van een alternatief adjuvant is echter moeilijk omdat weinig 
informatie beschikbaar is over zowel effectiviteit als bijwerkingen van deze 
producten. De in dit proefschrift beschreven studies zijn uitgevoerd om informatie Ie 
verzamelen over FCA en alternatieve adjuvantia en op basis hiervan aanbevelingen 
Ie doen voor hel gebruik van adjuvantia in proefdieren, met als uiteindelijk doel het 
ongerief te verminderen. 
De immuunrespons in proefdieren wordt door vele factoren be'fnvloed zoals type 
en hoeveelheid antigeen, injectieroute en gebruik van adjuvantia. Een overzicht van 
deze faeloren wordt gegeven in Hoofdstuk 2. am informatie over immuunresponsen 
en bijwerkingen te verkrijgen werden evaluatie studies uitgevoerd in konijnen en 
muizen. In deze studies werden FCA en alternatieve adjuvantia (Specol, RIBI, 
TiterMax, Montanide ISA50, ISCOMs, Qui! A, Lactobacillus, OOA, Gerbu) verge-
leken op basis van de ge'fnduceerde antilichaamproductie en de bijwerkingen 
(Hoofdstuk 3, 4, 5 en 6). FCA en sommige alternatieve adjuvantia blijken ernstige 
pathologische veranderingen te veroorzaken, echter, aanwijzingen voor ernstig 
ongerief op basis van klinische en gedragsveranderingen werden met de door ons 
gebruikte method en niet waargenomen. Uit de experimenten, zoals beschreven in 
Hoofdstuk 3, 4, 5 and 6, kan onder andere geconcludeerd worden dat Montanide 
ISA50 en Specol alternatieven kunnen zijn voor het gebruik van FCA ten behoeve 
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van de productie van polyclonale antistoffen. Daarnaast wordt de voorkeur gegeven 
aan de subcutane toedieningsroute boven de intramusculaire route bij konijnen en 
de intraperitoneale route bij muizen. 
Omdat vele factoren de uilkomst van een immunisatie bepalen, werd geprobeerd 
een model op te zetten om deze uilkomst te voorspellen. Cytokinen worden over het 
algemeen beschouwd als belangrijke regulatoren van de immuunrespons en zouden 
dan ook in een vroeg stadium informatie kunnen verschaffen over het immunisatie 
resultaat. De cytokine profielen en de antilichaamresponsen na immunisatie werden 
bestudeerd teneinde een relatie tussen deze twee parameters vast te stellen 
(Hoofdstuk 6 en 7). Het bleek zeer moeilijk om op basis van de cytokine profielen 
een uitspraak te doen over de ge'induceerde antilichaamresponsen. 
Omdat de kennis omtrent de werkingsmechanismen van adjuvantia van belang 
kan zijn voor het efficienter opwekken van antilichamen, werden deze mechanismen 
nader bestudeerd en daarbij werd de nadruk gelegd op water-in-olie emulsies 
(Hoofdstuk 8 and 9). Aigemeen wordt aangenomen dat macrofagen ('veel etende 
cell en') een belangrijke stimulerende rol spelen bij de adjuvant werking van water-in-
olie emulsies. De rol van macrofagen in de effectiviteit van water-in-olie emulsies 
werd onderzocht door macrofagen plaatselijk (in de Iymfeklier) te verwijderen en 
vervolgens een adjuvant toe te dienen (Hoofdstuk 8). Uit de resultaten van deze 
studies kan worden geconcludeerd dat macrofagen een rol spelen in de effectiviteit 
van water-in-olie emulsies maar dat dit ook een onderdrukkende rol kan zijn. Om 
deze opvallende bevinding verder te onderzoeken werd een methode ontwikkeld om 
de olie fase van water-in-olie emulsies te labellen (Hoofdstuk 9). Na toediening van 
water-in-gelabelde olie emulsies werd de localisatie van de emulsie bestudeerd. 
Water-in-olie emulsie bleek zich met name in en rond het kapsel van de milt te 
bevinden en niet in de macrofagen. Dit suggereert dat een tweede depot van water-
in-olie emulsie (naast dat op de plaats van toediening) wordt gevormd dat zorgt voor 
extra stimulatie van het immuunsysteem. 
Aan het einde van het proefschrift worden de belangrijkste bevindingen uit de 
studies bediscussieerd en worden aanbevelingen gegeven voor het gebruik van 
adjuvantia in proefdieren (Hoofdstuk 10). 
De algemene conclusie van het proefschrift is dat de gereserveerde houding die 
internationaal bestaat ten aanzien van het gebruik van FCA genuanceerd dient te 
worden. Weliswaar veroorzaakt FCA (ernstige) pathologische veranderingen maar dit 
leidt niet tot aanwijzingen voor blijvend ernstig ongerief, tenminste niet op grond van 
de door ons gebruikte modellen voor klinisch en gedragsonderzoek. Bij tege-artis 
gebruik van FCA, konden slechts minimale klinische en gedragsveranderingen, die 
een indicatie zouden kunnen zijn van ongerief, worden waargenomen bij konijnen en 
niet meer dan een paar dagen na inspuiten bij muizen. Daarnaast geven sommige 
alternatieve adjuvantia, net als FCA, ernstige pathologische veranderingen, maar 
geen acceptabele antilichaamresponsen. 
203 
Samenvatting 
Aanbevelend wordt gesteld dat het gebruik van alternatieve adjuvantia niet wordt 
aangeraden als slechts sen enkel experiment met een klein aantal dieren wordt 
uitgevoerd en niets bekend is over de te gebruiken adjuvanVantigeen combinatie. Oit 
om het aantal dieren dat gebruikt wordt voor immunisaties te beperken en te 
voorkomen dat ernstige pathologische veranderingen ge'induceerd worden zonder 
acceptabele immuunresponsen. Omdat het niet duidelijk is of de pathologische 
veranderingen door gebruik van een adjuvant ongerief veroorzaken, dient bij de keuze 
van een adjuvant de voorkeur gegeven te worden aan een adjuvant dat minimale 
pathologische veranderingen veroorzaakt en acceptabele immuunresponsen 
induceert. Het bestuderen van pathologische veranderingen is essentieel om de 
bijwerkingen van (alternatieve) adjuvantia te beoordelen. Het antigeen en de 
inspuitroute zijn mede bepalend voor de pathologische veranderingen. 
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APPENDIX A 
Overview of results of studies in rabbits comparing FCA with Specol, RIBI, TiterMax and/or Montanide ISA50 
on antibody responses and (in several cases) clinical, behavioural and pathological changes. 
adjuvant antigen route Ab clinicallbehavioural pathogical changesC reference 
{volume in ml} titre3 changesb 
FCA 
- glycolipid - sc (0.5) 
-' s + Leenaars et al., 1994 
·;m (0.5) 
- subunit enzyme - sc (5xO.2) + s.c. mass> 3cm n.d. Mallon et al., 1991 
- synth. pept - sc (0.5) + + Leenaars et a/ .. 1994 
-;m (0.5) + + 
- M. pneu. - sc (0.5) + s u,9,a Leenaars et al .. 1994 
-;m (0.5) + + 
- synth. polypept (Mw 240 kDa) • ;m (2x0.25) + +q,ck,b m Deeb et al., 1992 
- pept.!BSA - im (2xO.4) + + deep tissue reaction r, S, Johnston et al .• 1991 
;d (2x0.1) u « 1 em) 
- TNP/HEA - fp (2x0.04) + r. s n.d. Bennett et al .. 1992 
- LHRH/BSA -;m (0.5) + r. s n.d. Bennett et al .. 1992 
- protein/polymer - sc (4xO.25) + 9 (9-32 em:':), t, U Smith et al .. 1992 
- synth .pept/ tetanus toxoid - sc (4xO.1) + s Leenaars et al .• subm. 
• BSA -sc(0.1) + s + Leenaars et al., subm . 
- im (0.5) + + 
- virus (Rubella) - sc (0.1) + s + Leenaars et aI., subm. 
- im (0.5) + + 
Specol 
~ glycolipid - sc (0.5) Leenaars et al., 1994 
-;m (0.5) 
~ synth. pept - sc (0.5) + Leenaars et al .. 1994 
-;m (0.5) + 
~ M. pneu. • sc (0.5) + s +1· Leenaars et a/., 1994 
·;m (0.5) + +1· 
~ synth. pept./tetanus-toxoid -sc(4xO.1) + s + Leenaars et aI., subm. 
-BSA - sc (0.1) + s + Leenaars et al., subm. 
-;m (0.5) + 
- v;rus (Rubella) -$c(0.1) + Leenaars et al., subm. 
-;m (0.5) + 
RIBle 
111 ~ glycolipid - sc (2x0.5) s ++,g,u,a Leenaars et a/., 1994 
-;m (2x0.5) ++,g 
= 
adjuvant antigen 
R1B1 
II - subunit enzyme 
I - subunit enzyme 
III - synth. pept 
III - M. pneu. 
III - synth. polypept. (Mw 240 kDa) 
III - peptJBSA 
II - LHRH/BSA 
III - protein/polymer 
TiterMax 
- glycolipid 
- protein/polymer 
- synth. pept. 
- M. pneu. 
- TNP/HEA 
Montanide ISA50 
- peptJBSA 
- synth. pepUtetanus toxoid 
-BSA 
- virus (Rubella) 
route Ab clinical/behavioural pathological changes 
(volume in ml) titre changes 
- se (5xO.2) 
- se (5xO.2) 
- se (2x0.5) 
- 1m (2x0.5) 
- se (2xO.5) 
- 1m (2x0.5) 
- 1m (2x025) 
- im (2x0.4) + 
Id (2x0.1) 
- sc (0.1) + 
;p (02)+ 
1m (2x0.2) + 
Id (6xO.05) 
- sc (0 .. 1) + 
Ip (02)+ 
im (2x0.2) + 
Id (6xO.05) 
- 1m (0.08) 
- se (0.08) 
- 1m (2x0.05) 
- 1m (0.08) 
- se (0.08) 
- 1m (0.08) 
- se (0.08) 
- 1m (2x0.04) 
+/-
+/-
+/-
+/-
+/-
+/-
+/-
+ 
- im (2x0.4) + + 
Id (2x0.1) 
-sC(4xO.1) + 
-se(0.1) + 
- im (0.5) + 
-sc(0.1) + 
- im (0.5) + 
s (2-3 em) 
s « 2 cm) 
s 
+/-
mild transient 
s 
mild transient 
s 
n.d. 
n.d. 
++,g,a,u 
++,g 
+,g,u,a 
+,9 
m (+/-) 
deep tissue reaction r, S, 
u «1 cm) 
n.d. 
+/-
+/-
+/-
n.d. 
deep tissue reaction r, s, 
u «1 cm) 
+ 
+/-
+/-
+/-
+/-
reference 
MaJlon et al., 1991 
Leenaars etal., 1994 
Leenaars et al., 1994 
Oeeb etal., 1992 
Johnston et aI, 1991 
Bennett et al., 1992 
Smith et al., 1992 
Leenaars et al., 1994 
Smith et al .. 1992 
Leenaarsetal.,1994 
Leenaars et al., 1994 
Bennett et al., 1992 
Johnston et al .. 1991 
Leenaars et al., subm. 
Leenaars et aI., subm. 
Leenaars et a/., subm. 
.. antibody titre 
b clinical and behavioural changes: b=body weight loss; ck = elevated creatinine kinase levels; q = muscle Quivering; r-redness; s=swelling 
c: pathological changes: a=abscess; f=fistulous extension; g=granulomatous lesion; m=myositis; r-redness; s=swelling; u=ulceration; 
d n.d. :;; not detennined; - :;; not found; +/- = less than FCA; + :;; comparable to FCA; ++ ::: exceeding FCA 
e RIBII is RIBI containing MPL: RIBIII is RIBI containing MPL + TDM: RIBIIII is RIBI containing MPL + TOM + CWS. 
APPENDIXB 
Overview of results of studies in mice comparing FCA with Specol, RlBl, TiterMax and/or Montanide ISA50 
on antibody responses and (in several cases) clinical, behavioural and pathological changes. 
adjuvant antigen route Ab clinical/behavioural pathological changes!; reference 
{volume in ml} titreO chansesb 
FCA - self antigen - sc (0.2) +/.d b.s 9 (>4 mm), fi Leenaars et al., 1995 
-;p (0.2) + b, pi a,w,p 
- synth. pept. - sc (0.1) + b,s n.d. Leenaars et a/ .. 1995 
- synth. pept. -sc(0.1) + pi,s 9 (2-4 mm). fi Leenaars et al., subm. 
-;p (0.2) + pi, h a.p 
- idiotype -sc(1) + n.d. n.d. Zhau and Afshar, 1995 
- fusion protein - sc (2x0.1) + n.d. n.d. Daly and Long, 1996 
- BGGfhapten -;p (02) + a,w Upman etal., 1992 
- syoth.pept/OVA -;p (0.1) + n.d. n.d. Geerligs, et ai, 1989 
- synth.peptJBSA -;p (0.1) + n.d. n.d. Geerligs, et al. 1989 
- LHRH/BSA -;m (0.5) + r, S n.d. Bennett,1992 
- TNP/HEA - fp (2xO.04) + r. S n.d. Bennett,1992 
- M. pneu. -sc(0.1) + P.S 9 (>4mm), fi Leenaars et al .. 1995 
-;p (0.2) + b, pi w.p 
- synth. peptJdiphtheria toxoid -;p (?) + n.d. n.d. Jones et al., 1990 
- LHRH/avidin - sc (0.2) +1- n.d. n.d. Tiong etal .. 1993 
~ human serum albumin (HSA) -;p (0.15) + + n.d. n.d. Kenney et al., 1989 
fp (2x0.025) 
- HSA - sc (0.2) + n.d. n.d. Kenney et al.,1989 
- influenza virus micelles - sc (0.1) + n.d. n.d. Sjolander et al., 1996 
- whole killed parasite - sc (0.05) + n.d. n.d. Ten Hagen etal., 1993 
- toxic protein -sc (?) + n.d. n.d. Hewetson et al., 1993 
Specol 
~ self antigen. - sc (0.2) b Leenaars et al., 1995 
- ;p (0.2) w.P 
- synth. pept. -sc(0.1) + b Leenaars et al .. 1995 
-;p (0.1) + b w.p 
~ synth. pept. -sc(0.1) + +1- Leenaars et al., subm. 
- ;p (0.2) + pi. h a.p 
- M. pneu. - sc (0.1) + pi, S 9 (>4mm). fi Leenaars et al .• 1995 
-;p (0.2) + pi, b w.P 
<: 
adjuvant antigen route Ab clinical/behavioural 
{volume in ml) titre chanqes 
RIBI'" 
II - synth. pept. -se(0.1) 
- ip (0.2) h, pi 
II - fusion protein -se(2x0.1) ++ n.d. 
II - BGG/hapten - ip (0.2) ++ 
II - synth.pept/OVA -ip(0.1) + n.d. 
- synth.pept/BSA -ip(0.1) + n.d. 
II - LHRH/BSA - se (02) +/- n.d. 
II - TNP/HEA -se(2x0.1) n.d. 
III - LHRH/avidin - sc (0.2) +/- n,d. 
II - HSA - ip (0.15) + +/- n.d. 
fp (2xO.025) 
- toxic protein -set?) + n.d. 
TiterMax 
- synth. pept. - se (0.05) pi, h, s 
- ip (0.2) ++ pi, h 
- fusion protein - se (2x0.1) ++ n.d. 
- LHRH/BSA - se (0.04) + n.d. 
- TNP/HEA - se (0.08) ++ n.d. 
- fp (2x0.04) + n.d. 
- influenza virus micelles - se (0.05) + n.d. 
- whole killed parasite - se (0.05) + n.d. 
Montanide ISA50 
- synth. pept. -sc(0.1) ++ s 
- ip (0.2) ++ pi, h 
-virus - im + 
- synth. peptJdiphtheria toxoid - ip (?) ++ n.d. 
.. antibody titre 
b clinical changes: b= body weight loss; h = hunched posture; pi = pilo-erection; s = swelling 
pathological changes 
w. p (+/-) 
n.d. 
a, w (+/-) 
n.d. 
n.d. 
mild transient 
mild transient 
n.d 
n.d, 
n.d. 
g (>4 mm),fi 
a.p 
n.d. 
mild transient 
mild transient 
mild transient 
n.d. 
n.d. 
9 (2-4 mm). fi 
W.P 
n.d. 
n.d . 
e pathological changes: a=adhesions; fi=fibrosis; g=granuloma; n=necrosis; p=peritonitis; w=white plaques on organs 
oj n.d. = not determined; - = not found; +/- = less than FCA; + = comparable to FCA; ++ = exceeding FCA 
e RIBI II is R[BI containing MPL + TOM; R[B[ 1[[ is RlB[ containing MPL + TOM + CWS. 
reference 
Leenaars et al., subm. 
Daly and Long, 1996 
Lipman et al., 1992 
Geerligs et al., 1989 
Geerligs et al., 1989 
Bennett et al .. 1992 
Bennett et al., 1992 
Tiong et al., 1993 
Kenney et al., 1989 
Hewetson et al., 1993 
Leenaars et al .. subm. 
Daly and Long, 1996 
Bennett et al., 1992 
Bennett et al., 1992 
Sjolander et al., 1996 
Ten Hagen etal., 1993 
Leenaars et al., subm. 
Ganne et al., 1994 
Jones at al .. 1990 



